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Abstract 
The ADAM (A Disintegrin and Metalloprotease) family of multi-domain proteins 
modulates a number of cellular signaling pathways in both normal and cancerous cells.  
ADAM12 has been shown to be a candidate cancer gene for breast cancer and its expression is 
up-regulated in breast tumors.  The human ADAM12 transcript is alternatively spliced.  One of 
these splice variants encodes a transmembrane ADAM12 isoform, ADAM12-L, which has been 
demonstrated to release cell signaling molecules from the cell surface.  Another variant encodes 
a secreted protease, ADAM12-S, which cleaves extracellular matrix proteins and other secreted 
proteins.  Although these variants are expressed from the same promoter, their relative 
expression levels are highly discordant.  Here, I demonstrate variant-specific regulation of 
ADAM12 transcripts by microRNAs.  Members of the microRNA-29 and microRNA-200 
families target the unique 3’UTR of the ADAM12-L transcript and cause transcript degradation.  
Additionally, I show the presence of a novel ADAM12 splicing event in which 9 additional 
nucleotides are inserted in the region encoding the autoinhibitory pro-domain.  I demonstrate that 
this novel variant is expressed in breast epithelial cells and breast cancer cell lines.  The resulting 
protein isoform does not undergo proteolytic processing to activate the protease.  Additionally, 
trafficking of the novel isoform to the cell surface is impaired and this isoform is localized to the 
endoplasmic reticulum.  Finally, I determined a role for ADAM12-L in the progression of triple 
negative breast cancers (TNBCs).  These tumors are lacking expression of hormone receptors 
and the HER2 receptor.  HER2 is a member of the epidermal growth factor receptor (EGFR) 
family and the loss of the HER2 receptor causes tumors to rely on EGFR for propagating pro-
growth signals.  I show here that, in TNBC tumors, ADAM12-L expression is strongly correlated 
with poor patient prognosis and increased activation of EGFR.  These data suggest that in 
TNBCs, ADAM12-L enhances tumor growth via EGFR activation.  Collectively, the data 
presented here demonstrate (a) transcript-specific regulation of ADAM12 in breast cancer, (b) the 
existence of a novel splice variant and protein isoform with impaired cellular trafficking, and (c) 
an important role of the ADAM12-L isoform in EGFR activation in TNBC. 
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Abstract 
The ADAM (A Disintegrin and Metalloprotease) family of multi-domain proteins modulates a 
number of cellular signaling pathways in both normal and cancerous cells.  ADAM12 has been 
shown to be a candidate cancer gene for breast cancer and its expression is up-regulated in breast 
tumors.  The human ADAM12 transcript is alternatively spliced.  One of these splice variants 
encodes a transmembrane ADAM12 isoform, ADAM12-L, which has been demonstrated to 
release cell signaling molecules from the cell surface.  Another variant encodes a secreted 
protease, ADAM12-S, which cleaves extracellular matrix proteins and other secreted proteins.  
Although these variants are expressed from the same promoter, their relative expression levels 
are highly discordant.  Here, I demonstrate variant-specific regulation of ADAM12 transcripts by 
microRNAs.  Members of the microRNA-29 and microRNA-200 families target the unique 
3’UTR of the ADAM12-L transcript and cause transcript degradation.  Additionally, I show the 
presence of a novel ADAM12 splicing event in which 9 additional nucleotides are inserted in the 
region encoding the autoinhibitory pro-domain.  I demonstrate that this novel variant is 
expressed in breast epithelial cells and breast cancer cell lines.  The resulting protein isoform 
does not undergo proteolytic processing to activate the protease.  Additionally, trafficking of the 
novel isoform to the cell surface is impaired and this isoform is localized to the endoplasmic 
reticulum.  Finally, I determined a role for ADAM12-L in the progression of triple negative 
breast cancers (TNBCs).  These tumors are lacking expression of hormone receptors and the 
HER2 receptor.  HER2 is a member of the epidermal growth factor receptor (EGFR) family and 
the loss of the HER2 receptor causes tumors to rely on EGFR for propagating pro-growth 
signals.  I show here that, in TNBC tumors, ADAM12-L expression is strongly correlated with 
poor patient prognosis and increased activation of EGFR.  These data suggest that in TNBCs, 
ADAM12-L enhances tumor growth via EGFR activation.  Collectively, the data presented here 
demonstrate (a) transcript-specific regulation of ADAM12 in breast cancer, (b) the existence of a 
novel splice variant and protein isoform with impaired cellular trafficking, and (c) an important 
role of the ADAM12-L isoform in EGFR activation in TNBC. 
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Chapter 1 - Literature Review 
The ability to classify tumors into subtypes with similar characteristics, such as stage of 
disease, prognosis and susceptibility to certain treatments, is critical in order to provide the most 
effective therapy.   In addition to determining the cell type in which the tumor originated, 
pathologists use a staging scale that incorporates information about tumor size, lymph node 
involvement and the presence of any metastatic lesions as well as a grading scheme that 
determines the degree of differentiation the cancer cells exhibit [1, 2].  This information has 
proven to be valuable in determining overall prognosis, as the tumors with lower stage and grade 
values, or smaller-sized and more differentiated tumors, tend to have a better overall prognosis 
[1, 2].  However, these metrics offer no information about aberrant metabolic pathways that are 
operating within the cancer cells that may be targetable for therapeutic intervention. 
 Clinical Subtypes of Breast Cancer 
  Additional analysis for the presence of certain important drivers of tumor growth is now 
done routinely at diagnosis.  Breast cancer patient biopsies are tested using 
immunohistochemistry for 3 major proteins markers; the estrogen receptor (ER), progesterone 
receptor (PR) and the overexpression of the HER2 receptor, a member of the Epithelial Growth 
Factor Receptor family.  Clinically, the tumors are categorized based on the presence or absence 
of each of these markers and the optimal course of treatment is determined, whether it will be 
targeted therapy, conventional chemotherapy or a combination of the two. 
 Hormone Receptor Positive Subtype 
 ER is encoded by the ESR1 gene and generates the major estrogen receptor isoform, 
ERα.  The receptor itself is a 67-kDa protein that, in response to estrogen binding, undergoes a 
conformational change, translocates to the nucleus and acts as a transcription factor [3–6].  One 
of the many proteins whose expression is activated by ER activity is PR [7].  PR is encoded by 
the PGR gene and the receptor works in a very similar manner to ER; in response to 
progesterone binding, the receptor changes conformation and gains transcription factor activity 
[8].  The ER and PR hormone receptors are so strongly linked that only 5% of PR+ tumors are 
ER-, and therefore these two markers are often listed together as hormone receptor positive or 
2 
HoR+ [4].  Typically, tumors in this class are lacking overexpression of the HER2 receptor, as 
those tumors which are positive for all 3 major immunohistochemical markers are usually 
classified as HER2+ rather than HoR+ [9].  HoR+ tumors are the most common type of breast 
carcinomas and represent ~60-70% of all cases [10]. 
  In general, HoR+ tumors are poorly proliferative and usually have good prognoses, 
especially when both receptors are present [4, 11].  However, there is some variability within the 
HoR+ group and a smaller subset has a higher proliferation index [4, 10, 11].  Interestingly, 
despite the overall good prognosis for patients, HoR+ tumors respond poorly to conventional 
cytotoxic chemotherapy [12–14].  The good prognosis is due to the widespread use of anti-
estrogen therapies alone or in addition to chemotherapy.  There are 3 major types of anti-
estrogens: selective estrogen receptor modulators (SERMs), aromatase inhibitors (AIs) and 
fulvestrant [6, 14].  Each of these compounds works to prevent the action of the ER, but by 
different mechanisms.  SERMs, like tamoxifen, work by binding to the ER in the ligand binding 
site and causing a conformational change in the protein; however, the resulting structure is an 
inhibited receptor that lacks transcription factor activity [3].  Fulvestrant also binds directly to 
the ER but, in this case, binding causes degradation of the protein [4].  AIs inhibit the enzymes 
responsible for estrogen production, thereby limiting ER activity by reducing ligand 
concentrations [3].  Most HoR+ tumors are treated only with anti-estrogen therapy, however, if 
the tumor is advanced or assessed as being highly proliferative, chemotherapy may be added to 
the treatment plan [15].  Overall, the anti-estrogen therapies are quite effective and have greatly 
improved prognosis for patients with HoR+ tumors.   
 HER2-Amplified (HER2+) Subtype 
HER2-amplified or HER2+ tumors are tumors in which the HER2 protein is 
overexpressed.  Approximately 20% of all patients present with these types of tumors [16].  
HER2 is the product of the ERBB2 gene which is found on chromosome 17.  Overexpression 
usually occurs due to amplification of this region of the chromosome and can be identified at the 
protein level by immunohistochemistry or at the DNA level by in situ hybridization.  
Additionally, overexpression can occur without gene duplication by aberrant transcriptional up-
regulation and therefore can only be detected by the immunohistochemical method [16]. 
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HER2 is a member of the Epidermal Growth Factor Receptor (EGFR) family.  The 
EGFR family consists of 4 receptor tyrosine kinases, EGFR/HER1, HER2, HER3 and HER4, 
which are activated by Epidermal Growth Factor (EGF) and EGF-like ligands.  The ligands are 
synthesized as transmembrane proteins and activated via proteolytic cleavage; this cleavage 
event is a source of pathway regulation [17].  Upon binding of the ligand to the receptor, the 
receptor forms a homo- or heterodimer with other HER family members and the cytosolic kinase 
domains are activated.  The kinase domains perform multiple phosphorylation events on the 
cytoplasmic tails which creates binding sites for proteins like Ras, mitogen-activated protein 
kinases (MAPK), Src tyrosine kinase, and phosphoinositide-3 kinase (PI3K) [18].  The activation 
of these signaling proteins by the EGFR family of receptors promotes cell growth.  HER2 is the 
only member of this family that does not require ligand binding for activation and therefore a 
major regulatory step is lost.  In tumors where HER2 is overexpressed, it dimerizes readily 
which results in strong, sustained activation of the pro-growth signaling pathways and little 
negative regulation of this pathway activation [18, 19]. 
Not surprisingly, HER2+ tumors are highly proliferative.  Before the advent of anti-
HER2 therapy, patients with HER2+ tumors had higher rates of recurrence and poorer overall 
survival [16, 19, 20].  These patients are now typically treated with trastuzumab, a monoclonal 
antibody specific for the extracellular portion of HER2, and a cytotoxic chemotherapy which has 
dramatically improved survival for these patients [15, 16, 20–22].  Since the success of 
trastuzumab, other anti-HER2 therapies have been developed including the small molecule 
inhibitor lapatinib [16, 20].  Lapatinib blocks the tyrosine kinase activity of both EGFR and 
HER2 and has been shown to improve the response to chemotherapy in patients whose tumors 
progressed after trastuzumab treatment [20].  Additional anti-HER2 therapies are now available 
including pertuzumab, which is an antibody that inhibits HER2 receptor dimerization, and other 
small molecule inhibitors of the tyrosine kinase domain [20].  The success of targeting the HER2 
receptor has yielded a variety of treatment options and has improved overall prognosis for 
patients with HER2+ tumors. 
 Triple Negative Subtype 
Triple negative breast cancers (TNBC) are defined as tumors that lack expression of ER 
and PR and do not overexpress HER2.  Approximately 10-20% of breast tumors are triple 
4 
negative [23].  Typically, these tumors are poorly differentiated and patients with TNBCs have a 
poor 5 year prognosis compared to patients with HoR+ tumors.  However, TNBC patients are 
less likely to recur more than 5 years post-diagnosis [23, 24].  These tumors are found 
disproportionately more often in younger women, women with oncogenic mutations of  breast 
cancer susceptibility proteins 1 and 2, BRCA1 or BRCA2, and women of African or Hispanic 
descent [13, 23, 24]. 
TNBCs are clearly unable to be treated with the targeted anti-estrogen or anti-HER2 
therapies that have been so successful in improving survival for patients with HoR+ and HER2+ 
tumors.  As a result, the only available options for these patients are radiotherapy and systemic 
cytotoxic chemotherapy [15, 25].   Interestingly, triple negative tumors are much more 
responsive to chemotherapy than HoR+ and HER2+ tumors,  85% of TNBC patients experience 
partial or complete response to chemotherapy, meaning that the tumor is decreased in size or 
eliminated by chemotherapy [13].  In comparison, only 47% of HoR+ patients and 64% of 
HER2+ patients show the same response.   Despite early success of treatment, TNBCs are more 
likely to recur than HoR+ cancers and are much more comparable to HER2+ tumors in this 
respect [13].  TNBCs preferentially metastasize to the lungs and the brain which diverges from 
the typical pattern of bone and liver metastasis in non-TNBC patients [23].  There is a need for 
more effective, targeted therapies for TNBCs.  Researchers have been working to identify 
required genes in these tumors that may make effective drug targets, but thus far there has not 
been enough evidence of additional benefit to patients and the recommended standard treatment 
is still traditional chemotherapy only [6, 15]. 
 Molecular Subtypes of Breast Cancer 
In response to this need for more druggable targets and with the development of rapid, 
inexpensive methods to survey global gene expression, researchers began studying gene 
expression differences between breast tumors.  Early studies utilized microarrays to identify 
transcriptomic differences and, more recently, next generation RNA sequencing has been used 
[26, 27].   The results of these investigations revealed 5 unique subtypes of breast cancer that 
vary in incidence, prognosis, and treatment [27–29].  These studies use the expression of ~1900 
“intrinsic” genes, which are defined as genes whose expression differs substantially between 
tumors but rarely change in duplicate samples from the same tumor or its metastases [27, 30, 31].  
5 
It should be noted that these classifications are less commonly used clinically due to the cost of 
analysis, the requirement for larger amounts of raw tumor tissue and the complexity of the post-
analysis computations [32].  However, a subset of 50 genes, known as PAM50, was shown to 
adequately classify tumors into 4 of the 5 known subtypes as well as offer value in determining 
patient prognosis without therapy and response to therapy [31, 33].   
 Luminal A and Luminal B Tumors 
The luminal subtypes were identified early due to the high prevalence of these tumors; 
they represent an estimated 60-70% of new diagnoses [10, 27].  Both subtypes express the 
hormone receptors, ER and PR, and luminal markers such as cytokeratins -8 and -18 [10, 27, 29].   
Luminal A tumors express higher levels of transcription factors such as FOXA1 and 
GATA3 than luminal B tumors [10, 27, 30].  These transcription factors, in combination with the 
hormone receptors, drive expression of luminal genes and are responsible for the maintenance of 
the luminal phenotype.  In fact, expression of FOXA1 and GATA3 correlate strongly with ER 
expression [34].  It has also been suggested that FOXA1 is a marker of improved prognosis 
because this transcription factor, in combination with BRCA1, activates expression of p27
Kip1
, 
the cyclin-dependent kinase inhibitor that prevents the cell from entering the cell cycle [35].  
Additionally, FOXA1 has been shown to activate transcription of E-cadherin, an important 
protein involved in epithelial cell-cell interactions [36].   Down-regulation of E-cadherin induces 
cells to become more migratory and invasive [37], therefore maintenance of E-cadherin 
expression in the breast tumor improves the patient’s overall prognosis.  It has been shown that 
GATA3 expression is also correlated with more differentiated, less metastatic tumors [34, 38].  
Additionally, GATA3 correlates with ER expression and is associated with longer survival; 
however specific molecular mechanisms that explain this activity are only beginning to be 
elucidated.  One such mechanism suggests that GATA3 induces the expression of microRNA-
29b, which is responsible for down-regulating numerous proteins involved in angiogenesis, 
remodeling of surrounding collagens, and metastasis [38].   
Overall, luminal A tumors are less proliferative and less invasive, therefore this subtype 
of tumors has the best prognosis of the major subtypes, and the course of treatment is more 
clearly defined.  Similarly to HoR+ tumors determined by immunohistochemistry, luminal A 
tumors are often treated with SERMs or AIs [15].  These treatments provide the best rate of 
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success for luminal A tumors, since only 7% of these tumors respond well to cytotoxic 
chemotherapy [10].  However, current convention states that patients with luminal A tumor 
should be treated with chemotherapy if the disease is advanced or present in multiple lymph 
nodes at the time of diagnosis [15]. 
Luminal B tumors express many of the luminal genes including ER and PR but the level 
of expression of these receptors is typically lower than in luminal A tumors [39].  Additionally, 
expression of FOXA1 and GATA3 is lower in luminal B tumors and the beneficial effects of 
these genes are absent [10, 40].  The major difference between the luminal A and B subtypes is 
that luminal B tumors have much higher expression of proliferation genes [10, 28, 39].  Luminal 
B tumors are often being assigned by a more clinically accessible, surrogate assay involving 
immunohistochemistry, where they are HoR+, HER2- and scored as highly proliferative by the 
Ki67 marker [41].  Patients with luminal B tumors have less favorable prognoses than patients 
with luminal A tumors.  Luminal B tumors are more likely to recur and, therefore, more 
aggressive therapy is recommended.  These tumors are often treated with AIs in addition to 
conventional chemotherapies [10, 15].  In general, luminal tumors do not respond well to 
chemotherapy, however, luminal B tumors respond better than luminal A tumors, with ~17% of 
patients exhibiting a favorable response [10]. 
 HER2-Enriched Tumors 
Similar to HER2+ tumors identified by immunohistochemistry, the tumors in this subtype 
are identified by strong expression of the HER2 receptor and/or several co-regulated genes [27].  
HER2-enriched tumors exhibit high levels of proliferation markers and are characterized by 
having low expression of luminal markers and virtually no expression of basal markers [42].  
These tumors represent ~10-20% of all breast carcinomas and usually have poor patient 
prognosis; however, the development of anti-HER2 therapy has greatly improved the treatment 
[10].   Patients with HER2-enriched tumors also have a higher risk of recurrence and breast 
cancer-related death than those with luminal A tumors [43].  As with HER2+ cancers, HER2-
enriched tumors are treated with trastuzumab, the anti-HER2 monoclonal antibody, and 
concurrent chemotherapy [15].   Interestingly, patients with HER2-enriched tumors respond 
better to anti-HER2 therapy than patients with clinically HER2+ tumors [44], presumably due to 
the dependence on HER2-related pathways observed in these tumors.  Additionally, HER2-
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enriched tumors respond quite well to chemotherapy, with 43% of patients exhibiting pathologic 
complete response, comparing to 7% and 17% of luminal A and luminal B tumors, respectively 
[10]. 
 HER2-enriched tumors do not perfectly align with the HER2+ tumors, in fact almost one 
third of the HER2-enriched tumors are classified as HER2- by immunohistochemistry [42].  A 
recent analysis of over 2000 tumor samples showed that among clinically HER2+ tumors, only 
47% have the HER2-enriched intrinsic subtype [44].   This is especially important since the 
tumors that are ER-/HER2+ by immunohistochemistry are often roughly categorized as HER2-
enriched [42].  It is also worth noting that HER2 overexpression is observed in all major 
molecular subtypes of breast cancer [45], therefore identifying tumors of this molecular subtype 
is more complicated than the name suggests.  
HER2-enriched tumors typically exhibit overexpression of HER2, due to gene 
amplification, and many of the neighboring genes are also markers of this amplification event.  
Since the HER2-enriched subtype is determined by the high expression of multiple genes related 
to the HER2 signaling pathway rather than just the overexpression of HER2, more information 
about the metabolic demands of these tumors can be extracted than from HER2+ tumors alone.  
The 17q12-21 amplicon contains genes encoding HER2, STARD3, and the SH2 adapter protein 
GRB7 [46–48].  Many of these co-amplified genes are thought to be involved in tumor 
progression and even in acquired resistance to anti-HER2 therapy [49].  The non-oncogene 
addiction theory suggests that tumors become dependent on the actions of certain gene products 
that are often co-regulated with HER2 which helps explain the discrepancies observed between 
the HER2+ tumors and the HER2-enriched tumors.   
 Basal Tumors 
Basal tumors represent approximately 10-20% of all invasive breast carcinomas and are 
characterized by expression of so-called “basal” genes [10, 27, 50].  These tumors have high 
expression of basal cytokeratins like cytokeratins-5, -6 and -17, while having low expression of 
ER, GATA3, HER2 and the luminal cytokeratins -8 and -18 [10, 42].  Additionally, basal tumors 
have increased expression of P-cadherin, CD44 and EGFR [10].  P-cadherin has a role in normal 
mammary duct formation, however, its expression is restricted to the terminal end bud and in the 
myoepithelium of the mature breast [51].  In breast tumors, expression of P-cadherin has been 
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associated with poorer prognosis in patients and increased cell migration in vitro [51].   CD44 is 
a hyaluronan receptor, however, it also interacts with a variety of extracellular matrix 
components such as laminin, collagens, and fibronectin [52].  CD44 has been shown to be 
strongly relevant in normal breast and breast cancer biology.  Breast cancer cells with high CD44 
expression are enriched in mammary stem cells and initiate tumors more readily in mouse 
xenograft experiments [53, 54].  EGFR is related to HER2, however, this receptor requires ligand 
to initiate pro-growth signals, which means that activation of this pathway is regulated by the 
availability of ligand.  In addition to these gene expression alterations, basal tumors also have a 
high rate of mutation of the p53 oncogene and patients with germ-line mutations of BRCA1 and 
BRCA2 typically develop tumors that are basal in nature [10].   
Basal tumors most strongly resemble the triple-negative tumors identified by clinical 
subtyping, in fact, ~80% of basal tumors are triple-negative [10, 15].  Accordingly, patients with 
these tumors also have poor prognoses.  One study showed that the risk of death due to breast 
cancer was 6-8 times greater for basal tumors than luminal A tumors in the first 5 years after 
diagnosis [43].  The same study showed that the risk of relapse is significantly greater for 
patients with basal tumors than those with luminal A tumors.   Basal tumors express high levels 
of proliferation markers and are quite aggressive [10].  At the time of diagnosis, these tumors are 
more likely to have larger tumor volumes, lymph node involvement and higher histologic grade, 
or less cellular differentiation [10].  The current treatment recommendations are surgery and 
chemotherapy [15].  These tumors respond better to chemotherapy than the luminal tumors, in 
fact, basal tumors show the best response to chemotherapy of all subtypes [10, 28].  However, 
like TNBCs, these tumors have a high rate of relapse in the first 5 years [10, 42].  The lack of 
any therapies beyond conventional chemotherapy presents a real challenge to the treatment of 
these patients and there is a strong need to develop more targeted therapies for basal tumors. 
 Claudin-low Tumors 
Claudin-low tumors represent ~10% of all breast cancers [10].  This subtype was 
identified more recently [29] and it cannot be recognized using the common PAM50 test [28].  
Claudin-low tumors cluster near the basal subtype, because both subtypes express low levels of 
luminal genes and HER2-related genes [10, 28, 29].  Similar to basal tumors, claudin-low tumors 
are usually triple negative [42].  As the name suggests, these tumors have strongly down-
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regulated genes involved in cell-cell contacts, like the claudins, occludin and E-cadherin [10, 
28].  Furthermore, these tumors have high expression of immune response genes, which may be 
accounted for by the high level of lymphoid infiltration [28].  Claudin-low tumors are also very 
undifferentiated and therefore express many genes associated with mammary stem cells [28, 55].  
These tumors have been shown to express both markers of epithelial cells, like the breast tissue 
in which they originate, and markers of mesenchymal cells [28].  The percentage of cells that are 
positive for both sets of markers is significantly higher in claudin-low tumors than in luminal 
subtypes.   
Patients with claudin-low tumors have poor prognoses compared to luminal A tumors and 
comparable to patients with basal, luminal B or HER2-enriched tumors [42].  Interestingly, 
claudin-low tumors express lower amounts of proliferation genes than basal, HER2-enriched and 
luminal B tumors [28].  Claudin-low tumors are moderately responsive to chemotherapy, but the 
response rate is lower than for basal tumors, 39% versus 73%, presumably because many 
cytotoxic agents target replicating cells [28, 42].  Interestingly, analysis of other subtypes of 
tumors prior to therapy and the residual tumors after treatment with hormone or chemotherapy 
has shown that claudin-low features are increased during treatment [56].   There is less clinical 
information for this subtype, as it is new, rarer, and is usually mis-diagnosed as basal by the 
PAM50 test or the use of surrogate immunohistochemical tests.  However, there is interest in 
studying claudin-low tumors because these tumors are particularly enriched in breast tumor 
initiating cells (BTICs) [56].  BTICs are proposed to be responsible for resistance to therapy and 
breast tumor recurrence [57].   
 The ADAM Metalloproteases 
A Disintegin And Metalloproteases (ADAMs) are multi-domain proteins that are widely 
observed in eukaryotic organisms [58].  Canonical ADAMs contain a signal sequence, pro-
domain, metalloprotease domain, disintegrin domain, cysteine-rich region, EGF-like motif, a 
transmembrane helix, and a cytoplasmic domain (Figure 1.1).  The pro-domain exerts an 
autoinhibitory effect over the catalytic metalloprotease domain [59, 60].  The metalloprotease 
domain of ADAMs can be either active or inactive and this is determined by the presence of the 
HEXGHXXGXXHD motif, in which the histidine residues coordinate a zinc ion and the 
glutamate is the catalytic residue [59].  The disintegrin and cysteine-rich domains are involved in 
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protein-protein interactions with substrate molecules and in cell adhesion [59, 61].  The role of 
the EGF-like region is less clear and it may be involved in oligomerization of ADAMs [62].  The 
cytoplasmic domains of ADAMs contain interaction motifs for several cellular proteins. These 
interactions have been shown to activate signaling pathways, especially through activation of 
Src, and even affect localization of the ADAM itself [63–68]. 
Since ADAMs are integral membrane proteins, they are synthesized and trafficked via 
the cellular secretory pathway.  The signal sequence is removed in the endoplasmic reticulum 
and the protein is folded and glycosylated in this compartment before being trafficked to the 
Golgi apparatus [58, 69].  Once inside the Golgi, the pro-domain is proteolytically cleaved by 
pro-protein convertases, like furin or similar enzymes, at the R-X-K/R-R consensus site between 
the pro-domain and metalloprotease domain [58, 60, 69].  Additionally, in the Golgi apparatus 
the polysaccharides are modified to their mature form [70].  From the Golgi, the mature, active 
ADAM is trafficked to the cell surface. 
 Patterns of Expression of ADAMs 
In vertebrates, ADAMs show variable patterns of expression and a number of ADAMs 
are expressed only in select tissues.  A large number of ADAMs are expressed exclusively in the 
testes andothers are found predominantly in hematopoetic cells and tissues.  However, the 
majority of ADAMs are expressed in a more global manner.  The categorization of the 20 human 
ADAMs can be seen in Figure 1.2.  The expression pattern of each ADAM provides a clue 
toward the specific biological role(s) for each metalloprotease. 
 Testis-specific ADAMs 
 The first two members of the ADAM family, fertilin α and fertilin β (later re-named 
ADAM1 and ADAM2), were identified from guinea pig testes and were shown to be essential in 
sperm-egg interaction [71].  Interestingly, although the ADAM family is highly conserved in 
mammals, the major differences observed between the mouse and human genomes is in the 
presence and copy number of testis-specific ADAMs [72].  One half of all murine ADAMs and 
one third of all human ADAMs are testis-specific [58, 72].   Human ADAM2, ADAM18, 
ADAM20, ADAM21, ADAM29, and ADAM30 are expressed in spermatogenic cells and/or 
mature sperm cells while ADAM7 is expressed in the epididymus and on mature sperm cells 
[72].  Not all of the testis-specific ADAMs are proteolytically active, only ADAM20, ADAM21, 
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and ADAM30 contain the HEXGHXXGXXHD motif while ADAM2, ADAM7, ADAM18, and 
ADAM29 do not have this motif and are therefore catalytically inactive [58].  Thus far, the best 
evidence for the function of testicular ADAMs has come from knockout mice studies, which 
have shown that expression of these ADAMs is required for male fertility [58, 72, 73].  The 
sperm of knockout mice exhibit problems with egg adhesion and/or migration into the oviduct, 
resulting in male infertility [58, 72].  The ADAMs on the surface of the sperm cells have been 
shown to form heterodimers and heterotrimers that are involved in protein stabilization, cleavage 
of the extracellular matrix surrounding the egg, and interaction with integrins on the surface of 
the ovum [72].  However, less is known about the exact physiological roles for the individual 
human testicular ADAMs due to the poor evolutionary conservation of this subgroup of 
ADAMs.   
 Hematopoetic ADAMs 
This is a small subgroup of ADAMs, comprised only of ADAM8 and ADAM28, both of 
which are catalytically active metalloproteases [58].  Interestingly, ADAM8 and ADAM28  are 
the only two ADAMs capable of auto-activation, meaning that their own metalloprotease activity 
is responsible for cleavage of the pro-domain and they do not require pro-protein convertases 
[74, 75].  The expression of ADAM8 occurs primarily in myeloid and lymphoid cells of the 
blood and bone marrow and other lymphatic tissues, but it is also observed in osteoclasts and 
cells of the central nervous system [76, 77].  ADAM8 is thought to be involved in inflammatory 
processes due to its transcriptional induction by multiple inflammatory stimuli such as 
lipopolysaccharide, tumor necrosis factor α, interferon γ, and certain prostaglandins [78].  
ADAM8 is also up-regulated in asthma, Parkinson’s Disease, rheumatoid arthritis and cancers of 
the brain, lung, pancreas, prostate, and breast [79–82], indicating roles in numerous disease 
processes.  However, the knockout mouse revealed that the presence of ADAM8 is not necessary 
for normal murine growth and development [83].   
Human ADAM28 protein is found primarily in lymphocytes, monocytes, and neutraphils 
but it is also expressed in the lymph nodes, intestines, spleen, and the epididymus [73, 84, 85].  
In rodents, the epididymal expression is much higher than expression in other tissues and for this 
reason, ADAM28 is often included in the testicular ADAM subgroup.  However, unlike the other 
testicular ADAMs, the expression of ADAM28 is not restricted to the testes.  ADAM28 was 
12 
shown to be highly expressed in lymphocytes and is thought to mediate lymphocyte-leukocyte 
interactions through its interaction with the α4β1-integrin heterodimer [86, 87]. 
 Globally Expressed ADAMs 
The globally expressed group of ADAMs is the largest and most diverse group.  It 
includes most of the catalytically active ADAMs: ADAM9, ADAM10, ADAM12, ADAM15, 
ADAM17, ADAM19, and ADAM33.  It also includes ADAM11, ADAM22, ADAM23, and 
ADAM32, which are all catalytically inactive.  The two most heavily studied ADAMs, 
ADAM10 and ADAM17, belong to this group.   
Both ADAM10 and ADAM17 are globally expressed and are critically important in 
development, as evidenced by embryonic lethality of the knockout mice [88, 89].  ADAM10 is 
expressed in a variety of tissues including bone, brain, and hematological cells [58, 90].  The 
knockout mouse model exhibited early lethality due to severe defects in cardiovascular 
development [88].  ADAM10 is very widely studied due to the large number of known substrates 
and the importance of these substrates in pathologies.  For example, a substantial amount of data 
supports a role for ADAM10 in prevention of amyloid β formation and Alzheimer’s Disease 
[91].  ADAM17 is widely expressed and its pattern of expression varies from fetal development 
to the adult organism [92].  In adults, it is expressed in cardiac and skeletal muscles as well as 
pancreas, spleen, small intestine, ovaries, testes, and prostate; however, in fetal development, 
ADAM17 is predominantly expressed in the brain, lungs, liver and kidneys.  ADAM17 is best 
known for cleaving tumor necrosis factor α (TNFα), and is often called TNFα converting 
enzyme, or TACE, instead of the ADAM nomenclature.  Similar to ADAM10, ADAM17 is very 
heavily studied and has a large list of known substrates.  As an interesting note, the embryonic 
lethality observed in early mouse studies was a result of metalloprotease deletion by mutating the 
zinc binding sites, indicating that the major functions of ADAM17 are due to its metalloprotease 
activity [89]. 
ADAM9 and ADAM12 are both predominantly expressed in adult stem cells, 
mesenchymal stem cells, and placental tissues [58].  ADAM9 knockout mice exhibited no major 
defects in growth and development [93], whereas ADAM12 knockout mice exhibited 30%  
embryonic lethality and some brown fat abnormalities [58].  ADAM15 and ADAM19 are 
expressed rather widely, but they also show strong expression in mesenchymal stem cells.  
ADAM15 knockout mice exhibited no gross differences from their wild type littermates in 
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behavior, growth, and development [94].  However, despite normal vascular development, the 
knockout mice showed decreased ability to form vascular systems in models of retinal pathology 
and tumor development, suggesting a possible role for ADAM15 in pathology-specific 
angiogenesis.  ADAM19 knockout mice exhibited a strong perinatal lethality due to 
cardiovascular defects [58, 95]   All four of these ADAMs have been implicated in disease 
processes, particularly in cancers of the brain, breast, lung, stomach, and kidney [96]. 
ADAM33 is strongly expressed in the urinary, respiratory, gastrointestinal, and endocrine 
systems [58].  However, despite this strong expression in a variety of important tissues, the 
ADAM33 knockout mouse showed no phenotype [58].  Recently, polymorphisms in the 
ADAM33 gene have been shown to be good markers for asthma [97, 98].  The catalytically 
inactive ADAM, ADAM11, is primarily expressed in the nervous system, erythrocytes, and the 
liver.  The ADAM11 knockout mice exhibit alterations in pain response and spatial learning [99, 
100].   ADAM22 and ADAM23 are also predominantly expressed in the nervous system.  The 
ADAM22 knockout mouse showed signs of severe ataxia and all mice died due to convulsions 
within the first few weeks of life [101].  ADAM11, ADAM22 and ADAM23 have all been 
shown to interact with the neuronal protein leucine-rich glioma-inactivated protein 1, LGI1, 
which is involved in expression of neurotransmitter receptors and in regulating the voltage-gated 
channels in neurons, and the LGI1-ADAM interactions seem to be critical to these activities 
[102].  ADAM32 is highly expressed blood lymphoid cells and little else is known about its role 
in humans or in mice.   
 Activity of the ADAM Metalloproteases 
The expression patterns for each ADAM hinted at possible roles for each protease and 
many of the early studies of ADAMs began by analyzing roles in the area of maximal expression 
or in the areas most affected by gene deletion studies.  More recently, researchers have begun to 
identify novel roles for these proteins in disease conditions due to the abundance of 
transcriptomic data that is publicly available through databases like the Gene Expression 
Omnibus and The Cancer Genome Atlas.   Additionally, proteomic analyses of the degradomes 
of each protease are providing a wealth of information about the potential substrates of the 
catalytically active ADAMs.  It is important to note that due to the multi-domain structure of the 
ADAMs, the activity may be related to protein-protein interactions mediated by the disintegrin, 
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cysteine-rich, EGF-like, or cytoplasmic domains or through proteolytic activity in the cases of 
active metalloproteases, or some combination of the two.  Here, I will focus on the proteolytic 
functions of the ADAMs. 
 Shedding Membrane Proteins 
Much of the known information about the function of ADAMs relates to their activity as 
sheddases.  A sheddase is a protein responsible for cleaving membrane proteins near the 
membrane bilayer to “shed” an ectodomain into the surrounding space [69].  These shed proteins 
may be transmembrane precursors to soluble growth factors, membrane-anchored ligands, or 
membrane receptors.  The ultimate effect of shedding is the activation or deactivation of the 
signaling pathway downstream of the ADAM activity.  ADAMs, in particular, have been linked 
to shedding molecules involved in the EGFR, TNFα, and Notch signaling pathways. 
 Notch Signaling 
The Notch signaling pathway is an evolutionarily conserved pathway that is critically 
important in regulating cell proliferation, differentiation and death [103, 104].  Notch ligands are 
integral membrane proteins that interact in a trans manner with Notch receptors on a neighboring 
cell (Figure 1.3B).  In response to this interaction, the Notch receptor is cleaved near the 
membrane by ADAM10.  After this cleavage event, γ-secretase cleaves the receptor at an 
intramembrane site, thereby releasing the intracellular domain into the cytosol.  This domain 
translocates to the nucleus where it acts as a transcription factor [103–105].    ADAM10 is 
critical to the activation of the Notch pathway, and Notch signaling is necessary for stem cell 
maintenance as well as normal organismal growth and development.  Consistently, the loss of 
Notch receptors in mice phenocopies the ADAM10 knockout indicating that the most important 
role for ADAM10 in fetal development is related to Notch activation [58].  Alternatively, 
ADAM17 has also been shown to be capable of cleaving the Notch receptors [106].  The 
difference between the phenotypes of the knockout mice suggests that ADAM10 and not 
ADAM17 is the primary protease responsible for Notch activation during embryonic 
development.  However, ADAM17 cleavage of Notch may be specific to certain cell types, 
developmental stages or even disease processes [91].  In addition to cleavage of the Notch 
receptors, the ligands themselves are cleaved as well, and ligand cleavage inhibits Notch 
signaling.   Several ADAMs have been shown to cleave the ligand Delta-like 1 (DLL1), 
15 
including ADAM9, ADAM10, ADAM12 and ADAM17.  Due to the requirement for proteolysis 
in Notch activation, the ADAMs are critically important in the propagation of signals through the 
Notch pathway. 
 EGFR Signaling 
The ADAMs are also vital to signaling through the EGFR pathway.  As previously 
mentioned, the EGFR pathway involves four receptor tyrosine kinases, EGFR/HER1, HER2, 
HER3 and HER4 and a number of ligands.  HER2 is constitutively active and has no known 
ligand-binding ability, whereas EGFR, HER3 and HER4 all bind EGF-like ligands.  However, 
HER3 is kinase-defective and must be phosphorylated by dimerization with another HER family 
receptor.  HER4 seems to be unique among the HER family of receptors in that activated HER4 
has been shown to reduce cell proliferation and promote apoptosis in breast cancer cells [107].   
Therefore, in breast cancer studies, EGFR and HER2 are the receptors that most critically 
mediate EGFR signaling and the downstream pro-growth signals.   
There are eleven EGFR ligands; amphiregulin, epiregulin, epigen, betacellulin, EGF, 
heparin-binding EGF, transforming growth factor α, and neureglins 1-4 [17].  Each of these 
ligands is synthesized as membrane-anchored precursor and must be shed by an ADAM in order 
to be functional (Figure 1.3A).  A large number of ADAMs have been shown to cleave the EGF 
ligands and a degree of redundancy exists, with the same ligand being cleaved by multiple 
ADAMs [17, 108].  Cleavage of EGF ligands can be performed by ADAM9, ADAM10, 
ADAM12, ADAM15, ADAM17, or ADAM19 [17].  Each ADAM shows some selectivity and 
will only shed a subset of EGF ligands [109].  Once the ligand is cleaved, the soluble ectodomain 
is free to interact with the ligand-dependent members of the HER family of receptors and initiate 
pro-survival signals within the receiving cell. 
 TNFα Signaling 
Similar to EGF ligands, TNFα is synthesized as a transmembrane precurser and must be 
activated by being released from the cell surface [58].  TNFα is a pro-inflammatory cytokine that 
can induce cell survival and expression of other pro-inflammatory signals or induce apoptosis in 
the receiving cell [110].  TNFα shedding is predominantly mediated by ADAM17 and this 
ADAM is central to regulating inflammation through its role in TNFα activation.  As a result, 
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ADAM17 is being investigated as a possible therapeutic in a number of inflammatory diseases 
[111]. 
 Other Proteolytic Activities 
In addition to shedding members of the aforementioned signaling pathways, ADAMs are 
known to cleave a number of adhesion and cell-cell interacting proteins like L-selectin, N-
cadherin, E-cadherin, VE-cadherin, L1 cell adhesion molecule (L1-CAM), V-CAM-1, and N-
CAM [58, 111].  These cleavage activities reduce cell-cell contacts and have been hypothesized 
to play vital roles in cancer metastasis [112].  In addition to decreasing cell-cell interactions, 
cleavage of E-cadherin stimulates proliferation in some cancer cells [113].  Furthermore, the 
cleavage of cell-cell contact proteins specific to endothelial cells enables migratory cells to enter 
or exit a blood vessel, which are required steps in tumor metastasis [112].     
 Regulation of the Catalytic Activity 
The proteolytic activity of ADAMs is responsible for activating numerous signaling 
pathways, so it follows that the activity of the metalloprotease domain is regulated.  The primary 
method of protease activity regulation is via interactions with the pro-domain.  The pro-domain 
blocks the active site through a “cysteine switch” mechanism, where a conserved cysteine 
residue in the pro-domain interacts with the zinc ion bound to the metalloprotease domain and as 
a result, excludes water from the active site [60].  In this state, the metalloprotease is inactive.  
Upon removal of the pro-domain, the active site is open and functional.  Pro-domain removal 
occurs in the Golgi apparatus and the ADAM is considered active once this has occurred.   
ADAM activity can also be modulated through interactions with a small class of proteins known 
as the tissue inhibitors of metalloproteases, TIMPs [58].  There are four TIMPs in the human 
genome, TIMP1-4.  These inhibitors have been shown to inhibit the activity of many, but not all, 
ADAMs, with TIMP3 showing the broadest range of the inhibitory activity [58, 96].  The TIMPs 
bind non-covalently in a 1:1 stoichiometry to the ADAM protease [96].   Finally, re-localization 
of the ADAM itself is an efficient method of modulating its activity [108].  For example, 
ADAM17 is often located in vesicles or in the Golgi apparatus until a signaling event (in this 
case, activation of protein kinase C) induces its transport to the cell surface.  Similarly, 
ADAM10 is re-localized to the surface in response to calcium ion influx [96, 108]. 
17 
 The ADAMs in Breast Cancer 
Many of the activities of ADAM proteases involve activating pro-survival or pro-growth 
signaling pathways, which are important for normal growth and development.  However, 
aberrant activation of these same pathways can prove beneficial to cancer cells.  Many of the 
pathways discussed here are being actively studied as potential targets for anti-tumor therapies.  
Consistently, many ADAMs are up-regulated in tumors when compared to normal tissues.  
Analysis of ADAM expression across the molecular subtypes of breast cancer revealed that 
ADAMs are most highly expressed in claudin-low tumors compared to the other molecular 
subtypes (Figure 1.4), and may therefore represent effective druggable targets in the treatment of 
these therapy-resistant tumors.  ADAM8, ADAM12, ADAM15 and ADAM17 have been shown 
to be involved in breast tumor growth and progression [82, 114–120].   
 ADAM8 
ADAM8 was previously demonstrated to have a role in both brain and lung cancers and 
its level of expression was indicative of overall survival [121, 122].  Recently, a new study 
revealed strong up-regulation of ADAM8 in breast carcinomas and a poorer prognosis for 
patients with high ADAM8 expression [82].  Knockdown of ADAM8 inhibited cell migration 
and invasion in vitro and prevented tumor growth in an orthotopic xenograft model.  
Additionally, mice implanted with ADAM8-depleted cells exhibited fewer metastatic lesions and 
fewer circulating tumor cells, consistent with the in vitro decrease in cell invasion and migration.  
Mechanistically, ADAM8 is up-regulated by the hypoxic conditions in early tumor development 
and functions to ameliorate the low oxygen environment by inducing neovascularization.  
ADAM8 knockdown cells shed fewer pro-angiogenic factors into the cell culture media and 
produced fewer tumors with decreased blood vessel density upon transplantation.  Additionally, 
these cells had a decreased ability to adhere to endothelial cells and transmigrate through the 
endothelial layer, which supports the observation of reduced metastasis of tumors formed by 
these cells.  An antibody raised against the ADAM8 metalloprotease and disintegrin domains 
mimicked the effect of ADAM8 knockout, causing reduced tumor volume, decreased 
vascularization and less metastasis in mice.  This report provides strong evidence of a pro-
tumorigenic role for ADAM8 in breast cancer and suggests a potential therapy for patients with 
tumors that highly express ADAM8. 
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 ADAM15 
The ADAM15 gene was shown to have a large increase in copy number in breast cancer 
cell lines, with 70% of cell lines having 5 or more copies [116].  ADAM15 was shown to be 
overexpressed at the mRNA and protein levels in breast tumors and related to increased angio-
invasion into the tumor [115].  ADAM15 was also shown to activate non-canonical EGFR 
signaling via shedding of E-cadherin [123].  The shed E-cadherin ectodomain interacts with a 
HER2-HER3 heterodimer and leads to receptor activation and increased proliferation and cell 
migration.   
The region of the ADAM15 mRNA that encodes the cytoplasmic tail is extensively 
alternatively spliced [116, 124].  The novel splice variants were initially discovered in breast 
cancer cells, yet, they were later shown to be the result of normal splicing events and are also 
present in non-cancerous tissues.  However, two of these variants, ADAM15B and ADAM15C, 
are up-regulated specifically in breast tumors and ADAM15B is associated with poor prognosis in 
patients with lymph node-negative disease [125].  The ADAM15B isoform contains an inserted 
Src binding site in the cytoplasmic domain [125].  ADAM15 also sheds fibroblast growth factor 
receptor 2 (FGFR2) and this activity may be involved in breast cancer development.  ADAM15B 
sheds FGFR2 more efficiently than other ADAM15 isoforms and in a Src-dependent manner 
[126].  Thus, ADAM15 has been shown to promote breast tumor progression through multiple 
mechanisms and may represent a potential druggable target.  
 ADAM17 
ADAM17 is overexpressed in many breast tumors [114, 120, 127, 128] and, consistent 
with its critical roles in a number of key pro-survival, pro-growth signaling pathways, aberrant 
expression of ADAM17 has been linked to tumors with poorer prognoses [129].  Overexpression 
of ADAM17 increased cell proliferation and invasion in cell based assays, while in tumors, 
ADAM17 expression correlates with expression of the proliferating cell nuclear antigen (PCNA), 
a proliferation marker, and the serine protease uPA which has been implicated in cancer 
metastasis [128].  Another study demonstrated that invasive breast cancer cells showed increased 
EGFR signaling when compared to pre-invasive cells and that this is due to transcriptional up-
regulation of the ligands amphiregulin and TGFα and increased shedding of these EGFR ligands 
[114].  Non-specific metalloprotease inhibitors reverted the more aggressive cells to a less 
aggressive phenotype with respect to proliferation and invasive capabilities.  ADAM17 was 
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shown to be the primary protease responsible for EGFR ligand shedding.  In patients, expression 
of ADAM17 and TGFα were significantly correlated to each other and both were associated with 
poor prognosis.  Another study further investigated the downstream modulators of this EGFR 
signaling and found that inhibition of the PI3K/Akt pathways also abolished the deleterious 
effects of ADAM17 overexpression [130].  Additionally, this study demonstrated that ADAM17 
is capable of inducing expression of pro-angiogenic factors and increased tube formation, an in 
vitro assay for neovascularization.  Anti-ADAM17 antibodies were previously shown to inhibit 
growth of breast cancer cell lines in vitro [127], indicating that targeting ADAM17 may yield 
therapeutic benefit.  However, I will show here that in patients with TNBC, ADAM17 
expression does not correlate with poor prognosis (See Chapter 4).  However, high ADAM12 
expression does significantly associate with poor prognosis, indicating that the identity of the 
ADAM responsible for EGF ligand shedding is dependent upon the tumor subtype. 
 ADAM12 
ADAM12 was shown to be up-regulated in breast tumors and breast cancer cell lines 
[119, 120, 127, 131].  When ADAM12 was overexpressed in the polyoma middle T antigen 
(PyMT) model of breast cancer, the mice formed breast tumors more rapidly than control 
littermates and exhibited more metastatic lesions [131].  Conversely, knocking down ADAM12 
in this mouse model delayed tumor onset and resulted in less proliferative and less metastatic 
tumors [117].  This study also confirmed that ADAM12 expression by the tumor, rather than the 
surrounding stroma, was related to these effects.  Interestingly, the catalytic activity of ADAM12 
was not required for accelerated tumor formation and increased metastasis.  In the PyMT model, 
EGFR phosphorylation was unchanged between control mice, wild-type ADAM12 and inactive 
ADAM12 overexpressing mice.  However, in vitro studies have shown dramatic differences in 
EGFR activation and cellular migration in response to ADAM12 overexpression that are 
dependent upon the ADAM12 proteolytic activity [132].  The PyMT model produces luminal 
tumors whereas the in vitro studies utilized basal cell lines and therefore, shedding of EGFR 
ligands by ADAM12 may be specific to the basal subtype.  In patients, ADAM12 is somatically 
mutated more frequently than any other ADAM gene and it is the only ADAM identified as a 
candidate cancer gene by a global analysis [132–134].  Deactivating mutations in the ADAM12 
gene appear to be excluded from triple negative breast cancers, which rely upon EGFR signaling.  
Although this finding appears to contrast with the data from the mouse model [132], I show here 
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that, in triple negative breast cancer patients, ADAM12 expression is correlated with activated 
EGFR and high ADAM12 expression is associated with increased risk of relapse in patients with 
early stage tumors [135].  The apparent discrepancy between patient data and the PyMT mouse 
model is eliminated when the molecular subtype of the tumor is considered.  ADAM12 
overexpression has also been shown to promote orthotopic growth of poorly tumorigenic cell 
lines and induce greater degrees of metastasis [119].  Additionally, ADAM12 has been 
demonstrated to confer estrogen-independence to HoR+ cells through activation of the EGFR 
pathway [136], which is consistent with the observation that expression of ADAM12 is increased 
in residual tumors after estrogen-targeted therapy [118].  An abundance of clinical and pre-
clinical data suggest that ADAM12 is an important modulator of tumor growth and progression 
and that ADAM12 represents a promising potential target in the treatment of breast cancer. 
 The Major Isoforms of ADAM12 
ADAM12 is one of the small number of ADAMs that is alternatively spliced and 
produces more than one major protein isoform.  These different isoforms have distinct points of 
regulation at the mRNA and protein level, unique cellular localizations and, therefore, varying 
substrates and biological roles. 
 Alternative Splicing of the ADAM12 Transcript 
In humans, ADAM12 exists as two major splice variants, ADAM12-var1 and ADAM12-
var2 [137].  The ADAM12-var1 variant contains exons 1-18 and 20-24, while ADAM12-var2 
contains exons 1-19 (Figure  1.5a).  This splicing results in variants with two very different 3’ 
untranslated regions (3’UTRs).  The ADAM12-var1 3’UTR is approximately 5 kb long while the 
ADAM12-var2 3’UTR is only around 800 nucleotides in length.  Due to these large variable 
regions, the two splice variants are easily distinguished in molecular assays such as Northern 
blots, PCR, and microarrays.  It is currently unknown what factors regulate this splicing event 
and if the relative levels of ADAM12-var1 and ADAM12-var2 are altered due to cellular signals 
or during certain diseases or pathogenic processes.   
In addition to the major splicing event that results in generating ADAM12-var1 and 
ADAM12-var2, there is a previously uncharacterized alternative splicing site near exon 4 that 
will be described here [138].  This alternative splice site involves the inclusion of a nine 
nucleotide extension at the end of exon 4.  Exon 4 is therefore designated as having two forms, 
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exon 4a and exon 4b, and the transcripts containing these exons are denoted ADAM12-
var1a/ADAM12-var2a and ADAM12-var1b/ADAM12-var2b, respectively.  The four variants 
resulting from this splicing event currently cannot be differentiated by qRT-PCR or by existing 
microarray platforms.  Here, I show the occurrence of ADAM12-var1b in breast epithelial and 
carcinoma cells and I characterize the phenotypic effect of this insertion on protein localization 
and function (See Chapter 3). 
 ADAM12-L 
ADAM12-L is the protein isoform encoded by ADAM12-var1 and is consistent with the 
canonical ADAM structure (Figure 1.5b).  ADAM12-L is the transmembrane isoform with a 
large cytoplasmic domain; therefore, this isoform is localized to the cell membrane.  Because of 
the membrane localization, the ADAM12-L metalloprotease domain is ideally positioned for the 
juxtamembrane cleavage events that are typically associated with ADAM activities.  ADAM12-
L has been shown to shed the EGFR ligands EGF, heparin-binding EGF, and betacellulin as well 
as a Notch ligand DLL1, Sonic hedgehog protein, the endothelial receptor tyrosine kinases Tie-2 
and Flk-1, and the endothelial cell adhesion proteins VE-cadherin, and VCAM-1 [109, 139–142]. 
Additionally, ADAM12-L contains the large cytosolic domain that has been shown to 
interact with Src tyrosine kinase, integrin-linked kinase (ILK), and α-actinin-1 [66–68].  The 
interaction with α-actinin-1 has been shown to direct ADAM12-L to focal adhesions, where it 
may play a role in cell-cell contacts [67].  The interaction with ILK also recruits ADAM12-L to 
focal adhesions in response to integrin activation [66].  Once localized to focal adhesions, 
ADAM12-L is involved in cell adhesion to the extracellular matrix and in activation of the pro-
survival PI3K/Akt pathway.  The interaction with Src has been shown to activate Src and to 
induce invadopodia formation in cancer cells [68, 143].  Invadopodia are cellular projections that 
are involved in cancer cell invasion into the surrounding tissues, and ADAM12-L-mediated 
shedding of heparin-binding EGF has been shown to further increase invadopodia formation 
[139]. 
 ADAM12-S 
ADAM12-S is a shorter, secreted isoform of ADAM12 which is encoded by the 
ADAM12-var2 variant (Figure 1.5) [137] .  This isoform lacks the transmembrane and 
cytoplasmic domains and includes a 34-residue C-terminal sequence unique to ADAM12-S.  
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This isoform is secreted into the extracellular space and is not in the correct orientation to shed 
molecules from the cell surface.  ADAM12-S has been shown to cleave insulin-like growth 
factor binding proteins 3 and 5 (IGFBP-3 and IGFBP-5) [144].  This cleavage releases insulin-
like growth factor (IGF) and increases its bioavailability, thereby increasing signaling through 
the IGF receptor.   
Elevated levels of ADAM12-S were found in the urine of breast cancer patients and 
higher levels were correlated with more advanced disease [145].  However, this view has been 
challenged recently, when another study indicated that the levels of urinary ADAM12-S are not 
significantly different between control participants and pre-operative cancer patients [146].  
Interestingly, the elevated urinary ADAM12-S levels detected in patients with advanced disease 
may be related to the more radical surgical procedures utilized when treating these patients 
[146]. Despite this contradiction, it has been demonstrated that ADAM12-S expression by the 
cancer cells is important in breast tumor invasion and metastasis [119].  The increased number of 
metastases was reportedly dependent upon the catalytic activity of ADAM12-S and might have 
been related to the ability of this isoform to degrade extracellular matrix components, like type 
IV collagens and fibronectin [145].  Surprisingly, in these studies, overexpression of ADAM12-
L did not show increased invasion or metastasis [119].  The difference between the two isoforms 
may, in fact, be related to the model system used in the referenced study, i.e. HoR+ cancer cells.  
I will show here that high expression of ADAM12-L or ADAM12-S does not affect patient 
prognosis in patients with HoR+ tumors but, in TNBC, ADAM12-L, and not ADAM12-S, is 
associated with poor prognosis (See Chapter 4).   
 Regulation of Expression of ADAM12 
Since ADAM12 has been demonstrated to be involved in the development and metastasis 
of breast tumors, it is important to understand what factors influence its expression.  The 
ADAM12 gene is regulated by a number of signaling pathways that are also implicated in cancer 
development, metastasis, and recurrence.   The ADAM12 mRNA and protein are also subjected 
to regulatory mechanisms that govern the rate of translation and protein turnover.  Additionally, 
the two major splice variants/isoforms are differentially regulated at the mRNA and protein 
levels, which will be more thoroughly investigated in this dissertation. 
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 Induction by Transforming Growth Factor β Signaling 
Transforming growth factor β (TGFβ) is particularly interesting to cancer researchers 
because of its role in a global cellular transdifferentiation program known as epithelial-
mesenchymal transition (EMT).   EMT is a normal developmental process that has been shown 
to also occur in tumors, where it modulates tumor growth and progression.  Cells that undergo 
EMT lose cell-cell contacts and cell polarity, becoming more elongated in appearance, more 
motile and more resistant to apoptosis than the original cell [147].  EMT is clearly observed by 
studying cell morphology and the presence of epithelial or mesenchymal markers.  Epithelial 
markers are often cell-cell contact proteins like ZO-1 and E-cadherin, while mesenchymal 
markers are α-smooth muscle actin, vimentin, and a number of transcription factors, including 
ETS1, ZEB1, ZEB2, Twist, Snail, and Slug, which are drivers of EMT.  Tumor cells that have 
undergone EMT are more migratory, and are, therefore, hypothesized to be more likely to 
metastasize.  This hypothesis is strongly supported by the studies showing that EMT increases 
cell migration in vitro and induces characteristics of tumor-initiating cells [148], and that tumor 
cells circulating in the bloodstream of cancer patients are more mesenchymal [149].   
ADAM12 was demonstrated to be transcriptionally induced in cultured cells by treatment 
with TGFβ.  Initially, this induction was discovered in hepatic stellate cells and analyzed in the 
context of liver carcinomas [150], however, it was also observed in murine fibroblasts, murine 
mammary epithelial cells, and human breast cancer cell lines [151], suggesting that the effect is 
not cell-type specific.  A mechanism involving TGFβ-dependent degradation of the SnoN 
transcriptional repressor was described [151].  However, a site that responds to TGFβ was not 
identified in the mouse [151] or human ADAM12 promoters (my unpublished work).  This could 
mean that the site of regulation is further upstream of the transcription initiation site or is actually 
located in the first intron of the ADAM12 gene.  Another study determined that TGFβ activated 
transcription of  the ADAM12 gene indirectly and demonstrated strong up-regulation of an 
ADAM12 promoter reporter [152].  However, the reporter used in this study lacked a known 
negative regulatory element and the absence of this element may explain the difference observed 
between our work [ref.151 and my unpublished data] and this study where a strong induction of 
the ADAM12 promoter by TGFβ was observed [152].  In addition to being transcriptionally 
induced by TGFβ signaling, ADAM12-L also enhanced TGFβ signaling forming a positive 
feedback loop [153].  ADAM12-L protein stabilized the TGFβ receptor and modulated 
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intracellular localization of the receptor.  Interestingly, this activity was not dependent on the 
proteolytic activity of ADAM12-L and a catalytically inactive mutant was capable of inducing 
the same effects.  Given this positive feedback loop with TGFβ, it follows that ADAM12-L is 
also strongly correlated with features of EMT and tumor-initiating cells [118].       
 Induction by HER2 Signaling 
Recently, ADAM12 expression has been shown to be modulated by HER2 signaling in 
squamous cell carcinomas [154, 155].  Expression of HER2 correlated with ADAM12 
expression in cell lines and overexpression of HER2 resulted in a several fold increases in the 
levels of ADAM12-L and ADAM12-S transcripts [154].  This induction was dependent upon 
HER2 tyrosine kinase activity.  Topical application of a small molecule tyrosine kinase inhibitor 
dramatically reduced the expression levels of ADAM12 compared to control-treated mice.  In the 
proposed model, the HER2 receptor activates PI3K, which is upstream of Akt and mammalian 
target of rapamycin (mTOR), and ultimately this is responsible for the up-regulation of 
ADAM12.  It was not specifically determined whether this up-regulation occurred at the 
transcriptional level, and no promoter analyses or treatments with transcriptional inhibitors were 
performed.  Additionally, ADAM12 and HER2 were shown to form a positive feedback loop, 
where, in a squamous cell carcinoma cell line, overexpression of either isoform of ADAM12 
induced transcriptional up-regulation of HER2 through the action of the ETS1 transcription 
factor [154].  A more complete mechanism, detailing the manner in which ADAM12 might up-
regulate ETS1, has not be determined. 
 Induction by Nuclear Factor κB Signaling 
Nuclear factor κB (NFκB) belongs to a superfamily of evolutionarily conserved 
transcription factors.  These transcription factors activate genes involved in cell survival, 
proliferation, and cytokine production.  Highlighting the importance of NFκB in tumor 
development, constitutive activation of this pathway has been observed in breast cancers [156].  
NFκB signaling has also been linked to ADAM12 expression.  Studies have demonstrated that 
activation of TGFβ and Notch pathways ultimately result in NFκB activation [152, 157], and that 
an active NFκB pathway is critical for induction of ADAM12.  An NFκB responsive element was 
identified in the human ADAM12 promoter and was demonstrated to interact with NFκB 
transcription factors only in the context of cancer cells, whereas non-transformed cells did not 
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exhibit binding of NFκB to the ADAM12 promoter [152].  This study showed that TGFβ 
activates NFκB, which then induces ADAM12 expression in breast cancer cell lines, however, it 
did not rule out direct activation of the ADAM12 promoter by the canonical TGFβ pathway.  For 
example, it was demonstrated that NFκB is important for up-regulation of ADAM12 by TGFβ.  
However, while ADAM12 expression is dramatically induced by TGFβ in MCF10A non-
cancerous cells, NFκB does not bind to the ADAM12 promoter in these cells.  This suggests that, 
in the context of tumor cells, TGFβ may act to activate ADAM12 transcription both directly and 
indirectly through NFκB. 
 Post-transcriptional Regulation 
ADAM12 is also regulated post-transcriptionally.  Regulation at the mRNA level is 
mediated by the action of microRNAs (miRNAs) that interact with the ADAM12 mRNA and 
cause decreased translation or degradation of the mRNA.  miRNAs typically interact with the 
3’UTRs of transcripts and therefore this mechanism allows for differential regulation of the long 
and short variants of ADAM12 mRNA since the 3’UTRs are dissimilar.  Currently, little is 
known about miRNA regulation of the ADAM12 transcripts.  In Chapter 2, I will investigate the 
roles of three miRNA families to selectively regulate ADAM12-L expression in breast cancer 
cells. 
One known mechanism of ADAM12 regulation by miRNAs involves the Notch signaling 
pathway.  ADAM12 is up-regulated by Notch, however, this induction is indirect and does not 
seem to affect the transcription of the ADAM12 gene itself.  Rather, Notch increases ADAM12 
mRNA stability [157].  In murine fibroblast cells, Notch activation was shown to decrease the 
transcription of microRNA-29a (miR-29a), which targets the 3’UTR of murine Adam12 mRNA 
and causes its degradation.  This mechanism requires a functional NFκB pathway, since NFκB 
acts as a repressor inhibiting transcription of miR-29a.  In human cells, miR-29a targets the 
ADAM12-L 3’UTR specifically, causing mRNA degradation.  When Notch is activated, cells 
therefore selectively up-regulate ADAM12-L but not ADAM12-S as its 3’UTR is not targeted by 
miR-29a.  The miRNA-29 family has also been shown to target ADAM12 in trabecular 
meshwork cells [158] and in renal fibrosis [159], however, the stimuli modulating miR-29 levels 
were not related to Notch signaling in these studies.   
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At the protein level, ADAM12 is regulated primarily by turnover and altering protein 
localization.  Mature, cell-surface ADAM12-L protein is internalized rapidly via clathrin-
mediated endocytosis and knockdown of clathrin heavy chain mRNA decreases the amount of 
ADAM12-L internalization [160].  After endocytosis, ADAM12-L co-localizes with markers of 
early and recycling endosomes but not late endosomes that are targeted towards the lysosomes.  
Consistently, the authors observed recycling of ADAM12-L proteins in which internalized 
molecules are re-directed to the cell surface.  A proline-rich region in the cytoplasmic tail of 
ADAM12-L seems to be responsible for the internalization.  This region interacts with the 
adapter protein Grb2 and the ADAM12-L/Grb2 interaction is required for clathrin-mediated 
endocytosis of ADAM12-L.  Interestingly, the proline-rich region in ADAM12-L involved 
interactions with Grb2 is also responsible for binding Src, which has been demonstrated to 
localize ADAM12-L to focal adhesions [143].  A model in which Src and Grb2 compete for the 
same binding site, where Src mediates trafficking of ADAM12-L to the cell surface and 
Grb2/clathrin mediate ADAM12-L internalization, has been proposed [160]. 
 Main Goals of This Study 
Since the major isoforms of ADAM12 are significantly different in terms of membrane 
association and cellular localization and, therefore, may cleave a different group of substrate 
molecules, these isoforms should have unique physiological roles.  In this dissertation, I aimed to 
study the differential regulation of the ADAM12 mRNA variants and the role of each variant in 
breast tumor biology. 
 I sought to investigate the cellular mechanisms for isoform/variant-specific regulation.  I 
focused on miRNA regulation of the ADAM12-L 3’UTR by three miRNA families.  I 
selected the miRNA families that are specific to the claudin-low molecular subtype of 
breast cancer since ADAM12, and particularly ADAM12-L, is strongly up-regulated in 
these tumors (Figure 1.4 and 2.1a,b). 
 I also discovered a novel splice variant of ADAM12 expressed in several breast cancer 
cell lines.  My goal was to express the new variant and characterize the resulting protein 
isoform in terms of proteolytic activation and cellular localization. 
 Finally, I wanted to investigate the effect of each ADAM12 isoform on breast tumor 
progression.  Specifically, I determined a role for ADAM12-L in the biology of triple 
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negative breast cancers.  
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Figure 1.1 Domain organization of the ADAM metalloproteases 
 ADAM domain organization diagram.  SS, signal sequence; Pro, pro-domain; Met, 
metalloprotease; Dis, disintegrin; Cys, cysteine-rich; EGF, EGF-like; TM, transmembrane; Cyto, 
cytoplasmic.  The scissors represent the site of pro-protein convertase cleavage.  In the case of 
active metalloprotease domains, the inhibitory effects of the pro-domain and the TIMPs are 
indicated. 
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Figure 1.2 The human ADAM proteins grouped by site of expression and catalytic activity 
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Figure 1.3 The roles of ADAM-mediated proteolysis in selected cellular signaling pathways 
Schematic diagram illustrating the membrane proximal events in the cellular signaling 
pathways discussed in this dissertation and the roles for ADAM activity within these pathways.  
The scissors represent a catalytically active ADAM.  The red objects represent transmembrane 
proforms of soluble growth factors or cytokines, such as members of the EGF family or TNFα.  
The green objects represent the membrane receptors for these growth factors.  ADAM cleavage 
of the growth factor or cytokine proform sheds a soluble molecule.  The released factor interacts 
with its receptor to activate cellular signaling either in the same cell or a nearby cell.  The purple 
object represents a membrane-bound ligand, such as DLL-1, while the blue object represents the 
receptor for membrane-bound ligands, such as the Notch receptors.  ADAM cleavage of the 
Notch receptor is required for pathway activation in the cell that expresses the receptor; however, 
ADAM cleavage of the ligand inhibits Notch signaling in neighboring cells since ligand 
availability is reduced. 
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Figure 1.4 Expression of ADAM proteases across the molecular subtypes of breast cancer 
 The majority of ADAMs are most strongly expressed in tumors of the claudin-low molecular 
subtype.  Raw RNA-Seq expression values for all human ADAMs were downloaded from The Cancer 
Genome Atlas Breast Invasive Carcinoma provisional dataset via the cBioPortal for Cancer Genomics 
(n=507 complete records at the time of analysis).  ADAMs with mean expression values <10 were 
eliminated, which included all the testes-specific ADAMs and ADAM11.  The remaining values were 
log2-transformed and an average value for each molecular subtype was calculated.  The values were 
mean-centered and then used to generate a heat map. Each square represents the relative abundance of 
the transcript, with red squares indicating that expression is greater than the mean value for all subtypes 
and green squares indicating expression lower than the mean value. 
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Figure 1.5 The major splice variants and protein isoforms of human ADAM12 
(A)  Schematic diagram of the exons included in the four splice variants of human 
ADAM12.  The 9-nucleotide extension that is unique to exon 4b is shown in lavender.  Exons are 
not drawn to scale.  This panel was reproduced from the following journal article:  Duhachek-
Muggy, S., Li, H., Qi, Y., and Zolkiewska, A. (2013).  PLoS ONE 8(10):e75730 (See Chapter 3).  
(B)  Cartoon diagram of the two major ADAM12 protein isoforms in their activated states after 
pro-domain removal.  The ADAM12-L and ADAM12-S isoforms both contain the 
metalloprotease, disintegrin, cysteine-rich, and EGF-like domains.  In the transmembrane 
isoform, ADAM12-L, the EGF-like domain is followed by a transmembrane helix and the 
cytoplasmic tail.  In the secreted isoform, ADAM12-S, the EGF-like domain is followed by a 
unique 34-residue C-terminus. 
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Chapter 2 - ADAM12-L is a direct target of the miR-29 and miR-
200 families in breast cancer 
This chapter has been submitted for publication as a journal article: 
Duhachek-Muggy, S and Zolkiewska, A. 
ADAM12-L is a direct target of the miR-29 and miR-200 families in breast cancer. 
 Abstract 
Background ADAM12-L and ADAM12-S represent two major splice variants of human 
metalloproteinase-disintegrin 12 (ADAM12) mRNA, which differ in their 3’-untranslated regions 
(3’UTRs).  ADAM12-L, but not ADAM12-S, has prognostic and chemopredictive values in breast 
cancer.  The expression levels of the two ADAM12 splice variants in clinical samples are highly 
discordant, suggesting post-transcriptional regulation of the ADAM12 gene.  The miR-29, miR-
30, and miR-200 families have potential target sites in the ADAM12-L 3’UTR and thus they may 
negatively regulate ADAM12-L expression. 
Methods miR-29b/c, miR-30b/d, and miR-200b/c mimics or control miRNA mimic were 
transfected into SUM159PT and SUM1315MO2 breast cancer cells.  The levels of ADAM12-L 
protein in transfected cells were measured by Western blotting. ADAM12-L and ADAM12-S 
mRNA levels were measured by qRT-PCR.  Direct targeting of the ADAM12-L 3’UTR by 
miRNA-29b/c, miR-30b/d, and miR-200b/c was tested by using a luciferase reporter vector 
containing the wild-type or mutated ADAM12-L 3’UTR.  Indirect effect of miR-29b/c, miR-
30b/d, and miR-200b/c on transcription of the ADAM12 gene was investigated by using an 
ADAM12 promoter reporter construct.  Possible correlations between ADAM12, miR-29b/c, 
miR-30b/d, and miR-200b/c were examined for 284 breast tumors from The Cancer Genome 
Atlas (TCGA) database. 
Results Transfection of miR-29b/c and miR-200b/c mimics strongly decreased the level 
of ADAM12-L protein, while miR-30b/d mimics had a more modest, although noticeable, effect.  
miR-29b/c and miR-200b/c significantly decreased ADAM12-L mRNA levels, whereas 
ADAM12-S levels were not changed.  miR-29b/c and miR-200b/c also significantly diminished 
the activity of an ADAM12-L 3’UTR reporter, and this effect was abolished when miR-29b/c and 
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miR-200b/c target sequences were mutated.  In addition, miR-200b/c significantly decreased the 
activity of the ADAM12 promoter, most likely through down-regulation of transcription factors 
that are essential for expression of the ADAM12 gene.  Furthermore, we found a significant 
negative correlation between all miRNAs tested here and ADAM12 in breast invasive carcinomas 
from the TCGA database.  
Conclusions The ADAM12-L 3’UTR is a direct target of the miR-29 and miR-200 
families.  As miR-29 and miR-200 play important roles in breast cancer progression, these 
results may help explain the different prognostic and chemopredictive values of ADAM12-L and 
ADAM12-S in breast cancer.  
 Background 
 
Deregulated expression and activity of ADAM12 (A Disintegrin And Metalloproteinase 
12) have been frequently observed in human breast cancer [1, 2].  Overexpression of ADAM12 
in the Polyoma virus middle T antigen (PyMT) mouse model of breast cancer accelerates tumor 
progression, and ADAM12 deficiency delays PyMT-induced mammary tumorigenesis [3, 4].  
The human ADAM12 gene is the most frequently somatically mutated ADAM in breast cancer, 
and four missense mutations, D301H, G479E, T596A, and G668A, have a significant impact on 
protein functionality in cancer cells [5-7].  
Human ADAM12 mRNA is alternatively spliced, with several different transcript variants 
giving rise to distinct ADAM12 protein isoforms.  Transcript variant 1 (exons 1-18 and 20-24, ~ 
8,000 nt, RefSeq NM_003474) encodes a long, transmembrane protein isoform ADAM12-L.  
Transcript variant 2 (exons 1-19, ~3,400 nt, RefSeq NM_021641) gives rise to a short, secreted 
protein isoform ADAM12-S [8].  ADAM12-L and ADAM12-S mRNAs contain entirely different 
3’ untranslated regions (3’UTRs) and are readily distinguishable by variant-specific probe-sets in 
several microarray platforms.  Each of these two variants can further exist as an “a” or “b” form, 
which differ by a 9-nt extension at the end of exon 4.  The “a” and “b” variants are not 
distinguishable in microarray profiling experiments [9].  
There is a striking difference in the prognostic value of ADAM12-L and ADAM12-S, and 
the expression levels of these two ADAM12 splice variants in clinical samples are highly 
discordant.  ADAM12-L, but not ADAM12-S, is significantly elevated in the claudin-low 
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molecular subtype of breast cancer, which has features of epithelial-mesenchymal transition 
(EMT), high expression of immune and endothelial genes, and gene expression signature 
reminiscent of mammary stem cells [10-12].  ADAM12-L is also induced during EMT in 
mammary epithelial cells [12-16], is enriched in mammary epithelial cells or breast cancer cells 
grown in suspension as mammospheres [12, 17, 18], is up-regulated in residual tumors remaining 
after endocrine therapy for estrogen receptor (ER)-positive disease [12, 18, 19], and the level of 
ADAM12-L expression predicts resistance to chemotherapy in ER-negative breast tumors [12, 
20-22].  In patients with lymph node-negative breast tumors who did not receive systemic 
treatment, ADAM12-L expression level is significantly associated with decreased distant 
metastasis-free survival times [23-26].  In contrast, ADAM12-S is not related to any of these 
characteristics [12, 26]. 
The discrepancy between expression patterns of ADAM12-L and ADAM12-S in breast 
cancer clinical samples suggests that ADAM12-L expression may be regulated at the post-
transcriptional level, through microRNAs targeting the unique 3’UTR present in this variant.  Of 
particular interest are the miR-200, miR-29, and miR-30 families, which all have been linked to 
the mesenchymal phenotype, invasion, or metastasis in breast cancer [27, 28], and which all have 
predicted target sites in the ADAM12-L 3’UTR, but not in the ADAM12-S 3’UTR.  The miR-200 
family, by forming a double-negative feedback loop with transcription factors of ZEB1 and 
ZEB2, is a key negative regulator of EMT and is down-regulated in breast cancer stem-like cells 
and in normal mammary stem/progenitor cells [28-32].  The miR-29 family, in particular miR-
29b, is enriched in luminal breast cancers and inhibits metastasis by repressing regulators of 
angiogenesis, collagen remodeling, and tumor microenvironment [33].  Loss of miR-29b 
promotes a mesenchymal phenotype and increases metastasis.  Furthermore, the miR-29 family 
members directly target Krüppel-like factor 4 (KLF4), a transcription factor required for the 
maintenance of breast cancer stem cells, and down-regulation of miR-29 family members results 
in increased stem-like properties in vitro and in vivo [34].  The miR-30 family appears to 
modulate the stem-like properties of breast cancer cells as well.  Reduction of miR-30 levels was 
reported to promote self-renewal and to inhibit apoptosis in breast tumor-initiating cells [35].  
Down-regulation of miR-30 family members was observed in non-adherent mammospheres 
compared to breast cancer cells under adherent conditions [36]. 
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In this report, we asked whether ADAM12-L expression in breast cancer cells is 
regulated by members of the miR-200, miR-29, and miR-30 families.  We established that 
transfection of miR-29b/c and miR-200b/c mimics strongly decreased the level of ADAM12-L 
protein in claudin-low SUM159PT and SUM1315MO2 cells, while miR-30b/d mimics had a 
more modest, although noticeable, effect.  Down-regulation of ADAM12-L by miR-29b/c 
occurred at the post-transcriptional level and was mediated through direct targeting of the 
ADAM12-L 3’UTR.  The decrease in ADAM12-L in response to miR-200b/c involved both 
direct targeting of the ADAM12-L 3’UTR and indirect targeting of the ADAM12 promoter, most 
likely through down-regulation of transcription factors that are essential for expression of the 
ADAM12 gene.  Importantly, we found a significant negative correlation between miR-29b/c, 
miR-30b/d, and miR-200b/c and ADAM12 in breast invasive carcinomas, for which gene 
expression profiles are available at The Cancer Genome Atlas (TCGA) database [37].  These 
results underscore a novel post-transcriptional mode of regulation of ADAM12 expression and 
help explain the different prognostic and chemopredictive value of ADAM12-L and ADAM12-S 
in breast cancer. 
 Methods 
 Reagents 
MiRIDIAN microRNA mimics and mimic negative control were obtained from 
Dharmacon.  The ADAM12-L 3’UTR luciferase reporter construct containing nt 3097-6065 from 
the ADAM12-L transcript was obtained from Origene.  The ADAM12 promoter reporter vector, 
containing 2599 nt upstream of the translation start site and the complete 5’UTR cloned into the 
pEZX-PG04 vector, was custom-synthesized by GeneCopoeia.  Anti-ADAM12-L rabbit 
polyclonal antibody (#3394), raised against the cytoplasmic domain of human ADAM12-L, was 
generated in our laboratory, as previously described [26].  This antibody was used for 
immunoblotting at a 1:10,000 dilution, with overnight incubation.  
 Cell culture 
SUM159PT and SUM1315MO2 cell lines were obtained from Asterand (Detroit, MI).  
SUM159PT cells were cultured in Ham’s F-12 medium supplemented with 5% fetal bovine 
serum (FBS), 10 mM HEPES, 5 µg/ml insulin, and 1 µg/ml hydrocortisone.  SUM1315MO2 
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cells were cultured in Ham’s F-12 medium supplemented with 5% FBS, 10 mM HEPES, 10 
ng/ml epidermal growth factor, and 5 µg/ml insulin.  Cells were maintained at 37° C under 
humidified atmosphere containing 5% CO2.  
 Cell transfections 
Cells were seeded onto new plates one day prior to transfection.  MicroRNA mimics 
were resuspended in 1X siRNA buffer (Dharmacon) and transfected at a final concentration of 
50 nM using DharmaFECT 1 transfection reagent (Dharmacon) according to the manufacturer’s 
instructions.  Transfection complexes were removed after 24 hours and cells were analyzed after 
an additional 48-72 hours.  Plasmid transfection was performed using 0.1 µg DNA per well of a 
24-well plate and X-tremeGENE HP transfection reagent (Roche), at a 2:1 reagent:DNA ratio.  
For cells transfected with both miRNA and plasmid DNA, the transfections were performed 
sequentially, with the miRNA mimics introduced first and the plasmid introduced the following 
day. 
 Western blotting 
Cells were treated with lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% Triton 
X-100, 0.5% sodium deoxycholate, 0.1% sodium dodecylsulfate (SDS), 5 mM EDTA, 1 mM 4-
(2-Aminoethyl) benzenesulfonyl fluoride hydrochloride (AEBSF), 5 μg/mL pepstatin, 5 μg/mL 
leupeptin, 5 μg/mL aprotinin, and 10 mM 1,10-phenanthroline).  Extracts were centrifuged for 15 
minutes at 16,000g at 4°C.  After centrifugation, the supernatants were incubated with 
concanavalin A agarose (Sigma; 50 µl resin per 1 ml cell lysate) for 2 hours at 4°C to enrich for 
glycoproteins.  The resin was washed three times and the glycoproteins were eluted with 3X SDS 
gel loading buffer.  Proteins were resolved using SDS-PAGE (8% gel) and were transferred to a 
nitrocellulose membrane.  The membrane was stained with Ponceau S and an image was saved.  
The membrane was blocked using 5% milk and 0.3% Tween-20 in Dulbecco’s Phosphate 
Buffered Saline (DPBS).  Primary antibody was diluted in blocking buffer and incubated with 
the membrane.  Horseradish peroxidase-conjugated anti-rabbit antibody was used as a secondary 
antibody.  Detection was performed using the SuperSignal West Pico Chemiluminescent 
Substrate (Pierce). 
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 3’UTR luciferase reporter assays 
Cells were sequentially transfected with miRNA mimics and the 3’UTR reporter 
plasmids as described above.  A Renilla luciferase vector, pRL-TK (Promega) was co-transfected 
with the reporter plasmid as a transfection control.  Forty eight hours after vector transfection, 
the cells were washed with DPBS containing calcium and magnesium and then lysed using 1X 
Passive Lysis Buffer (Promega), according to the manufacturer’s instructions.  The lysates were 
analyzed for firefly and Renilla luciferase using the Dual Luciferase Reporter Assay System 
(Promega).  
 Mutagenesis 
The predicted miR-29, miR-30, and two miR-200 target sites in the ADAM12 3’UTR 
reporter plasmid were mutated by site-directed mutagenesis.  The primers to mutate the miR-29 
site were: 5’-TGC TGT GCT GTG CTA CTT TGC TCT GTC TAC TTG C-3’ (F) and the 
reverse complement.  The primers to mutate the miR-30 site were: 5’- TAT ACT ATT AAA 
AAG TCC TAC AGA ATT TTA TGG-3’ (F) and the reverse complement.  The primers used to 
mutate the first miR-200 site were: 5’-TTC CCT TAC AAT ATG GAT CTT ATT AAT CCT 
TCC AAG A-3’ (F) and the reverse complement.  The primers used to mutate the second miR-
200 site were: 5’-TTA ATC CTT CCA AGA TGT CTT ATT TAT CAA GTG AAG C-3’ (F) 
and the reverse complement.  The underlined portions represent the mutated bases.  Mutations 
were confirmed by DNA sequencing. 
 Promoter reporter assay 
Cells were sequentially transfected with miRNA mimics and the promoter reporter 
plasmids as described above.  The ADAM12 promoter reporter construct contained a secreted 
Gaussia luciferase coding sequence downstream of the ADAM12 promoter.  The same vector 
encoded secreted alkaline phosphatase (SEAP) driven by the constitutively active CMV 
promoter.  Therefore, SEAP served as an internal transfection control.  The control vector lacked 
the ADAM12 promoter.  Twenty four hours after vector transfection, fresh medium was added 
and collected for analysis 48 hour later.  The medium was centrifuged for 3 minutes at 3,200 rpm 
and the supernatant was analyzed using the Secrete-Pair Dual Luminescence Assay kit 
(GeneCopoeia) according to the manufacturer’s protocol.  
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 cDNA preparation and qRT-PCR analysis  
Total RNA was extracted using the Qiagen RNeasy kit and was subjected to on-column 
digestion with deoxyribonuclease I (Qiagen).  One microgram of the total RNA was reverse-
transcribed using the SuperScript III First Strand Synthesis system (Invitrogen) and oligo(dT) 
primers.  Real time quantitative PCR (qRT-PCR) was performed using 15 µl volumes in a 96-
well format on a CFX96 cycler.  The final reaction mixture contained 7.5 µl iQ SYBRgreen 
Supermix, 6 µl diluted cDNA (1:10 for ADAM12 analysis and 1:100 for ACTIN analysis) and 0.5 
µM primers.  The primers used for ADAM12-L analysis were 5’-AGC CAC ACC AGG ATA 
GAG AC-3’ (F) and 5’-CGC CTT GAG TGA CAC TAC AG-3’ (R).  The primers used for the 
ADAM12-S analysis were 5’-TCC ATC CAA GCA AAC TGA AT-3’ (F) and 5’-GTT GGT 
GAC TCT GTG GGT TC-3’ (R).  The primers used for ACTIN analysis were 5’-TTG CCG 
ACA GGA TGC AGA A-3’ (F) and 5’-GCC GAT CCA CAC GGA GTA CT-3’ (R).  The PCR 
conditions were: 95°C, 10 s; 60°C, 15 s; 72°C, 30 s.  At the conclusion of each run, a melt curve 
analysis was performed to ensure that a single product had been synthesized.  The relative 
expression of ADAM12-L and ADAM12-S, normalized to ACTIN, was calculated using the 2
-ΔΔCt
 
method. 
 Data mining 
ADAM12-L and ADAM12-S expression data for a panel of breast cancer cell lines were 
retrieved from Gene Expression Omnibus (GEO) (http://www.ncbi.nlm.nih.gov/geo/) and 
ArrayExpress (http://www.ebi.ac.uk/arrayexpress/).  Expression data for ADAM12 and miRNAs 
were accessed from The Cancer Genome Atlas [37] via the cBioPortal for Cancer Genomics 
(http://www.cbioportal.org/public-portal/) [38, 39]. The Breast Invasive Carcinoma (TCGA, 
Provisional) database was searched and all cases with reported expression values were included 
in the analyses.  The Z-score data were downloaded and median-centered prior to analysis. 
 Statistics 
Correlation and t test analyses were performed using the GraphPad Prism 6.0 software. 
 Results 
Our previous analysis of a number of gene expression profiles of human breast cancers 
revealed significant discrepancies between ADAM12-L and ADAM12-S expression levels [12].  
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Here, we examined ADAM12-L and ADAM12-S levels in a panel of breast cancer cell lines, 
which were previously profiled using two different microarray platforms: an Agilent 4x44K 
platform (ref. [40], Figure 2.1A) or an Affymetrix HG-U133A platform (ref. [41], Figure 2.1B).  
In both cases, ADAM12-L was strongly up-regulated in claudin-low cell lines, whereas the level 
of ADAM12-S in claudin-low cells did not significantly differ from the rest of the cell lines.  This 
expression pattern of ADAM12-L and ADAM12-S in cell lines mirrored their expression patterns 
in clinical tumor samples [12].  
Selective up-regulation of ADAM12-L in claudin-low samples raised a possibility that 
ADAM12-L expression might be repressed by one or more miRNAs, which are down-regulated 
in claudin-low tumors/cell lines and which could directly target the sites present in the ADAM12-
L 3’UTR.  We focused on the miR-29, miR-30, and miR-200 families, which act as tumor 
suppressors in breast cancer.  The miR-29 family consists of three members with the same seed 
sequence, miR-29a-c.  The miR-30 family is made up of 5 members, miR-30a-e.  The miR-200 
family consists of five members: miR-200a-c, miR-141 and miR-429.  We have selected to study 
two representative miRNAs from each family: miR-29b (a potent inhibitor of breast tumor 
metastasis [33]) and miR-29c (associated with a significantly reduced risk of dying from breast 
cancer [42]), miR-30b and miR-30d (both significantly down-regulated in ER-negative and 
progesterone receptor (PR)-negative breast tumors [43]), and miR-200b and miR-200c (both 
representing key negative regulators of EMT and anoikis resistance [29-31]).  The 3’UTR of 
human ADAM12-L contains well conserved potential target sites for miR-29b/c, miR-30b/d, and 
two poorly conserved potential sites for miR-200b/c (Figure 2.1C).  miRNA profiling of 51 
breast cancer cell lines has previously established that miR-29b/c, miR-30d, and miR-200b/c are 
under-expressed in claudin-low breast cancer cell lines (ref. [44], Figure 2.1D; miR-30b was not 
measured in the referenced study).  
To determine whether low levels of miR-29b/c, miR-30b/d, and miR-200b/c are required 
for high expression of ADAM12-L in claudin-low cell lines, we transfected SUM159PT and 
SUM1315MO2 cells, two representative claudin-low cell lines, with miR-29b/c, miR-30b/d, 
miR-200b/c, or control miRNA mimics, and measured the level of ADAM12-L protein 
expression three days later by immunoblotting.  We observed that miR-29b/c and miR-200b/c 
strongly diminished the level of ADAM12-L protein in both cell lines, whereas miR-30b/d had a 
more modest effect (Figure 2.2).  Testing the effect of miRNAs on the expression level of the 
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ADAM12-S isoform was not possible, because specific antibodies against ADAM12-S are not 
currently available.  In parallel experiments, we examined the effects of miR-29b/c, miR-30b/d, 
and miR-200b/c on the levels of ADAM12-L and ADAM12-S mRNAs by qRT-PCR.  We found 
that miR-29b/c mimics decreased the level of ADAM12-L in SUM159PT and SUM1315MO2 
cells by ~70%, and this effect was statistically significant (Figure 2.3A,B).  miR-200b/c 
diminished ADAM12-L expression by ~20%, and this effect did not reach statistical significance 
in SUM159PT cells, but it was significant in SUM1315MO2 cells.  Finally, miR-30d exerted a 
~30%, statistically significant, down-regulation of ADAM12-L expression in SUM159PT cells 
and no apparent inhibition of ADAM12-L expression in SUM1315MO2 cells.  miR-30b did not 
diminish ADAM12-L levels in either cell line (Figure 2.3A,B).  Importantly, none of the tested 
miRNAs had a significant effect on ADAM12-S expression in SUM159PT or SUM1315MO2 
cells (Figure 2.3C,D). 
Decreased ADAM12-L protein or mRNA levels after transfection of miR-29b/c, miR-
30b/d, or miR-200b/c suggested that these miRNAs might be directly targeting the ADAM12-L 
3’UTR or that they might indirectly target the ADAM12 promoter, through down-regulation of 
transcription factors that are essential for expression of the ADAM12 gene.  The latter possibility 
seemed less likely, because of the lack of the effect of the tested miRNAs on the level of 
ADAM12-S mRNA.  Nevertheless, to directly test whether miR-29b/c, miR30b/d, or miR-200b/c 
regulate ADAM12 expression at the transcriptional level, we transfected SUM159PT cells with 
individual miRNA mimics, followed by transfection with an ADAM12 promoter reporter vector.  
The ADAM12 promoter reporter contained the 2.6 kb region upstream of the transcriptional start 
site in the ADAM12 gene and the entire 5’UTR of ADAM12 (Figure 2.4A), cloned upstream of 
the secreted Gaussia luciferase (GLuc) gene.  The activity of GLuc in the culture medium was 
measured two days after transfection of the reporter, and it was normalized to the secreted 
alkaline phosphatase as the internal control for transfection efficiency.  We observed that the 
activity of the ADAM12 promoter was significantly down-regulated by miR-200b and miR-200c 
(Figure 2.4D).  The other four miRNAs did not exert any effect on the ADAM12 promoter 
(Figure 2.4B,C).  As the miR-200 family directly targets ZEB1/2 [30, 31] and the ETS1 
transcription factor [45], and both ZEB1/2 and ETS1 transcription factors have potential binding 
sites in the ADAM12 promoter (identified with the MatInspector tool of the Genomatix software 
at www.genomatix.de/matinspector.html), we tested the effect of ZEB1 and ETS1 siRNA on 
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ADAM12 expression in SUM159PT cells.  Despite potent down-regulation of ZEB1 and ETS1, 
the level of ADAM12-L protein was not diminished (results not shown), indicating that either 
ZEB1 and ETS1 do not regulate ADAM12 expression or that down-regulation of any these 
transcription factors alone is not sufficient to elicit a noticeable decrease in ADAM12 
expression.  
To examine whether miR-29b/c, miR-30b/d, or miR-200b/c regulate ADAM12-L at the 
post-transcriptional level, we performed a miRNA target reporter luciferase assay using the 
pMirTarget reporter vector comprising a ~3-kb region of the ADAM12-L 3’UTR down-stream of 
the firefly luciferase gene.  An approximately 50-60% reduction in the luciferase activity was 
observed in miR-29b/c, miR-30b, and miR-200b/c mimic-transfected SUM159PT cells 
compared to control mimic-transfected cells (Figure 2.5A).  miR-30d did not produce significant 
decrease in the luciferase activity.  Disruption of the predicted miR-29, miR-30, and miR-200 
target sites by site-directed mutagenesis largely diminished the effects of miR-29b/c (Figure 
2.5B), miR-30b (Figure 2.5C), and miR-200b/c (Figure 2.5D).  
To determine whether miR-29b/c, miR-30b/d, or miR-200b/c might regulate ADAM12 
expression in breast cancer in vivo, we examined the relationship between these miRNAs and 
ADAM12 expression in a cohort of 284 breast cancer patients from The Cancer Genome Atlas 
(TCGA) [37], using the cBioPortal for Cancer Genomics [38, 39].  ADAM12 expression data 
were available as median values from three different mRNA expression platforms (microarrays 
and RNA-Seq) and they contained contributions from both ADAM12-L and ADAM12-S.  Despite 
this fact, there was a significant negative correlation between ADAM12 and each of the six 
miRNAs tested (Figure 2.6).  This result is consistent with a role of the miR-29, miR-30, and 
miR-200 family members in the regulation of ADAM12 expression. 
 Discussion 
In this report, we examined whether three miRNA families, miR-29, miR-30, and miR-
200, directly target the ADAM12-L 3’UTR in human breast cancer cells.  Since the ADAM12-S 
3’UTR lacks predicted target sites for these miRNA families and since miR-29, miR-30, or miR-
200 levels are highly variable in breast cancer, selective targeting of the ADAM12-L 3’UTR by 
these miRNAs might explain why ADAM12-L and ADAM12-S expression patterns in breast 
tumors in vivo and in response to experimental manipulations in vitro often differ significantly.  
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Among the three miRNA families tested, miR-30 elicited the least consistent effects.  
While miR-30b diminished the ADAM12-L 3’UTR reporter activity, the level of ADAM12-L 
mRNA in SUM159PT and SUM1315MO2 cells was not affected upon transfection of miR-30b.  
In contrast, miR-30d seemed to down-regulate ADAM12-L in SUM159PT cells, but this effect 
was not reproduced in SUM1315MO2 cells, and the ADAM12-L 3’UTR reporter activity was not 
diminished in response to miR-30d.  Both miR-30b and miR-30d had only a minor effect on 
ADAM12-L protein levels in SUM159PT and SUM1315MO2 cells.  We conclude that the miR-
30 family does not contribute significantly to the regulation of ADAM12-L expression in the two 
cell lines examined here.   
In contrast, miR-29b/c consistently produced strong down-regulation of ADAM12-L 
expression at the mRNA and protein levels in both SUM159PT and SUM1315MO2 cell lines 
and decreased the ADAM12-L 3’UTR reporter activity.  Mutation of the single miR-29 target site 
in the ADAM12-L 3’UTR blunted the effect of miR-29b/c on the reporter activity, confirming 
direct targeting of the ADAM12-L 3’UTR region by miR-29b/c.  The levels of the ADAM12-S 
splice variant were not changed by miR-29b/c, consistent with the lack of any predicted miR-29 
target sites in the ADAM12-S 3’UTR.  
The miR-29 family was reported previously to target the Adam12 transcript in NIH3T3 
cells [46].  miR-29 has been also implicated in the regulation of Adam12 expression in response 
to transforming growth factor β (TGFβ) in experimental renal fibrosis in mice [47].  Adam12 is 
the only splice variant known to exist in mice and, similar to human ADAM12-L, it contains a 
miR-29 target site.  In humans, ADAM12-L was identified as one of the direct targets of miR-29b 
in trabecular meshwork cells, and increased expression of ADAM12-L in response to oxidative 
stress-induced down-regulation of miR-29b may contribute to the elevation of intra-ocular 
pressure in glaucoma [48].  In the context of breast cancer, miR-29b has been recently identified 
as a part of a GATA3-miR-29b axis, which regulates the tumor microenvironment and inhibits 
metastasis [33].  Down-regulation of miR-29 members also results in increased expression of the 
transcription factor KLF4 and expansion of stem-like cell populations in vitro and in vivo [34].  
The miR-29 family is down-regulated in claudin-low cell lines and tumors, in which ADAM12-L, 
but not ADAM12-S, is strongly elevated.  Thus, increased expression of ADAM12-L in claudin-
low cell lines and tumors could be facilitated, at least in part, by low levels of miR-29 family 
members. 
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The third miRNA family tested here, miR-200, has not been previously reported to 
regulate ADAM12 expression.  We have found that two members of this family, miR-200b and 
miR-200c, strongly diminished ADAM12-L protein in SUM159PT and SUM1315MO2 cells.  
Although the decrease in ADAM12-L mRNA was more modest, it reached statistical significance 
in SUM1315MO2 cells.  The ADAM12-L 3’UTR reporter activity was reduced by miR-200b/c, 
despite the fact that the two predicted miR-200 target sites present in the ADAM12-L 3’UTR are 
not well conserved between species.  Mutations within these two miR-200 target sites abolished 
the effect of transfected miR-200b/c mimics, suggesting direct interaction between miR-200b/c 
and the ADAM12-L 3’UTR.  Similarly to miR-29, the miR-200 family is down-regulated in 
claudin-low tumors and cell lines.  Thus, low expression of miR-200 family members, together 
with low expression of miR-29, may create permissive conditions for high expression of 
ADAM12-L in claudin-low tumors and cell lines.  
Unexpectedly, transfection of miR-200b/c also down-regulated the ADAM12 promoter, 
and the most logical explanation of this result is that miR-200b/c targeted a transcription factor 
(or factors) essential for ADAM12 expression.  We tried to test this possibility by knocking-
down the expression levels of two candidate transcription factors, ZEB1 and ETS1, which both 
have predicted binding sites in the ADAM12 promoter and both are known targets of miR-200b/c 
[30, 31, 45].  However, we did not observe any changes in ADAM12-L protein levels after ZEB1 
or ETS1 knock-down, indicating that either these factors are not involved in transcription of the 
ADAM12 gene, or that their function is highly redundant and a loss of ZEB1 or ETS1 is readily 
compensated by other closely related transcription factors.  The mechanism by which miR-
200b/c down-regulates the ADAM12 promoter is currently not known, and further studies are 
needed to identify transcription factors targeted by miR-200b/c.   
By analyzing gene expression profiles of a panel of breast tumors available at the TCGA 
database and accessed via the cBioPortal, we found significant negative correlations between 
miR-29b/c, miR-30b/d, miR-200b/c, and ADAM12 mRNA.  This finding strongly supports a role 
for miR-29, miR-30, and miR-200 families in the regulation of ADAM12 gene expression.  It 
should be noted, however, that the cBioPortal contains only gene-level data, i.e., data for 
different splice variants of a given gene are merged together.  If miR-29b/c, miR-30b/d, and 
miR-200b/c regulate ADAM12-L at the post-transcriptional level, and ADAM12-S is not 
regulated by these miRNAs post-transcriptionally, then merging the expression data for 
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ADAM12-L and ADAM12-S should make any correlations between miRNAs and ADAM12-L less 
evident.  The fact that despite merging ADAM12-L and ADAM12-S expression data into single 
ADAM12 values, significant negative correlations exist between miRNAs and ADAM12 may 
indicate that a) the actual correlations between miRNAs and ADAM12-L are even higher and/or 
b) ADAM12-L is expressed at much higher levels than ADAM12-S in breast tumors and thus 
contributes more strongly to the merged ADAM12 values.  Since the protein products of 
ADAM12-L and ADAM12-S differ in their biochemical properties, cellular localization, and most 
likely substrate specificity and function, better understanding of the mechanisms controlling 
expression of each splice variant is an important step in the research on ADAM12 in breast 
cancer.  
 Conclusions 
The ADAM12-L 3’UTR is a direct target of the miR-29 and miR-200 families.  As miR-
29 and miR-200 play important roles in breast cancer progression, these results may help explain 
different prognostic and chemopredictive values of ADAM12-L and ADAM12-S in breast cancer. 
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Figure 2.1 Pattern of expression of ADAM12-L, ADAM12-S, and miRNAs in breast cancer 
cell lines 
(A) Discrepancy between ADAM12-L and ADAM12-S levels in a panel of human breast 
cancer cells profiled with the Agilent 4x44K microarray platform, based on ref. [40].  The 
expression data were retrieved from GEO:GSE50470.  Expression values of ADAM12-L were 
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calculated as the average readouts for three probe-sets (A_23_P202327, NM_003474_2_4965, 
and NM_003474_2_4854).  Expression values of ADAM12-S are based on the A_23_P350512 
probe-set.  (B) Discrepancy between ADAM12-L and ADAM12-S expression levels in a panel of 
human breast cancer cells profiled with the Affymetrix HG-U133A platform, based on ref. [41].  
The expression data were retrieved from ArrayExpress, accession number E-TABM-157.  (C) 
Predicted miR-29b/c, miR-30b/d, and miR-200b/c target sites in the human ADAM12-L 3’UTR, 
based on TargetScan Release 6.2.  (D) miR-29b, miR-29c, miR-30d, miR-200b, and miR-200c 
levels in a panel of claudin-low cell lines, based on ref. [44].  Expression data for miR-30b were 
not available.  In (A),(B), and (D), each colored square in the heatmaps represents the relative 
transcript abundance, in log2 space.  Expression values were median-centered across all cell 
lines; in panel (D) only claudin-low cell lines are shown. 
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Figure 2.2 The effect of miRNAs on ADAM12-L protein levels 
SUM159PT cells (A) or SUM1315MO2 cells (B) were transfected with the indicated 
miRNA mimics or mimic control.  Cell lysates were enriched for glycoproteins and analyzed by 
Western blotting using an anti-ADAM12-L antibody.  The arrow indicates the nascent, inactive 
ADAM12-L and the arrowhead indicates the processed, active form.  For miR-30b/d-transfected 
cells, both long and short exposures of the Western blots are shown to better visualize the 
processed and the  nascent forms, respectively.  A band in the Ponceau S-stained membrane was 
used as a loading control.  The images are representative blots from at least two repeated 
experiments. 
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Figure 2.3 The effect of miRNAs on ADAM12-L and ADAM12-S mRNA levels in breast 
cancer cells 
SUM159PT cells (A,C) or SUM1315MO2 cells (B,D) were transfected with the indicated 
miRNA mimics or mimic control.  ADAM12-L (A,B) and ADAM12-S (C,D) mRNA levels were 
measured by qRT-PCR and normalized to β-ACTIN.  Fold changes in mRNA levels in miRNA-
transfected cells versus control cells were calculated.  Graphs represent average values obtained 
in three (for SUM159PT) or two (for SUM1315MO2) independent experiments, ± SEM.  
Statistical significance was determined by one-sample t tests.  * P<0.05 **P<0.01 
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Figure 2.4 miR-200b/c, but not miR-29b/c or miR-30b/d, decrease the activity of the 
ADAM12 promoter 
(A) Diagram of the ADAM12 promoter construct.  The genomic region extending from    
-2599 nt to +414 nt, where +1 is the transcriptional start site (TSS), was cloned into the pEZX-
PG04 vector upstream of the Gaussia luciferase gene.  Nucleotides +1-413 represent the entire 
ADAM12 5’UTR. The vector also contained a secreted alkaline phosphatase gene under the 
control of the CMV promoter for use as an internal transfection control.  (B-D) SUM159PT cells 
were transfected with miR-29b/c (B), miR-30b/d (C), miR-200b/c (D), or mimic control.  The 
cells were then transfected with either the ADAM12 promoter construct or a promoter-less 
pEZX-PG04 vector.  Secreted luciferase and alkaline phosphatase were allowed to accumulate in 
the media for 48 hours prior to assaying.  Graphs show the average values of Gaussia luciferase 
activity, normalized to alkaline phosphatase activity, ±SEM, obtained in six independent 
experiments.  Significance was determined by Student’s t test.  * P<0.05.  
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Figure 2.5 ADAM12-L 3’UTR is a target for miR-29b/c, miR-30b and miR-200b/c 
(A) SUM159PT cells were transfected with the indicated miRNAs, and then with the 
ADAM12 3’UTR reporter or an empty reporter vector, and a Renilla luciferase control vector.  
The firefly luciferase activity was measured after 48 h and was normalized to Renilla luciferase 
and to the empty vector.  Graph shows the average values for six independent experiments, ± 
SEM.  Significance was determined by one-sample t-tests.  *P<0.05, **P<0.01, ***P<0.001, 
****P<0.0001.  (B-D) Upper Three nucleotides in each putative miRNA target site (shown in 
black) were mutated to destroy the site.  The mutated residues are shown in red above the wild-
type sequence.  The position in the ADAM12-L 3’UTR relative to the stop codon is indicated.  
Lower The effect of miR-29b/c (B), miR-30b/d (C) and miR-200b/c (D) on the wild-type and 
mutated ADAM12-L 3’UTRs.  Samples were prepared and analyzed as in panel (A).  The 
average values obtained in two independent experiments, ± SEM, are shown. 
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Figure 2.6 ADAM12 mRNA negatively correlates with miR-29b/c, miR-30b/d and miR-
200b/c in breast tumors 
Correlation analyses of ADAM12 mRNA and miR-29b/c, miR-30b/d, and miR-200b/c in 
284 breast tumors from the TCGA database.  ADAM12 mRNA and miR29b/c, miR-30b/d or 
miR-200b/c were downloaded as Z-scores via the cBioPortal and were median-centered.  
Spearman r and P values are shown for each comparison. 
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Chapter 3 - Alternative mRNA splicing generates two distinct 
ADAM12 pro-domain variants 
This chapter has been published as the following journal article: 
Duhachek-Muggy, S., Li, H., Qi, Y., and Zolkiewska, A. (2013).  Alternative mRNA 
splicing generates two distinct ADAM12 pro-domain variants.  PLoS ONE 8(10):e75730. 
 Abstract 
Human ADAM12, transcript variant 1 (later on referred to as Var1b), present in publicly 
available databases contains the sequence 5'-GTAATTCTG-3' at the nucleotide positions 340-
348 of the coding region, at the 3' end of exon 4.  The translation product of this variant, 
ADAM12-Lb, includes the three amino acid motif 
114
VIL
116
 in the pro-domain.  This motif is not 
conserved in ADAM12 from different species and is not present in other human ADAMs.  
Currently, it is not clear whether a shorter variant, Var1a, encoding the protein version without 
the 
114
VIL
116
 motif, ADAM12-La, is expressed in human.  In this work, we have established that 
human mammary epithelial cells and breast cancer cells express both Var1a and Var1b 
transcripts.  Importantly, the proteolytic processing and intracellular trafficking of the 
corresponding ADAM12-La and ADAM12-Lb proteins are different.  While ADAM12-La is 
cleaved and trafficked to the cell surface in a manner similar to ADAM12 in other species, 
ADAM12-Lb is retained in the EnR and is not proteolytically processed.  Furthermore, the 
relative abundance of ADAM12-La and ADAM12-Lb proteins detected in several breast cancer 
cell lines varies significantly.  We conclude that the canonical form of transmembrane ADAM12 
is represented by Var1a/ADAM12-La, rather than Var1b/ADAM12-Lb currently featured in 
major sequence databases. 
 Introduction 
The Disintegrin and Metalloprotease (ADAM) proteins belong to the M12B adamalysin 
protease subfamily (http://merops.sanger.ac.uk/, Ref. [1]).  Canonical ADAMs are comprised of 
a pro-domain, a metalloprotease domain, a disintegrin domain, a cysteine-rich domain, an 
epidermal growth factor-like domain, a transmembrane helix, and a cytoplasmic tail.  The human 
genome contains 21 different ADAM genes; however, only 13 of these genes encode functional 
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proteases [2, 3].  The catalytically active ADAMs contain the HEXXHXXGXXH motif in their 
metalloprotease domain, with three zinc-binding histidine residues and a catalytic glutamic acid 
[4].  The proteolytic activity of the metalloprotease is inhibited by the pro-domain.  The 
mechanism of inhibition typically involves a cysteine-switch mechanism, in which a conserved 
cysteine residue from the pro-domain interacts with the zinc ion in the active site and prevents 
binding and cleavage of the substrate [5].  During maturation in the Golgi, the pro-domain is 
cleaved by furin-like enzymes and the metalloprotease is rendered active, although other modes 
of ADAM activation have also been postulated [6-9]. 
ADAM12 has an active metalloprotease domain, which has been shown to cleave a range 
of transmembrane substrate proteins.  Depending on a cellular context, substrates include 
members of the epidermal growth factor (EGF) family of ligands (EGF and heparin-binding-
EGF) [10–13], the Notch pathway ligand Delta-like 1 [14], sonic hedgehog [15], receptor 
tyrosine kinase Tie-2 [12], vascular endothelial (VE) cadherin [12], vascular endothelial growth 
factor receptor 2, or Flk-1 [12], Kit ligand 1 (Kitl1) [12], Vascular cell adhesion protein 1 
(VCAM-1) [12], and ephrin-A1 [16].  In addition, ADAM12 facilitates Transforming Growth 
Factor β (TGFβ) signaling by a mechanism that is independent of its proteolytic activity and 
involves the accumulation and stabilization of TGFβ type II receptor in early endosomes [17]. 
While ADAM12 is transiently expressed during embryonic morphogenesis of skeletal 
muscles, visceral organs, and bone [18], ADAM12-deficient mice do not show major 
developmental abnormalities [19].  Post-natal ADAM12 expression in healthy and non-injured 
organs is low, but it is highly elevated in diseases accompanied by fibrosis, such as liver cirrhosis 
[20], muscle injury [21], scleroderma [22], chronic wounds [23], and cardiac hypertrophy [24].  
Consistently, a recent genetic study in mice has shown that ADAM12 is expressed in 
mesenchymal perivascular cells (pericytes), which are programmed during vascular wall 
development, are activated in response to tissue injury, and generate pro-fibrotic myofibroblasts 
[25].  Furthermore, ADAM12 expression is strongly elevated in many cancers, including breast, 
head and neck, bone, lung, bladder, prostate, and brain cancers, as well as aggressive 
fibromatosis [26–39].  Recently, ADAM12 has been shown to be involved in the formation of 
invadopodia, cellular structures that aid cancer cell invasion, in head and neck, lung, and 
pancreatic cancer cells [13].  In breast cancers, ADAM12 is selectively up-regulated in the 
claudin-low subtype of tumors [40], which have aggressive characteristics, molecular signatures 
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of epithelial-to-mesenchymal transition, and are enriched in gene signatures of breast tumor-
initiating cells [41].  By analyzing survival data of a large group of breast cancer patients, we 
have recently concluded that ADAM12 is the primary protease responsible for the activation of 
EGF receptor in early stage, lymph node-negative triple negative breast cancer (lacking the 
expression of estrogen receptor, progesterone receptor, and HER2) [42]. 
The human ADAM12 gene is alternatively spliced, resulting in two major protein 
isoforms: a long, transmembrane form called ADAM12-L and a short, secreted form designated 
ADAM12-S [43].  The ADAM12-L isoform is encoded by transcript variant 1, or ADAM12-
var1, which includes exons 1–18 and 20–24.  ADAM12-S is encoded by transcript variant 2, or 
ADAM12-var2, which comprises exons 1–19.  Furthermore, analysis of human ADAM12 
sequences present in major databases suggests that there are two forms of exon 4, with two 
alternative 3′ ends.  The shorter form will be designated here exon 4a.  The longer form, which 
ends 9 bp further downstream from exon 4a, will be designated exon 4b (Figure 3.1A).  The 
alternative splicing event generating exon 4a and exon 4b is known as alternative 5′ splice site 
selection [44, 45]. 
Interestingly, according to the most recent releases of all major sequence databases, 
alternative splicing at exon 4a/b is present solely in the ADAM12-var2 transcript, but not in the 
ADAM12-var1 transcript. ADAM12-var1b and ADAM12-var2b, both containing the longer exon 
4b, were first described by Gilpin et al. [46] (Figure 3.1B).  These variants encode the ADAM12-
Lb and ADAM12-Sb protein isoforms, respectively. ADAM12-var2a, containing the shorter 
exon 4a and encoding the ADAM12-Sa isoform, was later identified in a screen for novel 
secreted proteins [47].  ADAM12-var1a transcript and ADAM12-La protein isoform are not 
featured in any of the DNA/protein databases analyzed (Table 3.1).  The 9-bp extension present 
selectively in exon 4b encodes a highly hydrophobic 
114
VIL
116
 motif in the ADAM12 pro-
domain (Figure 3.1C).  This motif is not conserved in ADAM12 from other species or in other 
human ADAMs (Figure 3.2).  Although the 
114
VIL
116
 sequence is not positioned in a close 
proximity to the known furin-like cleavage site (
204
RHKR
207
) or to the cysteine responsible for 
the switch mechanism (Cys179), it can potentially affect the structure and/or function of the 
ADAM12 protein.  The high hydrophobicity of this motif might change the stability of structural 
motifs in the pro-domain or may create a hydrophobic interface for interaction with other 
proteins. 
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In this study, we sought to determine whether ADAM12-var1a is expressed in human 
cells and whether any functional differences between the ADAM12-La and ADAM12-Lb protein 
isoforms exist.  We found that breast epithelial cells, as well as breast cancer cells, do express 
ADAM12-var1a.  Most importantly, while ADAM12-La protein is proteolytically processed and 
trafficked to the cell surface, ADAM12-Lb is poorly processed and is retained in the EnR.  
Furthermore, we show that the relative abundance of the endogenous ADAM12-La and 
ADAM12-Lb proteins detected in several breast cancer cell lines varies significantly.  As the 
114
VIL
116
 motif is not conserved between species and is not found in other members of the 
ADAM family, we conclude that the canonical form of ADAM12-L is ADAM12-La and not 
ADAM12-Lb. 
 Materials and Methods 
 Vector Construction 
Full-length human ADAM12var-1a cDNA was amplified from MCF10DCIS.com cells 
using two consecutive PCR reactions with nested primers.  The first set of primers was: 5′-GGA 
AAT CCC TCC GGT CGC GAC-3′ (F) and 5′-ACT GAC GGC AGT AGC TCA AAG-3′ (R).  
The second set of primers was: 5′-TAC CTT CAA TTG TGA AGG CCG GCG ACG ATG GC-
3′ (F) and 5′-ACA CGT CGA CTC ACT TAA TAT AGG CGG TGT G-3′ (R).  The underlined 
sequences in the forward and reverse primers of the second set correspond to the beginning and 
the end of the coding region of human ADAM12-var1, respectively.  The PCR product was gel-
purified, digested with MfeI and SalI, and cloned into the pBABEpuro retroviral expression 
vector at the EcoRI and the SalI sites.  The nine-nucleotide insertion 5′-GTAATTCTG-3′ in exon 
4b was generated using the QuickChange Site-Directed Mutagenesis kit (Stratagene).  The entire 
lengths of the coding regions of ADAM12-var1a and ADAM12-var1b were sequenced to confirm 
the presence of the insertion and to exclude any PCR errors. 
 Cell Culture 
MCF10DCIS.com cells were obtained from Asterand (Detroit, MI).  MCF10A, MDA-
MB-231, HEK293, and Hs578T cells were purchased from American Type Culture Collection 
(Manassas, VA).  Phoenix Ampho cells, the retroviral packaging line, were obtained from Dr. 
Garry P. Nolan (Stanford University).  MCF10DCIS.com cells were cultured in 1:1 (v/v) 
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Dulbecco’s Modified Eagle Medium (DMEM)/Ham’s F-12 containing 15 mM HEPES and 
supplemented with 5% horse serum and 29 mM sodium bicarbonate.  MCF10A cells were 
cultured in DMEM/F-12 and supplemented with 5% horse serum, 0.5 µg/mL hydrocortisone, 20 
ng/mL human EGF, 10 µg/mL insulin, 100 ng/mL cholera toxin and 1% penicillin/streptomycin.  
HEK293 and Phoenix Ampho cells were cultured in DMEM supplemented with 10% fetal 
bovine serum (FBS).  Hs578T cells were cultured in DMEM containing 10% FBS and 10 µg/mL 
insulin.  MDA-MB-231 cells were cultured in DMEM/F-12 with 10% FBS.  All cells were 
maintained at 37°C in 5% CO2. 
 Antibodies 
Polyclonal rabbit anti-ADAM12 antibody (Ab#3394) raised against the cytoplasmic tail 
of human ADAM12-L [42] was used at a dilution of 1:20,000 for Western blotting and 1:500 for 
immunofluorescence.  Mouse monoclonal anti-ADAM12 antibody (R&D Biosciences; clone 
632525) was used for flow cytometric analysis at a dilution of 1:100.  Other antibodies were: 
anti-β-actin (Sigma, clone AC-15; 1:20,000 dilution), anti-α-tubulin (Sigma, clone DM 1A; 
1:40,000 dilution), anti-KDEL, an endoplasmic reticulum marker (Enzo Life Sciences, clone 
10C3; 1:100 dilution), anti-TGN38, a trans-Golgi marker (BD Biosciences, clone 2; 1:50 
dilution), anti-EEA1, an early endosomal marker (BD Biosciences, clone 14; 1:50 dilution), and 
anti-epidermal growth factor receptor (EGFR) (Cell Signaling Technologies, clone D38B1; 
1:5,000 dilution). 
 Generation of Cells with Stable Overexpression of ADAM12-La or ADAM12-Lb 
ADAM12-La and ADAM12-Lb were stably overexpressed in MCF10A cells using 
retroviral transduction.  Phoenix Ampho cells were seeded in 100-mm plates 16 hours prior to 
transfection.  pBabePuro retroviral expression vectors containing ADAM12-var1a or ADAM12-
var1b sequences, or empty pBabePuro vector, were transfected into Phoenix Ampho cells using 
the calcium phosphate method (15 µg DNA/plate); 25 µM chloroquine was added to the medium 
prior to adding the DNA/CaCl2 solution.  Cells were incubated at 37°C for 24 h, then the 
medium was changed to fresh DMEM +10% FBS, and cells were incubated for additional 48 h at 
32°C.  The medium containing retroviruses was then collected and centrifuged at 500×g for 5 
min.  Supernatants were supplemented with 5 µg/mL polybrene (Sigma), and were added 
76 
without further dilution to MCF10A cells.  Forty eight hours post-infection, cells with stable 
overexpression of ADAM12 proteins were selected using 2 µg/mL puromycin for 10 days. 
 Knock-down of ADAM12 Expression 
siRNAs specific for exon 4a and exon 4b were designed using the Thermo Scientific 
siDESIGN Center.  The antisense strand sequence of the exon 4a specific siRNA was 5′-UAG 
UAA CAG UGA CCC GUG UUU-3′ and was prepared as a regular siRNA.  The antisense 
strand sequence of the exon 4b specific siRNA was 5′-UGA CCC AGA AUU ACC GUG UUU-
3′ and was prepared with the proprietary ON-TARGET modifications.  The siRNAs were diluted 
to 20 µM in 1×siRNA buffer (Thermo Scientific) and stored at -20°C.  For transfection, siRNAs 
were used at a final concentration of 50 nM.  DharmaFECT 1 transfection reagent was used 
according to the manufacturer’s instructions.  Transfection complexes were removed after 24 
hours and cell lysates were collected for immunoblotting after 72 hours.  In an alternative 
approach, ADAM12 was knocked-down using MISSION™ Lentiviral shADAM12 Transduction 
Particles (Sigma, clone ID TRCN0000047037), as described [40].  This shRNA clone targets the 
sequence GCCTGAATCGTCAATGTCAAA at the nucleotide position 1922–1942 in the 
ADAM12-var1a coding sequence and 1931–1951 in the ADAM12-var1b coding sequence.  
Control treatment included cell incubation with MISSION™ Non-Target shRNA Control 
Transduction Particles (Sigma, SHC002V).  Transduction was performed according to the 
manufacturer’s instructions.  After one day, media containing lentiviral particles were replaced 
with fresh media, and after additional 24 h, stably transduced cells were selected with 3 µg/ml of 
puromycin for 7 days. 
 Immunoblotting 
Cells were treated with lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% Triton 
X-100, 0.5% sodium deoxycholate, 0.1% sodium dodecylsulfate (SDS), 5 mM EDTA, 1 mM 4-
(2-Aminoethyl) benzenesulfonyl fluoride hydrochloride (AEBSF), 5 µg/mL pepstatin, 5 µg/mL 
leupeptin, 5 µg/mL aprotinin, and 10 mM 1,10-phenanthroline).  Extracts were centrifuged for 
15 minutes at 21,000×g at 4°C.  For overexpressed ADAM12, the supernatants were resolved 
using SDS-PAGE (8%) and transferred to a nitrocellulose membrane.  For endogenous 
ADAM12 detection, supernatants were enriched for glycoproteins by binding to concanavalin A 
agarose (Sigma; 25 µl resin/500 µl lysate) for 2 hours at 4°C prior to SDS-PAGE.  Membranes 
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were blocked in 5% milk and 0.3% Tween-20 in Dulbecco’s Phosphate Buffered Saline (DPBS).  
Rabbit anti-human ADAM12 (Ab#3394), mouse anti-β-actin, mouse anti-α-tubulin, and rabbit 
anti-EGFR antibodies were diluted in blocking buffer and incubated with the membranes.  
Horseradish peroxidase-conjugated anti-rabbit or anti-mouse antibodies were used as secondary 
antibodies.  Signal detection was performed using SuperSignal West Pico Chemiluminescent 
Substrate (Pierce). 
 cDNA Preparation and RT-PCR 
Total RNA was extracted using the Qiagen RNeasy kit.  One microgram of the total RNA 
was treated with deoxyribonuclease I (Qiagen) and reverse-transcribed using the SuperScript III 
First Strand Synthesis system for RT-PCR (Invitrogen).  A 100-bp fragment of ADAM12 cDNA 
including the exon 4-exon 5 splice junction was amplified using the following primers: 5′-GGT 
ACT GAT GTC TCC CTC GCT CG-3′ (F) and 5′-CGT GCT GAG ACT GAC TGC TGA ATC-
3′(R).  PCR products were resolved in a 2.0% agarose/TAE gel, visualized with ethidium 
bromide and UV illumination, and then extracted using the Qiaex II kit (Qiagen).  DNA 
sequencing was performed at the Kansas State University DNA Sequencing and Genotyping 
Facility using the Applied Biosystems 3730 DNA Analyzer.  The sequence of the ADAM12-
var1a has been deposited in GenBank under the accession number KF444157. 
 Cell Surface Biotinylation 
Cells grown in 6 well plates were washed with DPBS, then incubated at 4°C for 60 
minutes with 2.5 mM EZ-link N-hydroxysuccinimide -PEG12-biotin (Pierce) in DPBS.  
Remaining free reagent was quenched using 100 mM glycine.  After washing cells several times 
with DPBS, cell lysates were collected as described above, and a fraction was retained as the 
input sample.  The remaining lysate was allowed to adsorb onto Neutravidin agarose resin 
(Pierce) for 60 minutes at 4°C.  The resin was washed three times with cell lysis buffer, followed 
by elution with SDS sample buffer.  Samples were resolved by SDS-PAGE and transferred to a 
nitrocellulose membrane for immunoblotting. 
 Endo H Digestion 
Cell lysate supernatants were prepared as described above.  Supernatants were treated 
with 10×glycoprotein denaturation buffer (New England Biolabs) and boiled for 10 minutes.  
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After cooling, 10×G5 buffer (New England Biolabs) was added, and each sample was divided 
into two parts; each part was treated with or without Endo H (New England Biolabs) at 37°C for 
1 hour.  The reaction was stopped by adding SDS sample buffer and boiling.  Samples were 
resolved by SDS-PAGE and transferred to a nitrocellulose membrane for immunoblotting. 
 Immunofluorescence 
Cells were plated onto sterile coverslips and allowed to attach overnight.  Cells were then 
washed and treated with 3.7% paraformaldehyde in DPBS for 20 minutes at room temperature.  
After the fixative was removed, cells were permeabilized with 0.1% Triton X-100 in DPBS for 5 
minutes.  The blocking step was performed using 1% bovine serum albumin (BSA) and 5% 
donkey serum in DPBS at for 30 minutes 37°C.  Primary antibodies were diluted in 1% BSA in 
DPBS and incubation was performed for 60 minutes at 37°C.  Red X-conjugated anti-rabbit 
(1:200) and AlexaFluor 488-conjugated anti-mouse (1:200) antibodies were diluted in 1% BSA 
in DPBS and incubated with the coverslips for 45 minutes at 37°C.  After washing, coverslips 
were mounted onto slides and allowed to dry overnight.  Slides were imaged at 63×magnification 
using a Zeiss Axiovert-200 inverted fluorescent microscope. 
 Flow Cytometry 
Cells were trypsinized into a single cell suspension, washed with DPBS and incubated 
with monoclonal anti-ADAM12 antibody or isotype control antibody for 30 minutes on ice.  
Cells were then washed 3 times, incubated with allophycocyanin (APC)-conjugated anti-mouse 
antibodies (Jackson ImmunoResearch; 1:100) for 30 min on ice, and then with 1 µg/ml 
propidium iodide (Sigma) for viability.  Analysis was performed using a BD FACSCalibur flow 
cytometer.  Only the cells negative for propidium iodide (PI) staining (viable cells) were selected 
for the ADAM12 analysis. 
 Results 
 ADAM12 Transcripts Present in Human Mammary Epithelial Cells Contain Exon 4a 
and 4b 
To determine which forms of exon 4 are present in ADAM12 transcripts expressed by 
human mammary cells, we amplified a ~100-bp region surrounding the exon 4-exon 5 splice 
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junction using cDNA isolated from MCF10A mammary epithelial cell line.  After PCR products 
were resolved by agarose gel electrophoresis, two bands were clearly visualized (Figure 3.3A).  
The two bands were excised from the gel and subjected to DNA sequencing.  The lower band 
produced a single sequence that was identical to the sequence of the control vector containing a 
cloned ADAM12-var1a insert (Figure 3.3B).  The upper band produced two sequences that had 
identical 5′-ends but then diverged at the site corresponding to the 3′-end of exon 4a, as indicated 
by the arrow.  This might be due to the presence of heteroduplexes containing the 4a and 4b 
sequences in a non-denaturing gel, as well as unresolved 4a and 4b homoduplexes.  Importantly, 
the chromatogram obtained for the upper band was indistinguishable from the chromatogram 
obtained for a mixture of ADAM12-var1a and ADAM12-var1b vector controls.  We have 
concluded that the upper band represented, therefore, a mixture of ADAM12 variants containing 
exon 4a and exon 4b. 
 ADAM12-Lb is Poorly Processed and is Retained in the EnR 
Next, we examined the effect of the 
114
VIL
116
 motif on the proteolytic processing and 
intracellular trafficking of ADAM12-L.  The ADAM12-La and ADAM12-Lb isoforms were 
stably overexpressed in MCF10A cells, and cell lysates were subjected to immunoblotting using 
antibody specific for the intracellular domain of ADAM12-L.  Cells overexpressing ADAM12-
La produced two bands of similar intensities: the ~120-kDa band representing the nascent 
protein, and the ~90-kDa band corresponding to the processed form, after cleavage of the pro-
domain (Figure 3.4A).  In contrast, cells overexpressing ADAM12-Lb produced a major band of 
~120 kDa, and a very weak band of ~90 kDa (Figure 3.4A).  A similar pattern of bands was 
observed when ADAM12-La and ADAM12-Lb were stably overexpressed in HEK 293 cells.  
Thus, while ADAM12-La was readily processed in cells, the proteolytic processing of 
ADAM12-Lb was much less efficient. 
Since the proteolytic processing of ADAMs occurs in the Golgi apparatus, we next 
probed the progression of ADAM12-La and ADAM12-Lb through the secretory pathway using 
endoglycosidase H (Endo H).  Endo H readily cleaves high mannose-type oligosaccharides but 
cannot remove the complex oligosaccharides that result from modification by Golgi enzymes.  
As expected, the ~120-kDa form of ADAM12-La was sensitive to Endo H, and thus must have 
resided in the EnR.  The ~90-kDa form of ADAM12-La was more resistant to Endo H and thus 
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must have been localized to the Golgi or post-Golgi compartments (Figure 3.4B).  Importantly, 
the ~120-kDa ADAM12-Lb form was fully sensitive to Endo H, was not modified by Golgi 
enzymes, and thus must have been localized to a pre-Golgi compartment. 
Next, we performed cell surface biotinylation of ADAM12-La and ADAM12-Lb.  Live 
cells were incubated with an amine-reactive, membrane impermeable biotinylation reagent, 
biotinylated proteins were then isolated by adsorption to Neutravidin agarose beads and analyzed 
by Western blotting using anti-ADAM12 antibody.  Comparison of the pattern of ~120-kDa and 
~90-kDa ADAM12 bands in total cell lysates (inputs) and in eluates showed that the 90-kDa 
form of ADAM12-La and ADAM12-Lb was the predominant form that was biotinylated (Figure 
3.4C).  Importantly, the total amount of ADAM12-Lb protein eluted from the Neutravidin beads 
(the ~120-kDa and the ~90-kDa forms combined) was much lower than that of ADAM12-La.  
This result indicated that ADAM12-Lb localized to the cell surface more poorly than ADAM12-
La. 
To directly visualize subcellular localization of ADAM12-La and ADAM12-Lb in cells, 
immunofluorescence staining was performed using anti-ADAM12-L antibody and three different 
antibodies marking distinct compartments of the secretory pathway.  Using anti-KDEL antibody, 
a marker of the EnR, we determined that ADAM12-La only partially localized to the EnR, and 
majority of ADAM12-La protein was found in post-EnR compartments (Figure 3.5A–C).  In 
contrast, anti-ADAM12 staining of ADAM12-Lb-expressing cells fully co-localized with anti-
KDEL staining (Figure 3.5D–F).  Using anti-TGN38 antibody, a trans-Golgi marker, we 
detected partial co-staining with anti-ADAM12 antibody in ADAM12-La-expressing (Figure 
3.5G–I), but not in ADAM12-Lb-expressing cells (Figure 3.5J–L).  Finally, we examined co-
localization of ADAM12 with EEA1, an early endosomal marker.  It was previously shown that 
ADAM12 is constitutively internalized from the cell surface via the clathrin-dependent pathway 
and is detected in both early and recycling endosomes [17, 48].  Indeed, we detected partial co-
localization of ADAM12-La with EEA1 (Figure 3.5M–O), but no co-localization was observed 
for ADAM12-Lb and EEA1 (Figure 3.5P–R).  In summary, these results confirmed that 
ADAM12-Lb is efficiently retained in the EnR.  To further explore whether ADAM12-Lb might 
have been misfolded and retained in the EnR by the EnR quality control system, we performed 
co-immunoprecipitation of ADAM12-Lb with several known EnR chaperones: BiP, ERp44, 
ERp72, Grp94, PDI and calnexin.  None of these chaperones was detected in the anti-ADAM12-
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Lb immunoprecipitates (results not shown).  This data, together with the relative stability of the 
ADAM12-Lb protein, implied that the protein was not grossly misfolded. 
 Breast Cancer Cell Lines Show Different Relative Expression Levels of ADAM12-La 
and ADAM12-Lb 
Next, we analyzed ADAM12-La and ADAM12-Lb expression in three cancer cell lines, 
Hs578T, MDA-MB-231, and MCF10DCIS.com.  Hs578T and MDA-MB-231 cell lines 
represent claudin-low breast cancer cell lines, in which high levels of ADAM12 transcript variant 
1 were detected by microarray profiling [41].  MCF10DCIS.com is a breast cancer cell line 
derived from a tumor originating from xenografting premalignant MCF10AT cells into severe 
combined immunodeficient mice [49, 50].  MCF10DCIS.com cells are frequently used to model 
early breast cancer, and they express high levels of ADAM12 transcript variant 1 [40].  First, we 
amplified a ~100-bp region surrounding the exon 4-exon 5 splice junction in ADAM12 
transcripts using cDNA isolated from Hs578T, MDA-MB-231, and MCF10DCIS.com cells and 
the same primer set as in Figure 3.3 above.  The PCR band pattern was different for each of these 
three cell lines, with a single band indicative of exon 4a present in Hs578T cells, a predominant 
band indicative of exon 4b in MDA-MB-231 cells, and two bands detected in MCF10DCIS.com 
cells (Figure 3.6A).  Consistently, Western blotting showed that Hs578T cells express high levels 
of ADAM12-La, whereas ADAM12-Lb is undetected in these cells (Figure 3.6B).  Conversely, 
MDA-MB-231 express high levels of ADAM12-Lb, while ADAM12-La is below the detection 
limit.  MCF10DCIS.com cells express both ADAM12-La and ADAM12-Lb isoforms.  The 
apparent molecular weight of ADAM12-Lb in MDA-MB-231 and MCF10DCIS.com cells 
(~125-kDa) was noticeably larger than the molecular weight of the full-length ADAM12-La 
(~120-kDa) despite only a three-amino acid difference (
114
VIL
116
) in their pro-domains, which 
might be due to different glycosylation or other post-translational modifications.  Analysis of live 
cells by flow cytometry using an antibody specific for the extracellular domain of ADAM12-L 
demonstrated that Hs578T and MCF10DCIS.com cells both had detectable levels of ADAM12-L 
at the surface, while MDA-MB-231 did not (Figure 3.6C).  Additional immunoprecipitation 
experiments confirmed that this antibody recognized ADAM12-La and ADAM12-Lb equally 
well (Figure 3.8).  Therefore, the lack of detection of ADAM12-L at the surface of live MDA-
MB-231 cells corroborates the notion that these cells express predominantly the ADAM12-Lb 
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form that is retained in the EnR and not proteolytically processed in the Golgi.  In contrast, 
Hs578T and MCF10DCIS.com cells express sizeable amounts of ADAM12-La that is 
transported out of the EnR, is proteolytically processed in the Golgi, and is trafficked to the cell 
surface. 
To further confirm the identity of the ADAM12-La and ADAM12-Lb proteins detected 
in cancer cells, we generated siRNAs selectively targeting each variant (Figure 3.7A).  The 
efficacy and specificity of these siRNAs were tested in HEK293 cells stably overexpressing 
ADAM12-La or ADAM12-Lb.  The exon 4a siRNA efficiently knocked down ADAM12-La and 
had much lesser effect on ADAM12-Lb (Figure 3.7B).  The exon 4b siRNA potently knocked 
down ADAM12-Lb and, unexpectedly, increased the level of ADAM12-La (Figure 3.7B).  
Although the mechanism of this increased expression of ADAM12-La by exon 4b siRNA is not 
clear, we have concluded that both siRNAs efficiently down-regulated the cognate ADAM12-L 
isoforms and thus were suitable for distinguishing between the endogenous ADAM12-La and 
ADAM12-Lb isoforms. 
We selected Hs578T and MCF10DCIS.com cells for the siRNA analysis, because these 
cells expressed significantly more ADAM12-L than MDA-MB-231 cells.  As expected, the two 
forms of ~120 kDa and ~90 kDa observed in Hs578T cells were down-regulated by an shRNA 
construct targeting both ADAM12-La and ADAM12-Lb (Figure 3.7C).  When Hs578T cells 
were transfected with exon 4a-specific siRNA, both ~120-kDa and ~90-kDa isoforms were also 
reduced.  In contrast, exon 4b siRNA did not down-regulate the ~120-kDa or the ~90-kDa form 
in Hs578T cells (Figure 3.7C).  Thus, ADAM12-La represents the major ADAM12-L form in 
Hs578T cells.  In MCF10DCIS.com cells, all three ADAM12-L forms of ~125 kDa, 120 kDa, 
and ~90 kDa were reduced by an shRNA construct targeting sequences common for both 
ADAM12-La and ADAM12-Lb (Figure 3.7D).  Furthermore, exon 4a siRNA primarily 
diminished the ~120-kDa and ~90-kDa forms, and exon 4b diminished the ~125-kDa form 
(Figure 3.7D), indicating that these cells express both the ADAM12-La and ADAM12-Lb 
isoforms.  Collectively, the results presented in Figures 3.6 and 3.7 suggest that both ADAM12-
La and ADAM12-Lb are expressed at the endogenous levels in breast cancer cells, but their 
relative contribution to the overall ADAM12-L expression varies. 
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 Discussion 
In this work, we show that two alternative versions of exon 4 in human ADAM12 
transcripts exist, namely exon 4a and 4b.  They arise as a result of alternative 5′ (or donor) splice 
site usage in intron 4-5.  The two alternative donor sites are located 9 nt apart and are an example 
of tandem sites [45]. Both versions of exon 4 can be detected in ADAM12 transcripts present in 
cultured human cells.  Remarkably, ADAM12 transcript variant 1 currently featured in all 
publicly available databases contains exclusively exon 4b. ADAM12 transcript variant 1 with 
exon 4a, ADAM12-var1a, is not included in any of these databases.  The translation products of 
variant 1 comprising exon 4a or 4b, ADAM12-La and ADAM12-Lb, differ by the sequence 
114
VIL
116
 in the pro-domain, which is present only in the ADAM12-Lb protein isoform.  Since 
the amino acid sequences of ADAM12 from other species, as well as sequences of other 
ADAMs, do not contain the VIL motif in their pro-domains, we believe that the ADAM12-La 
protein isoform (and the corresponding ADAM12 transcript variant 1a) should be considered the 
“canonical” form of ADAM12. 
We show that the 
114
VIL
116
 motif has a dramatic impact on the intracellular trafficking 
and proteolytic processing of ADAM12-L protein.  Unlike ADAM12-La, ADAM12-Lb protein 
containing this motif is retained in the EnR and is not transported to the cell surface.  The 
mechanisms responsible for the retention of ADAM12-Lb in the EnR are not known.  ADAM12-
Lb does not seem to be grossly misfolded because: (a) it does not interact with major EnR 
chaperones, (b) it is glycosylated, and (c) it is not rapidly degraded by the EnR-associated 
protein degradation (ERAD) [51].  The question then arises: Is ADAM12-Lb catalytically 
active?  According to the commonly accepted view of ADAM activation, proteolytic removal of 
the pro-domain in the Golgi is required for the disruption of the interaction between the 
inhibitory cysteine in the pro-domain and the zinc ion in the active site.  Since ADAM12-Lb 
contains an intact pro-domain, it is expected to be catalytically inactive.  However, according to 
other unconventional models of ADAM activation, conformational changes or protein-protein 
interactions involving the pro-domain may be sufficient to disrupt the cysteine-zinc interaction 
[6-9].  In such case, ADAM12-Lb may be, at least partially, catalytically active.  Direct detection 
of ADAM12-Lb activity might prove challenging, however, since no potential ADAM12 
substrates have been identified in the EnR so far.  Although we did not study the proteolytic 
processing and trafficking of ADAM12-S here, we predict that the 
114
VIL
116
 motif exerts a 
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similar effect on ADAM12-S as it does on ADAM12-L, i.e., ADAM12-Sa should be processed 
and secreted, whereas ADAM12-Sb is most likely retained in the EnR and is not processed. 
The mechanisms dictating the selection of two alternative donor splice sites in intron 4-5 
of the ADAM12 transcripts are not clear.  According to the Splice-Site Analyzer Tool 
(http://ibis.tau.ac.il/ssat/SpliceSiteFrame.htm, Ref. [52]), the splice site score for the sequence 
ACG/GTAATT at the donor site of exon 4a is 78.51, for the sequence CTG/GCACTG at the 
donor site of exon 4b this score is 63.57, and the score for a perfect donor site sequence 
CAG/GTAAGT is 100 (“/” indicate the exon/intron junction).  Thus, the strength of the donor 
site in exon 4a seems somewhat higher than that in exon 4b.  However, apart from the strength of 
donor sites, splice site selection is regulated by cis-acting elements such as exonic splicing 
enhancers (ESEs) or silencers (ESSs), and intronic splicing enhancers (ISEs) or silencers (ISSs).  
These splicing regulatory elements (SREs) recruit trans-acting splicing factors such as serine-
arginine-rich (SR) proteins or heterogeneous nuclear ribonucleoprotein (hnRNPs), which activate 
or suppress splice site recognition [44, 45].  Indeed, multiple SREs are detected in exon 4 a/b and 
intron 4-5 by the ESR Research (http://esrsearch.tau.ac.il/) and ACESCAN2 
(http://genes.mit.edu/acescan2/) site prediction tools (see also below). 
An important question is whether the ratio of splicing at the two tandem sites, eventually 
translating into the ratio of ADAM12-La and ADAM12-Lb proteins, is maintained at a fixed 
level or whether it varies.  Our examination of three different breast cancer cell lines indicates 
that the relative abundance of ADAM12-La and ADAM12-Lb is different in these lines.  
Interestingly, two of these cell lines, Hs578T and MDA-MB-231, have been classified as 
claudin-low, and all three express high levels of ADAM12 transcript variant 1 mRNA (ADAM12-
var1a and/or ADAM12-var1b), as determined by microarray profiling [41].  However, the 
predominant protein isoform in Hs578T cells is ADAM12-La, while MDA-MB-231 cells seem 
to express mainly the ADAM12-Lb protein isoform.  MCF10DCIS.com cells, in contrast, 
express both ADAM12-La and ADAM12-Lb forms at a comparable level.  Thus, individual 
genetic variations such as single nucleotide polymorphisms (SNPs) may contribute to the 
differences in the relative abundance of ADAM12-var1a/ADAM12-La and ADAM12-
var1b/ADAM12-Lb. 
It has been shown that naturally occurring polymorphisms can lead to the disappearance 
of a selective splice variant [53].  The donor splice site of exon 4b comprises an intronic SNP 
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C>T at chr10:127,843,783 (variation name: rs201532694).  However, the splice site score for the 
sequence containing this SNP, CTG/GCATTG, is 64.36, and thus it is similar to the score of the 
main variant CTG/GCACTG (see above).  There are five other intronic SNPs positioned close to 
the 5′ end of intron 4-5 and three synonymous SNPs in exon 4a 
(http://uswest.ensembl.org/Homo_sapiens/).  Interestingly, these SNPs are located within the 
predicted SREs and thus they may cause variations in alternative splicing at the exon 4a/4b 
tandem sites. 
Alternative splicing has been previously described for a number of ADAM genes.  The 
most common splicing events among ADAMs include the inclusion or skipping of entire exons.  
The alternative use of cytosolic-encoding exons in human ADAM15 generates ADAM15 protein 
isoforms with differential propensities to regulatory cytosolic interactions [54, 55].  Interestingly, 
aberrant patterns of ADAM15 splice variants have been observed in human breast cancer cells 
[56].  Tissue specific insertion or skipping of cytosolic-encoding exons has been also reported 
for ADAM22 [57, 58].  Furthermore, alternative usage of exons encoding membrane-proximal 
regions in the extracellular domains of ADAM9, -12, -19, -28, and -33 gives rise to circulating 
forms of the proteins, which lack the membrane-spanning and cytoplasmic domains [8, 37, 59–
64].  Our studies provide for the first time an evidence of alternative 5′ splice site selection in an 
ADAM mRNA that results in variations in the amino acid sequence of the pro-domain, altered 
intracellular protein trafficking, and most likely an altered enzyme functionality. 
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Figure 3.1 Alternative splicing of human ADAM12 transcripts generates two ADAM12-L 
isoforms 
(A) Diagram of the alternative mRNA splicing event at the exon 4-exon 5 junction.  
Capital letters represent exons and lower case letters represent the intron.  The nine nucleotide 
sequence 5′-GTAATTCTG-3′ missing in exon 4a and present in exon 4b are shown in italics.  
(B) Exon composition of human ADAM12 transcripts.  The nine-nucleotide extension in exon 4b 
is shown in magenta.  Exons are not drawn to scale.  (C) Diagram of the two transmembrane 
protein isoforms: ADAM12-La, which lacks the
114
VIL
116
 motif in the pro-domain, and 
ADAM12-Lb, which includes this motif. 
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Figure 3.2 The 
114
VIL
116
 motif is not conserved between different human ADAMs and 
between ADAM12 from different species 
Multiple sequence alignment of the region in ADAM proteins flanking the 
114
VIL
116
 
motif.  GenBank accession numbers are: ADAM2, NP_001455; ADAM7, NP_003808; 
ADAM8, NP_001100; ADAM9, NP_003807; ADAM10, NP_001101; ADAM11, NP_002381; 
ADAM12, NP_003465; ADAM15, AAS72997; ADAM17, NP_003174; ADAM18, NP_055052; 
ADAM19, NP_150377; ADAM20, NP_003805; ADAM21, NP_003804; ADAM22, 
NP_068369; ADAM23, NP_003803; ADAM28, NP_055080; ADAM29, NP_055084; 
ADAM30, NP_068566; ADAM32, NP_659441; ADAM33, NP_079496; Mouse, NP_031426; 
Rat, XP_001054670; Cow, NP_001001156; Horse, XP_001490097; Chicken, NP_001136322; 
Xenopus, NP_00035103.  The dog sequence was obtained from e!Ensembl 
(ENSCAFP00000041414) due to the lack of a signal peptide in the GenBank sequence.  
Conservation strength is shown in red (high), orange (medium), yellow (poor), and white (no 
conservation). 
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Figure 3.3 Breast epithelial cells express ADAM12 transcripts containing exon 4a and 4b 
(A) PCR amplification of a 100-bp region flanking the exon 4-exon 5 junction was 
performed using Var1a and Var1b vector controls (left) or cDNA samples from MCF10A cells.  
PCR products were resolved in a 2.0% agarose gel; two duplicate samples are shown for 
MCF10A cells.  Upper and lower bands observed for MCF10A cells are indicated with 
arrowhead and arrow, respectively.  (B) The PCR products were extracted from the gel and 
sequenced.  The chromatograms of the sequencing reactions are shown for Var1a and Var1b 
vector controls, a 1:1 mixture of the two vector controls, and the two PCR products 
(corresponding to the upper or the lower band in panel A) amplified from MCF10A cells.  The 
bar designates the nine-nucleotide region present exclusively in exon 4b, and arrow indicates the 
3′ end of exon 4a.  In samples containing mixed fragments, this arrow therefore indicates the site 
where the sequences diverge and the chromatogram begins to show multiple peaks.  Notice that 
the sequencing reaction was performed using a reverse primer, and the sequences shown 
represent reverse complements of ADAM12 transcripts. 
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Figure 3.4 ADAM12-Lb is poorly processed and is retained in a pre-Golgi compartment 
(A) Proteolytic processing of ADAM12-La and ADAM12-Lb in MCF10A cells.  Cells with 
stable expression of ADAM12 proteins were selected with puromycin after retroviral infection.  
Total cell lysates were analyzed by Western blotting.  The full-length protein is indicated by 
arrowhead, and the processed form after pro-domain removal is denoted with arrow.  (B) Mobility 
shift analysis of ADAM12-La and ADAM12-Lb after endoglycosidase H (Endo H) treatment.  The 
nascent full-length protein and the processed form are indicated with arrowhead and arrow, 
respectively.  The deglycosylated full-length species is denoted with grey arrow.  (C) Cell surface 
biotinylation of MCF10A cells stably expressing ADAM12-La or ADAM12-Lb.  Biotinylated 
proteins were isolated on Neutravidin agarose and subjected to SDS-PAGE and Western blotting.  
Input (1/40 of the sample volume) refers to total cell lysates prior to Neutravidin binding, and 
eluate (1/2 of the sample volume) refers to biotinylated proteins that bound to the resin.  β-actin, an 
intracellular protein, is not biotinylated and does not bind to Neutravidin. 
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Figure 3.5 ADAM12-Lb is localized to the endoplasmic reticulum 
MCF10A cells stably expressing ADAM12-La or ADAM12-Lb were fixed, 
permeabilized, and stained with anti- ADAM12 antibody (A, D, G, J, M, P), anti-KDEL 
antibody (an endoplasmic reticulum marker; B, E), anti-TGN38 antibody (a trans-Golgi marker; 
H, K), anti-EEA1 antibody (an early endosomal marker; N, Q), and DAPI.  Overlay images are 
shown in panels C, F, I, L, O, R.  Partial co-localization of ADAM12-La and EEA1 is indicated 
by white arrows. Bar, 20 µm. 
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Figure 3.6 Breast cancer cell lines express different levels of ADAM12-La and ADAM12-
Lb 
(A) A 100-bp region flanking the exon 4-exon 5 junction was PCR-amplified using 
duplicate cDNA samples isolated from Hs578T, MDA-MB-231, and MCF10DCIS.com cells and 
analyzed as in Figure 3.3.  Var1a and Var1b vectors served as controls.  Exon 4a- and exon 4b-
related bands are indicated with arrow and arrowhead, respectively.  (B) Glycoprotein-enriched 
fractions from Hs578T, MDA-MB-231, and MCF10DCIS.com cells were analyzed by Western 
blotting using anti-ADAM12-L antibody.  Full length ADAM12-La and ADAM12-Lb are 
indicated with solid and open arrowheads, respectively.  The processed form of ADAM12-La is 
shown with arrow.  (C) Cell surface localization of ADAM12-L was examined by flow 
cytometry.  Live cells were trypsinized and stained with an antibody specific for the extracellular 
domain of ADAM12-L (red) or with isotype control antibody (grey). 
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Figure 3.7 Confirmation of the identities of the endogenous ADAM12-La and ADAM12-Lb 
proteins detected in breast cancer cell lines 
(A) Sequences of two siRNAs designed to specifically target ADAM12 exon 4a (Ex4a) or 
exon 4b (Ex4b).  The siRNA antisense strands are shown, and possible base pairing between 
each siRNA and Var1a or Var1b mRNA is indicated.  The numbers refer to the nucleotide 
position in the coding sequence for each mRNA variant.  (B) Efficacies and specificities of the 
two siRNAs.  HEK293 cells stably expressing ADAM12-La or ADAM12-Lb were transfected 
with negative control siRNA (Ctrl), Ex4a siRNA, or Ex4b siRNA.  Total cell lysates were 
analyzed by Western blotting using anti-ADAM12 antibody.  β-actin is a loading control.  (C,D) 
ADAM12-L knockdown in Hs578T and MCF10DCIS.com cells.  Cells were stably transduced 
with lentiviruses bearing an shRNA construct targeting both ADAM12-var1a and ADAM12-
var1b or control viruses.  Alternatively, cells were transiently transfected with Ex4a siRNA, 
Ex4b siRNA, or negative control siRNA.  Total cell lysates in C and D were enriched for 
glycoproteins on concanavalin A agarose prior to analysis.  Full length ADAM12-La and 
ADAM12-Lb are indicated with solid and open arrowheads, respectively.  The processed form 
of ADAM12-La is indicated with arrow.  Epidermal Growth Factor Receptor (EGFR), ß-actin, 
and tubulin are gel-loading controls. 
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Table 3.1 Accession numbers of the individual splice variants of human ADAM12 
CCDS UniProt
mRNA Translation mRNA Translation mRNA Translation mRNA Translation
mRNA and 
Translation Translation
Var-1a - - - - - - - - - -
Var-1b AF023476 AAC08702 NM_003474 NP_003465 ENST00000368679 ENSP00000357668 OTTHUMT00000050961 OTTHUMP00000020726 7653 O43184-1
Var-2a AY358878 AAQ89237 - - - - - - - O43184-3
Var-2b AF023477 AAC08703 NM_021641 NP_067673 ENST00000368679 ENSP00000357665 OTTHUMT00000050962 OTTHUMP00000020727 7654 O43184-2
GenBank/EMBL/DDBJ NCBI RefSeq Ensembl Vega
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Figure 3.8 The anti-ADAM12 antibody used for flow cytometry recognizes both ADAM12-
La and ADAM12-Lb 
MCF10A cells stably transduced to express ADAM12-La or ADAM12-Lb were 
subjected to immunoprecipitation using mouse anti-ADAM12 antibody (R&D Biosciences, 
clone 632525) and Protein G agarose.  IgG isotype control was used as a negative control.  Equal 
volumes of total cell lysates of ADAM12-La- and ADAM-Lb-expressing cells (Inputs), as well 
as equal volumes of Protein G eluates, were analyzed by Western blotting using rabbit 
polyclonal anti-ADAM12 antibody #3394. 
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Chapter 4 - An essential role of metalloprotease-disintegrin 
ADAM12 in triple negative breast cancer 
This chapter has been published as the following journal article: 
Li, H., Duhachek-Muggy, S., Qi, Y., Hong, Y., Behbod, F., and Zolkiewska, A. 
An essential role of metalloprotease-disintegrin ADAM12 in triple negative breast 
cancer.  Breast Cancer Res Treat (2012) 135:759–769 (doi:10.1007/s10549-012-2220-4).  
The final publication is available at link.springer.com. 
 Abstract 
In the absence of HER2 overexpression, triple-negative breast cancers (TNBCs) rely on 
the signaling by epidermal growth factor receptor (EGFR/ErbB1/HER1) to convey growth 
signals and stimulate cell proliferation.  Soluble EGF-like ligands are derived from their 
transmembrane precursors by ADAM proteases, but the identity of the ADAM that is primarily 
responsible for ligand release and activation of EGFR in TNBCs is not clear.  Using publicly 
available gene expression data for patients with lymph node-negative breast tumors who did not 
receive systemic treatment, we show that ADAM12-L is the only ADAM whose expression level 
is significantly associated with decreased distant metastasis-free survival times.  Similar effect 
was not observed for patients with ER-negative non-TNBCs.  There was a positive correlation 
between ADAM12-L and HB-EGF and EGFR in TNBCs, but not in ER-negative non-TNBCs.  
We further demonstrate that ectopic expression of ADAM12-L increased EGFR phosphorylation 
in a mouse intraductal xenograft model of early breast cancer.  Finally, we detect strong 
correlation between the level of anti-ADAM12-L and anti-phospho-EGFR immunostaining in 
human breast tumors using tissue microarrays.  These studies suggest that ADAM12-L is the 
primary protease responsible for the activation of EGFR in early stage, lymph node-negative 
TNBCs.  Thus, our results may provide novel insight into the biology of TNBC. 
 Introduction 
Triple-negative breast cancer (TNBC) is an aggressive form of the disease, with poor 
prognosis, and limited treatment options [1-3].  TNBC, which accounts for ~20% of all breast 
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cancers, is characterized by the absence of estrogen receptor (ER) and progesterone receptor 
(PR) expression, and the lack of human epidermal growth factor receptor 2 (HER2) 
overexpression.  Based on their gene expression profiles, the majority of TNBCs fall into the 
basal-like or claudin-low molecular subtypes [4, 5].  Due to the absence of ER and HER2, 
established targeted therapies, such as endocrine therapy or anti-HER2 therapy, are not 
applicable.   
HER2 is a member of the ErbB family of receptors that include epidermal growth factor 
receptor (EGFR/ErbB1/HER1), ErbB2/HER2/Neu, ErbB3/HER3, and ErbB4/HER4 [6].  EGFR 
requires ligand binding for dimerization, autophosphorylation, and stimulation of its tyrosine 
kinase activity.  HER2 does not bind ligands but exists in an open conformation that is 
constitutively available for dimerization with other ErbBs.  HER3 lacks intrinsic tyrosine kinase 
activity.  Signaling by EGFR, HER2, and HER3 plays fundamental roles in breast tumor cell 
proliferation, survival, and metastasis [7].  HER4 also binds ligands and possesses tyrosine 
kinase activity but, unlike EGFR or HER2, it elicits anti-proliferative responses in mammary 
epithelium [8].  In the absence of HER2 overexpression, TNBCs depend on EGFR to convey 
growth signals, and ligand-mediated activation of EGFR becomes important for tumor 
progression.  Ligands for EGFR include epidermal growth factor (EGF), tumor growth factor α 
(TGFα), heparin-binding EGF-like growth factor (HB-EGF), amphiregulin (AREG), epigen 
(EPGN), epiregulin (EREG), and betacellulin (BTC) [9].  They are all synthesized as 
transmembrane precursors that need to be shed from the membrane to generate soluble, 
biologically active agonists.  The shedding is mediated by cell surface proteases (sheddases) that 
belong predominantly to the ADAM (A Disintegrin And Metalloprotease) family.  Studies in 
cells cultured in vitro showed that several different ADAMs are capable of generating soluble 
EGFR ligands [10-13].  ADAM17 has emerged as the primary sheddase of EGF-like ligands in 
breast cancer [14, 15], although its prognostic value is not limited to TNBC [15].  
Whether the expression levels of other ADAMs are linked to breast cancer outcome and 
whether the potential risk is particularly increased in TNBC has not been investigated.  The 
ADAM family comprises 20 members, 9 out of which are catalytically active and expressed 
beyond the reproductive system: ADAM8, -9, -10, -12, -15, -17, -19, -28, and -33 [16].  
ADAM12 is strongly up-regulated in breast tumors and it has been previously implicated in 
breast cancer [17-20].  ADAM12 mRNA is alternatively spliced, giving rise to two different 
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protein isoforms: ADAM12-L (a transmembrane form) and ADAM12-S (a secreted form) [17].  
Recently, ADAM12-S was reported to enhance tumor cell migration and invasion through 
Matrigel in vitro and to increase metastasis in mice in vivo [20].  It is currently unknown whether 
these pro-tumor roles of ADAM12 observed in laboratory settings translate into increased patient 
risk in clinical settings.  Furthermore, despite the fact that ADAM12 was shown to be a potent 
sheddase of at least two different EGF-like ligands, EGF and BTC, in cultured cells [10], it is not 
clear whether it plays any role in the activation of EGFR in breast tumors in vivo.  
The goal of this study was to examine whether ADAM12-L plays a role in activation of 
EGFR in TNBC.  Our results suggest that ADAM12-L is the primary protease responsible for the 
activation of EGFR in an early stage, lymph node-negative TNBC.  
 Materials and Methods 
 Cell culture  
MCF10DCIS.com cells (Asterand) were grown in Dulbecco’s modified Eagle’s medium 
(DMEM)/F12 nutrient mixture (1:1) supplemented with 5% horse serum and 29 mM NaHCO3, at 
37˚C in the presence of 5% CO2 under a humidified atmosphere.  Retroviral packaging cell line 
Phoenix Ampho (G. P. Nolan, Stanford University) was grown in DMEM supplemented with 
10% FBS.  Phoenix Ampho cells were transfected with hADAM12-L-pBABEpuro or empty 
pBABEpuro retroviral vector (15 µg plasmid DNA per 100-mm plate) using the calcium 
phosphate precipitation method.  Viral supernatants were harvested 48 hours later, supplemented 
with 5 µg/ml polybrene, and used without further dilution for infection of MCF10DCIS.com 
cells.  After one day, media containing retroviral particles were replaced with fresh media, and 
after an additional 24 h, stably transduced cells were selected with 3 µg/ml of puromycin for 7 
days.  For the EGF dose-response experiment, cells were starved in serum-free medium for 16 h, 
and then incubated for 30 min with the indicated concentrations of human EGF (R&D Systems).  
 Antibodies  
Rabbit polyclonal anti-phospho-EGFR (Y1173) antibody was obtained from R&D 
Systems and it was used at a 1:5,000 dilution for Western blotting and 1:20 for IHC.  Rabbit 
monoclonal anti-EGFR antibody (clone D38B1) XP® (Cell Signaling) was used at a 1:1,000 
dilution for Western blotting.  Mouse monoclonal anti-ADAM12 antibody (clone #632525) 
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recognizing the extracellular domain of human ADAM12 was purchased from R&D Systems 
and it was used at a 1:20 dilution for flow cytometry.  Rabbit polyclonal anti-ADAM12 antibody 
(Ab #3394) was raised against the recombinant cytoplasmic domain of human ADAM12-L 
(amino acids 730-909).  The recombinant protein was expressed in E. coli as a 6xHis-tagged 
protein, was purified using preparative SDS-PAGE, and was submitted to Open Biosystems for 
custom generation of the antibody.  Rabbit anti-ADAM12 Ab (whole serum) was used at a 
dilution 1:20,000 for Western blotting and 1:500 for IHC; pre-immune serum at the same 
dilution was used as a negative control for IHC.  
 Western blotting  
Cells were incubated in extraction buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 5 
mM EDTA, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 1 mM 4-(2-aminoethyl)-
benzene-sulfonyl fluoride hydrochloride (AEBSF), 10 µg/ml aprotinin, 10 µg/ml leupeptin, 10 
µg/ml pepstatin A, 10 mM 1,10-phenanthroline) for 15 minutes at 4˚C.  In the experiment in 
which EGFR phosphorylation was analyzed, the extraction buffer included 50 mM NaF, 2 mM 
Na3VO4, and 10 mM Na4P2O7.  Cell extracts were centrifuged at 21,000x g for 15 min, 
supernatants were resolved by SDS-PAGE and transferred to a nitrocellulose membrane.  The 
membrane was blocked in DPBS containing 3% (w/v) dry milk and 0.3% (v/v) Tween 20, then 
incubated with primary antibodies in blocking buffer, followed by incubation with horseradish 
peroxidase-labeled secondary antibodies and detection using the West Pico chemiluminescence 
kit (Pierce).  
 Flow cytometry  
Cells were trypsinized into single cell suspension, washed with PBS, and incubated with 
anti-ADAM12 monoclonal antibody or with isotype control for 30 min on ice.  Cells were then 
washed 3 times, incubated with anti-mouse IgG antibody conjugated to FITC, and analyzed on a 
BD FACSCalibur flow cytometer.  
 Intraductal transplantation of cells  
Intraductal transplantation of MCF10DCIS.com cells into NOD-SCID IL2 receptor γ 
knockout (NSG) mice was performed as described earlier [29].  Briefly, cells were trypsinized 
into single cells and resuspended in PBS at the 5,000 cells/µl density.  Eight to twelve week-old 
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female mice were anesthetized, and 2 µl of cell suspension were injected into the ducts, using a 
50-µl Hamilton syringe, with a blunt-ended 1/2-inch 30-gauge needle inserted directly through 
the nipple of the fourth inguinal gland.  After 6 weeks, mice were sacrificed and the mammary 
tissue was collected for histological and immunohistochemical examination.  All animal 
experiments were conducted by following protocols approved by the Animal Care and Use and 
Human Subjects Committee at the University of Kansas Medical Center.  
 Tissue Microarrays  
Breast cancer tissue microarrays (BR1503a) were purchased from US Biomax.  These 
arrays contained consecutive 4-µm sections of paraffin-embedded tissue samples from 3 cases of 
breast fibroadenoma, 2 cases of cystosarcoma phyllodes, 7 cases of intraductal carcinoma, 60 
cases of invasive ductal carcinoma and 3 cases of normal adjacent breast tissue.  Each case was 
represented by two different cores.  Two cores out of the total 144 tumor cores were not suitable 
for staining.  The ER-, PR- and HER2-status of each core had been previously determined by 
immunohistochemistry.  Test arrays (T086b) were also purchased from US Biomax, Inc. and 
used to assess specificity of staining.  
 Immunohistochemistry  
Samples were de-paraffinized in xylene and rehydrated in an ethanol gradient (100%-
50%).  Antigen retrieval was performed by boiling slides for 10 minutes in Acidic Antigen 
Retrieval buffer (R&D Systems).  Slides were stained using HRP-DAB Cell and Tissue Staining 
Kit (R&D Systems) according to the manufacturer’s protocol.  Incubation with primary 
antibodies was performed overnight at 4°C.  Samples were counterstained with hematoxylin 
prior to mounting with Permount solution (Fisher).   
 Quantification of immunohistochemical staining  
All samples to be quantified were stained simultaneously using the same staining 
conditions and were analyzed with Axiovert-200 Zeiss microscope using a 10x (for mouse 
xenografts) or a 4x objective (for tissue microarrays).  Samples were photographed with a RGB 
color camera using the same illumination conditions and a fixed exposure time.  The images 
were viewed using a linear display characteristic curve, and were exported as TIFF files.  The 
TIFF files were processed and analyzed by ImageJ software, version 1.46m.  First, the brown 
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and blue colors were separated using the color deconvolution plug-in and the hematoxylin/DAB 
built-in vector.  This color deconvolution plug-in implements stain separation algorithm 
developed by Ruifrok and Johnston [60] and it was downloaded from the following website: 
http://www.dentistry.bham.ac.uk/landinig/software/cdeconv/cdeconv.html.  Next, the 8-bit 
monochromatic image representing DAB staining was inverted, and a region of interest (ROI) 
was selected using a polygon tool (for xenograft sections) or a circle tool (for tissue 
microarrays).  For xenograft sections, ROIs either included the entire duct sections or, if a duct 
section was larger than the size of the image, the largest area of the duct captured in the image.  
This was followed by measuring the mean gray value within the ROI (i.e., the sum of the gray 
values of all the pixels in the ROI, divided by the number of pixels).  As most of the carcinomas 
formed inside mouse ducts contained irregular areas of comedo-like necrosis that were visible as 
hollow spaces within the ducts, a threshold value was set prior to the measurement to exclude all 
pixels that did not correspond to cancer cells.  The threshold value was the same for all analyzed 
images.  An example of quantification of DAB staining in a xenograft section is shown in Figure 
4.9.  A similar approach was used to quantify DAB staining in tissue microarrays.  For each core 
in the array, the entire area of the core was included in the ROI.  Since DAB staining method is 
not stoichiometric and since DAB does not follow the Beer-Lambert law, the relationship 
between the optical density of the brown color developed during the HRP-DAB reaction and the 
amount of antigen is not linear [61].  Nevertheless, quantification of DAB staining using the 
approach described here provided an objective, albeit qualitative, estimate of the amount of 
antigen in tissue sections. 
 Patient populations 
We used four datasets that are publicly available at Gene Expression Omnibus (GEO, 
http://www.ncbi.nlm.nih.gov/geo/): EMC286 (GSE2034) [21,22], Erasmus (GSE5327) [22], 
TRANSBIG (GSE7390) [23], and Mainz (GSE11121) [24].  We applied the following criteria 
for dataset selection: (a) patients with lymph-node negative tumors, (b) patients did not receive 
systemic adjuvant treatment, (c) distant metastasis free survival times (DMFS) were available, 
(d) gene expression profiling was performed using Affymetrix HG-U133A platform, and (e) the 
number of TNBCs identified by gene expression profiling (ref. [25], see below) was greater than 
15.  Patient clinical characteristics are reported in Table 4.1.  
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 Data analysis 
The EMC286, Erasmus, and TRANSBIG datasets contained information on the ER, but not PR 
or HER2 status.  The Mainz dataset lacked information on ER, PR, and HER2.  To identify 
TNBCs, we have adopted tumor classification based on bimodal filtering on ER, PR, and HER2 
expression determined by Lehman et al. [25].  Previous studies have shown that microarray-
based readout of ER, PR, and HER2 correlates well with immunohistochemical (IHC) 
determination of the ER, PR, and HER2 status [26, 27].  Overall, 53 tumors in the EMC286 
dataset were classified as TNBCs.  Nine tumors that were originally categorized as ER-positive 
based on IHC, but were classified as TNBC based on ER/PR/HER2 mRNA expression, were 
considered TNBC in our analyses.  Consistently, the set of ER-negative tumors comprised 77 
tumors that were called ER-negative by IHC, plus 9 ER-positive tumors that were classified as 
TNBC based on gene expression profiling.  The remaining 200 tumors were considered ER-
positive.  Erasmus, TRANSBIG and Mainz datasets contained 16, 29, and 19 TNBCs, 
respectively.  To evaluate the prognostic value of ADAM12-L in the combined set TNBCs from 
the fours cohorts, ADAM12-L expression data were merged.  Data were first log2-transformed, 
median-centered, and Z-score transformed [28] to normalize ADAM12-L expression across all 
samples in each cohort.  The flowchart of data analysis is shown in Figure 4.1.  The list of 
Affymetrix probes used to retrieve gene expression profiles is provided in Table 4.3.  
 Statistical analyses  
All data analyses were performed using GraphPad Prism version 5.0d.  Survival curves 
were calculated using the Kaplan-Meier method and compared by the log-rank (Mantel-Cox) 
test.  All reported P values are two-sided.  
 Results  
 High expression level of ADAM12-L is associated with poor prognosis in lymph node-
negative TNBC without systemic therapy 
 We assessed the prognostic value of ADAM12-L and ADAM12-S in 286 early stage 
breast cancer patients treated at the Erasmus Medical Center (the EMC286 dataset) [21].  All 
tumors were lymph node-negative, and patients did not receive neoadjuvant or adjuvant systemic 
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therapy.  Patients were divided into two groups with low and high expression of ADAM12-L 
(Figure 4.2A) or ADAM12-S (Figure 4.2B), with cut-offs set as median expression values.  
When all 286 tumors were analyzed together, the group with high expression of ADAM12-L had 
worse prognosis than the group with low expression of ADAM12-L, but the difference was not 
statistically significant.  When ER-negative and ER-positive tumors were considered separately, 
a striking difference in the prognostic value of ADAM12-L became evident.  In ER-negative 
tumors, high expression of ADAM12-L was associated with significantly lower distant 
metastasis-free survival (DMFS) rates (hazard ratio (HR) 2.154, 95% confidence interval (CI) 
1.071 to 4.332, P = 0.0314).  In ER-positive tumors, there was no difference in survival rates for 
patients with high or low levels of ADAM12-L. Most importantly, within ER-negative tumors, 
poor prognosis associated with high ADAM12-L was restricted to TNBCs (HR 2.492, 95% CI 
1.047 to 5.933, P = 0.0391).  Remarkably, in ER-negative non-TNBC, high expression of 
ADAM12-L was not linked to poor outcome.  Assuming that the difference between TNBC and 
ER-negative non-TNBC was mainly due to HER2 overexpression (the mean expression level of 
HER2 in TNBC was indeed ~12-fold lower than in ER-negative non-TNBC, P<0.0001, data not 
shown), this result indicates that the poor prognostic value of ADAM12-L was manifested only 
in the absence of HER2 overexpression.  Interestingly, although TNBCs overlap to a large extent 
with basal cancers (a majority of basal cancer are triple-negative, and 60-80% of TNBCs are 
basal tumors [1-4]), the prognostic value of ADAM12-L in basal cancers was lower than in 
TNBCs (Figure 4.7).  Thus, decreased DMFS in TNBC expressing high ADAM12-L were not a 
simple consequence of poor prognostic value of ADAM12-L in basal cancers.  Given the fact 
that the mean values of ADAM12-L were not statistically different between TNBCs and other 
tumor groups (Figure 4.8), these results suggest that ADAM12-L may activate EGFR via the 
cleavage of EGF-like ligands, and this function is masked or irrelevant in the presence of HER2 
overexpression.  In a marked contrast to ADAM12-L, ADAM12-S did not have a significant 
prognostic value in any of the tumor groups examined (Figure 4.2B).  
Efficient activation of the EGFR pathway requires three components: the receptor, a 
ligand, and a sheddase that generates the soluble ligand.  While the expression of these 
components may be regulated by entirely separate mechanisms, it is clear that increased levels of 
all three components create a particular advantage for tumor cells.  Therefore, we examined the 
correlation between ADAM12-L, EGF-like ligand mRNAs and EGFR.  We observed no positive 
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correlation in all 286 tumors or in ER-positive cancers (Table 4.2).  In contrast, in ER-negative 
tumors, there was a positive correlation between ADAM12-L and HB-EGF (Pearson r = 0.3038, 
P = 0.0045; Table 4.2).  Most importantly, this positive correlation between ADAM12-L and 
HB-EGF (Pearson r = 0.3632, P = 0.0075) and EGFR (Pearson r = 0.2728, P = 0.0481) was 
retained in the TNBC subset of ER-negative tumors.  In the remaining ER-negative non-TNBCs, 
ADAM12-L was not significantly correlated with any of the mRNAs tested.  Interestingly, 
despite their correlation with ADAM12-L, high expression of HB-EGF or EGFR mRNA alone 
was not significantly associated with decreased DMFS in TNBC (Figure 4.7).  This is not 
surprising, since high HB-EGF or EGFR protein levels do not inevitably lead to the activation of 
EGFR unless a sheddase, i.e., ADAM12-L, is also expressed at high level.  
Next, we asked whether other transmembrane, catalytically active ADAMs also 
contribute to poor prognosis in TNBCs.  Out of eight other catalytically active ADAMs whose 
expression is not limited to the reproductive system, the following seven were represented on the 
Affymetrix U133A array: ADAM8, -9, -10, -15, -17, -19, and -28.  Among TNBC patients from 
the EMC286 cohort, ADAM12-L was the only ADAM that was significantly associated with 
poor prognosis (Figure 4.3).  
In order to extend our investigations beyond the EMC286 cohort, we combined 
ADAM12-L expression profiles in TNBCs from the EMC286 dataset and from three other 
cohorts, Erasmus [22], TRANSBIG [23], and Mainz [24].  All tumors were node-negative and 
patients did not receive adjuvant chemotherapy.  In this combined dataset of 117 TNBCs, 
ADAM12-L levels were significantly higher in patients with distant metastases than in patients 
without metastasis (Figure 4.4A).  Patients with high expression of ADAM12-L had significantly 
lower survival rates than patients with low expression of ADAM12-L (HR 2.030, 95% CI 1.136 
to 3.628, P = 0.0168; Figure 4.4B).  
 ADAM12-L augments EGFR phosphorylation in vivo  
Next, we examined whether there is a cause-and-effect relationship between the level of 
expression of ADAM12-L protein and the extent of EGFR phosphorylation in vivo in a mouse 
model of an early ER-negative breast cancer.  We used the MIND (mouse intraductal) 
transplantation model, in which ER-negative MCF10DCIS.com breast tumor cells are 
transplanted directly into the mammary ducts [29].  MCF10DCIS.com cells express high levels 
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of EGFR [29].  We confirmed that this receptor is fully functional, as it became readily 
phosphorylated at Tyr1173, one of the major autophosphorylation sites [30], in response to 
added EGF (Figure 4.5A).  The endogenous expression level of ADAM12-L protein in 
MCF10DCIS.com cells was low and poorly detected by immunoblotting (Figure 4.5B).  Using a 
retroviral delivery system and selection with puromycin, we established cells with stable 
overexpression of ADAM12-L.  The ectopically expressed ADAM12-L produced two bands in 
Western blots (Figure 4.5B).  The ~120-kDa band represented the inactive intracellular 
ADAM12-L, and the ~90-kDa band represented the processed, active form that resides at the cell 
surface [31].  Flow cytometry using live cells further demonstrated surface expression of 
ADAM12-L in stably transduced cells (Figure 4.5B).  
ADAM12-L overexpressing cells and control cells transduced with vector only were 
transplanted into mammary ducts.  Six weeks later, the extent of EGFR phosphorylation in 
intraductal lesions was examined by immunohistochemistry.  As reported earlier, most of the 
lesions at this time point were DCIS-like, with some lesions already progressing to invasion [29].  
Figure 4.5C shows examples of anti-phospho-EGFR (Y1173) staining in the intraductal lesions.  
To assess the effect of ADAM12-L on the extent of EGFR phosphorylation, the intensity of anti-
phospho-EGFR staining was quantified, as described in Methods.  Analysis of 76 different 
intraductal lesions (38 lesions per each cell type, 6 mice total) showed significantly higher anti-
phospho-EGFR staining in lesions generated by ADAM12-L-overexpressing cells than control 
cells (Figure 4.5D).  This result suggested that ADAM12-L was capable of inducing EGFR 
phosphorylation in the MIND model in vivo.  As MCF10DCIS.com cells express oncogenic H-
RasG12V [32], it was not feasible to study downstream effects of EGFR activation.  
 EGFR phosphorylation in human breast tumors strongly correlates with ADAM12-L 
expression level  
To assess an association between EGFR phosphorylation and the level of ADAM12-L 
protein in human breast tumors, we performed IHC analysis of tissue microarrays.  We analyzed 
142 samples of 72 different breast tumors, using anti-ADAM12-L and anti-phospho-EGFR 
(Y1173) antibodies (Figure 4.6A,B).  The results show a strong correlation between staining 
intensities for ADAM12-L and for phospho-EGFR (Pearson r = 0.8353, P < 0.0001) (Figure 
4.6C).  Interestingly, this strong correlation was not limited just to TNBC, as a similar degree of 
110 
 
correlation was observed when only TNBC samples were included in the analysis (Pearson r = 
0.7663, P < 0.0001) (Figure 4.6C).  Thus, ADAM12-L may be a universal modulator of EGFR 
activation in all breast tumors, but this activity of ADAM12-L becomes biologically relevant 
only in the context of TNBC, where the EGFR pathway controls cell proliferation.  
 Discussion  
Due to the absence of ER and HER2 in TNBC, anti-estrogen or anti-HER2 therapies are 
not possible.  The only remaining option for systemic treatment is conventional chemotherapy.  
However, as chemotherapy typically aims at basic cellular processes such as cell division, it is 
non-specific and harmful to normal dividing cells.  Furthermore, many TNBCs acquire 
chemoresistance after prolonged exposure to cytotoxic drugs, compromising the efficacy of the 
treatment.  Thus, finding new molecular targets in TNBC and identifying novel predictive 
markers are of the utmost urgency.  
The ongoing clinical trials for patients with TNBC include novel cytotoxic drugs, 
poly(ADPribose) polymerase (PARP) inhibitors, antiangiogenic agents, Src and Abl kinase 
inhibitors, and EGFR-targeting agents [33].  EGFR seems to be a logical target in TNBC for 
several reasons.  First, in the absence of HER2-overexpression, TNBCs depend on signaling by 
EGFR to stimulate tumor cell proliferation and survival.  Second, 60-70% of all TNBCs show 
increased expression of EGFR [34-37].  Third, KRAS mutations are infrequent in TNBC [38], 
making the tumors amenable to EGFR inhibition.  Current EGFR-targeting agents being 
evaluated in clinical trials include small molecule inhibitors of the EGFR tyrosine kinase, as well 
as monoclonal antibodies (Cetuximab) [3, 39].  However, so far these strategies have produced 
limited success [1, 39].  One possible reason could be that the clinical studies involving EGFR 
inhibitors were conducted in unselected TNBC patients, and were not directed by any 
mechanistic hypotheses.  Since ligand binding is an absolute requirement for EGFR activation, 
and since activating mutations in EGFR that would nullify this requirement are rare [40, 41], 
limiting ligand availability represents another logical approach to block the EGFR pathway.  
Furthermore, one can postulate that TNBC patients with the highest sheddase activity, in which 
soluble EGF-like ligands are produced with the highest efficiency, are the best candidates for the 
existing anti-EGFR therapies.  This approach requires, however, precise knowledge of the 
sheddase responsible for the release of EGF-like ligands and activation of EGFR.  
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In this study, we demonstrate that high levels of ADAM12-L are associated with 
decreased DMFS in TNBC and we link this effect to the activation of EGFR.  Importantly, 
ADAM12-L was the only ADAM encoding a transmembrane, catalytically active protease 
whose expression level was significantly linked to poor prognosis in TNBC patients.  We further 
used an in vivo model to confirm a causal role of ADAM12-L protein in tyrosine 
phosphorylation of EGFR, which often serves as a read-out of the activation status of the 
receptor.  Importantly, we uncovered a strong correlation between ADAM12-L protein level and 
the extent of EGFR phosphorylation using tissue arrays.  
Although the significance of ADAM-mediated shedding of EGF-like ligands in breast 
cancer biology has been well recognized [42-44], the identity of the “perpetrator” ADAM that is 
actually responsible for ligand cleavage and activation of EGFR has not been conclusively 
determined.  To our best knowledge, the current study represents the first evaluation of the 
prognostic values of all catalytically active ADAMs in systemically untreated TNBCs.  This is 
also the first report that specifically links ADAM12-L to the activation of EGFR in TNBC.  This 
function of ADAM12-L has not been previously revealed by cell biology approaches or by 
mouse models.  Interestingly, the two breast cancer-associated loss-of-function mutations in 
ADAM12, i.e., D301H and G479E, were not found in TNBC [45, 46].  The third mutation, 
L792F, was found in TNBC, but this mutation does not alter the proteolytic activity of 
ADAM12-L (ref. [47] and our unpublished observations).  Thus, it appears that TNBCs express 
the active form of ADAM12-L, which is consistent with its role in EGFR activation in TNBC 
described here.  
One unexpected result of our survival analyses is the discrepancy between the prognostic 
values of ADAM12-L and ADAM12-S.  The distinction between ADAM12-L and ADAM12-S 
is important, because these two mRNAs encode transmembrane and secreted proteases, 
respectively, with potentially diverse biological functions during tumor progression and 
metastasis.  Recently, ADAM12-S has been recently shown to be more potent than ADAM12-L 
in inducing metastasis in an orthotopic mouse xenograft model [20].  This result does not agree 
with the results of our survival analyses presented here, but the discrepancy may be explained by 
the fact that the model used in the referenced study did not mimic human TNBC.  
Finally, an important question remains: what is the functional mechanism by which 
ADAM12-L promotes metastasis in node-negative TNBC, despite complete removal of the 
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primary tumor?  One possibility is that the ADAM12-L/EGFR axis increases the chance of an 
early dissemination of a small number of cancer cells prior to surgery, and these cells go 
undetected in the node analysis.  EGFR activation has been shown to promote epithelial-to-
mesenchymal-like transition (EMT), down-regulation of E-cadherin, tumor cell migration, and 
invasion [48-53], and these functions fit the proposed model of ADAM12-L/EGFR enhancing 
tumor cell dissemination.  Another possibility is that ADAM12-L-mediated activation of the 
EGFR pathway might enhance tumor cell colonization at a metastatic site.  Recent studies have 
shown that shedding of EGF-like ligands from tumor cells modulates in a paracrine manner the 
bone microenvironment and promotes osteolytic metastasis [54].  The sheddases implicated in 
this process are ADAMTS1 (a disintegrin and metalloproteinase with thrombospondin motifs1) 
and MMP1 (matrix metalloprotease 1).  These two proteases are not linked to poor prognosis in 
TNBCs from the EMC286 cohort (results not shown).  However, as the pattern of metastatic 
spread in TNBC is different from other types of breast cancer, with brain and liver metastases 
being more frequent than metastasis to bone or lung [55-57], the identity of the sheddases and 
the spectrum of EGF-like ligands involved may also be different.  Recently, HB-EGF has been 
shown to be a mediator of cancer cell passage through the blood-brain barrier [58].  Our 
preliminary examination of the gene expression data suggested that the expression level of 
ADAM12-L might be indeed higher in TNBCs that metastasized to the brain than in other 
TNBCs, but because of the limited number of cases available, the difference did not reach 
statistical significance (results not shown).  
The discovery of ADAM12-L as a prognostic factor in TNBC and linking its function to 
the EGFR pathway may have at least two potential implications.  First, it should promote further 
studies to establish whether ADAM12-L may serve as a novel therapeutic target in TNBC.  It 
should also encourage a quest for highly specific inhibitors that would effectively discriminate 
between ADAM12-L and other catalytically active ADAMs.  Second, stratification of TNBC 
patients based on the expression level of ADAM12-L may identify a group that could benefit the 
most from inhibition of EGFR and thus it may increase the efficacy of anti-EGFR treatment. 
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Figure 4.1 Flowchart of analysis according to REMARK criteria 
 Flowchart of analysis as required by the REMARK criteria [59]. 
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Figure 4.2 High expression of ADAM12-L is associated with poor prognosis in TNBC 
patients from the EMC286 cohort 
Kaplan-Meier analysis of distant metastasis-free survival fractions for all patients (top), 
patients with ER-negative or ER-positive tumors (middle), and patients with TNBC or ER-
negative non-TNBC (bottom).  Patients were rank-ordered according to the expression of 
ADAM12-L (a) or ADAM12-S (b) and divided into two groups with mRNA expression levels 
below or above the median values. 
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Figure 4.3 The prognostic value of ADAM12-L in TNBCs from the EMC286 dataset is the 
highest among other ADAMs encoding membrane-anchored, catalytically-active ADAM 
proteases 
Kaplan-Meier plots of distant metastasis-free survival fractions for TNBC patients from 
the EMC286 cohort are shown. 
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Figure 4.4 High expression of ADAM12-L is associated with poor prognosis in a combined 
set of node-negative TNBCs without chemotherapy 
Gene expression profiles obtained in four independent studies (GEO accession numbers 
GSE2034, GSE5327, GSE7390, and GSE11121) were merged, as described in Methods.  (a) 
Log2-transformed, median-centered ADAM12-L expression values in TNBC patients without vs 
with distant metastasis.  Mean expression values ± SEM are indicated.  (b) Kaplan-Meier plots of 
distant metastasis-free survival fractions are shown. 
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Figure 4.5 Increased expression of ADAM12-L augments EGFR phosphorylation in a 
mouse-intraductal (MIND) xenograft model of basal breast cancer 
(a) Detection of a functional EGFR in MCF10DCIS.com cells.  Cells were serum-starved 
for 16 h and then incubated for 30 min with indicated concentrations of EGF.  The extent of 
EGFR phosphorylation (pY1173) was examined by Western blotting.  (b) Stable expression of 
ADAM12-L in MCF10DCIS.com cells.  Cells stably transduced with ADAM12-L or with empty 
vector were analyzed by Western blotting using an antibody against the cytoplasmic tail of 
ADAM12-L (left).  The nascent form represents the full-length, catalytically inactive, 
intracellular form of ADAM12-L.  The mature form represents ADAM12-L lacking its N-
terminal pro-domain, which is catalytically active and resides predominantly at the cell surface.  
Cell surface localization of the mature form of ADAM12-L was confirmed by flow cytometry 
after staining of live cells with an antibody recognizing the extracellular domain of ADAM12-L.  
(c) Immunohistochemical detection of phosphorylated EGFR in mouse intraductal xenografts.  
MCF10DCIS.com cells stably transduced with ADAM12-L or with empty vector were injected 
into mammary ducts of NSG mice.  Six weeks after injection, paraffin-embedded mammary 
tissue sections were stained with anti-phospho-EGFR (Y1173) antibody, visualized with DAB 
(brown), and counterstained with hematoxylin (blue).  Four representative images are shown in 
the top and middle rows, respectively.  The specificity of staining was confirmed by incubation 
of duplicate sections with or without primary antibody (bottom row).  (d) Comparison of anti-
phospho-EGFR staining intensities in intraductal xenografts of MCF10DCIS.com cells stably 
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transduced with empty vector or ADAM12-L.  For each cell type, 38 tissue sections from three 
different mice were analyzed.  Quantification was performed as described in Methods.  All 
staining intensity values (in arbitrary units) were normalized to the mean value obtained for cells 
transduced with empty vector. 
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Figure 4.6 Positive correlation between the level of ADAM12-L expression and the extent of 
EGFR phosphorylation in human breast cancer tissue microarrays 
(a) Validation of the specificities of the antibodies used for IHC staining of tissue microarrays.   
Two cores of the same tumor were stained with anti-ADAM12-L antibody or with pre-immune serum 
(top).  Similarly, two cores of the same tumor were stained with anti-pEGFR (Y1173) or with the 
secondary antibody only (bottom).  Positive staining was observed mostly in epithelial cells, with 
much weaker staining in the stromal compartment.  (b) Two examples of duplicate sections in which 
epithelial cells stained strongly (top) or weakly (bottom) for both ADAM12-L and pEGFR.  (c) 
Correlation analysis of ADAM12-L staining versus pEGFR staining intensities in 142 cores, including 
33 cores of TNBC.  Staining intensities (in arbitrary units) were quantified as described in Methods. 
126 
 
       
 
Figure 4.7 Kaplan-Meier survival curves based on median cutoffs for ADAM12-L, HB-
EGF, and EGFR 
 Kaplan-Meier survival curves based on below-the-median and above-the-median 
ADAM12-L expression are shown for patients with basal (a) and non-basal tumors (b) from the 
EMC286 cohort.  Tumors were classified into the basal subtype according to Harrell et al. (2012) 
Breast Cancer Res Treat 132(2):523-535.  (c, d) Kaplan-Meier plots based on below-the-median 
and above-the-median HB-EGF (c) and EGFR (d) expression levels in TNBCs from the 
EMC286 cohort. 
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Figure 4.8 Expression levels of ADAM12-L and ADAM12-S mRNA in breast tumors from 
the EMC286 
All tumors were divided into ER-positive and ER-negative tumors, and the ER-negative 
group was further divided into TNBC and the remaining non-TNBC.  Box-and-whisker plots of 
log2-tranformed, median centered values are shown. 
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Figure 4.9 Flowchart of the procedure for quantification of the immunohistochemical 
staining 
An example of an image showing pEGFR (DAB, brown) and nuclei (hematoxylin, blue) 
staining in a mouse xenograft is shown.  The consecutive steps were performed using ImageJ 
software. 
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Table 4.1 Patient characteristics 
 EMC286 Erasmus TRANSBIG Mainz 
GEO Accession Number  GSE 2034  GSE5327  GSE7390  GSE11121 
No. of patients 286 58 198 200 
Age (y)     
   Median Unknown Unknown 46 60 
   Range Unknown Unknown 24-60 34-89 
T Stage     
   T1 0 0 102 111 
   T2 0 0 96 81 
   T3/T4 0 0 0 8 
   Unknown 286 58 0 0 
Tumor grade     
   Grade 1 0 0 30 29 
   Grade 2 0 0 83 136 
   Grade 3 0 0 83 35 
   Unknown 286 58 2 0 
Lymph node status     
   Positive 0 0 0 0 
   Negative 286 58 198 200 
   Unknown 0 0 0 0 
ER status     
   Positive 209 0 134 156 
   Negative 77 58 64 44 
   Unknown 0 0 0 0 
PR status     
   Positive 0 0 0 130 
   Negative 0 0 0 70 
   Unknown 286 58 198 0 
HER2 status     
   Positive 0 0 0 0 
   Negative 0 0 0 0 
   Unknown 286 58 198 200 
Endocrine Therapy 0 0 0 0 
Chemotherapy 0 0 0 0 
Median follow-up (y) 7.2 7.2 13.6 7.7 
Distant metastasis 107 11 62 46 
Reference 21 22 23 24 
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Table 4.2 Correlation analysis of ADAM12-L, EGF-like ligands, and EGFR in breast 
tumors from the EMC286 cohort. Values represent Pearson r 
 
All 
ADAM12-L 
EGF HB-EGF TGFα AREG BTC EREG EGFR 
-0.0525 0.0603 -0.0781 0.0432 -0.1097 0.0278 0.0067 
(P=0.3766) (P=0.3095) (P=0.1877) (P=0.4463) (P=0.0640) (P=0.6392) (P=0.9104) 
        
        
ER+ 
ADAM12-L 
EGF HB-EGF TGFα AREG BTC EREG EGFR 
-0.0520 -0.0068 -0.1431 0.0019 -0.1141 0.0258 0.0203 
(P=0.4646) (P=0.9243) (P=0.0432) (P=0.9784) (P=0.1077) (P=0.7174) (P=0.7750) 
 
   
ER- 
ADAM12-L 
EGF HB-EGF TGFα AREG BTC EREG EGFR 
-0.08296 0.3038 -0.0214 0.1193 -0.0497 0.0006 0.1703 
(P=0.4476) (P=0.0045) (P=0.8446) (P=0.2738) (P=0.6493) (P=0.9954) (P=0.1703) 
       
 
       
TNBC 
ADAM12-L 
EGF HB-EGF TGFα AREG BTC EREG EGFR 
-0.1004 0.3632 0.0504 02246 -0.1060 -0.0276 0.2728 
(P=0.4744) (P=0.0075) (P=0.7202) (P=0.1060) (P=0.4500) (P=0.8445) (P=0.0481) 
        
        
non-TNBC 
ADAM12-L 
EGF HB-EGF TGFα AREG BTC EREG EGFR 
-0.1030 0.2593 -0.2398 0.0735 0.1051 0.1093 0.1751 
(P=0.5685) (P=0.1450) (P=0.1789) (P=0.6843) (P=0.5605) (P=0.5448) (P=0.3297) 
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Table 4.3 List of Affymetrix probes used to retrieve gene expression profiles 
 
Gene Affymetrix probe 
ADAM8 205180_s_at 
ADAM9 202381_at 
ADAM10 202604_x_at 
ADAM12-L 202952_s_at 
ADAM12-S 204943_at 
ADAM15 217007_s_at 
ADAM17 205746_s_at 
ADAM19 209765_at 
ADAM28 205997_at 
EGF 206254_at 
HB-EGF 38037_at 
TGFα 205016_at 
AREG 205239_at 
BTC 207326_at 
EREG 205767_at 
EGFR 201983_s_at 
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Chapter 5 - Final Conclusions 
I have shown in this dissertation that the major ADAM12 transcripts are differentially 
regulated in breast cancer by miRNAs.  I have also demonstrated the existence of a novel 
ADAM12 splice variant that encodes a protein isoform with a unique pro-domain that results in 
impaired trafficking of ADAM12 to the cell surface.  Finally, I showed that the two major 
isoforms have distinct prognostic values in early stage TNBC.  Collectively, these studies 
demonstrate that the different splice variants/protein isoforms of ADAM12 vary in their 
regulation of expression and their biological roles within breast cancer cells. 
In Chapter 2, I determined that members of the miR-29 and miR-200 families selectively 
target the mRNA transcript encoding the transmembrane isoforms of ADAM12 causing mRNA 
degradation and reduced levels of ADAM12-L protein.  The miR-29 and miR-200 miRNA 
families are important in breast tumor biology because they are involved in metastasis and tumor 
recurrence.  The miR-200 family is a “master regulator” of the epithelial phenotype and loss of 
these miRNAs induces EMT [1].  Similarly, loss of miR-29 family members are associated with 
increased risk of metastasis [2].  Both of these miRNA families directly target the ADAM12-L 
transcript and cause degradation of the mRNA, whereas ADAM12-S transcript levels are 
unaffected.  The selective regulation of ADAM12-L by miRNAs explains the highly dissimilar 
patterns of expression between these two isoforms (See Figure 2.1A,B and ref [3]). 
However, regulation by miRNAs does not exclude the possibility that variant-specific 
regulation occurs during the splicing event as well.  Thus far, the splicing mechanisms that are 
responsible for generating the ADAM12-L and ADAM12-S variants have not been elucidated, nor 
has any study conclusively shown regulation of these two variants by modulating splicing factors 
directly.  A greater understanding of the molecular mechanisms involved in this particular 
splicing event and, perhaps, any regulation of these splicing factors/enhancers is critical to 
determining the major method of cellular regulation of the ADAM12 variants.  I have shown that 
loss of the miR-29 and miR-200 family members is, at least partially, responsible for the 
dramatic up-regulation of ADAM12-L in claudin-low cells lines and tumors.  However, cellular 
splicing factors such as ESRP1, ESRP2 and Fox2 are differentially regulated across the different 
subtypes of breast cancer [4–7] and, therefore, the splicing event itself may also be regulated. 
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One of the interesting questions raised by the targeted regulation of ADAM12-L by miR-
29 and miR-200 families is whether the association of ADAM12-L with claudin-low tumors, 
poor prognosis, and increased risk of metastasis is passive, or due to the loss of miR-29 and miR-
200, or whether ADAM12-L is a driving force in breast tumor metastasis and recurrence.  
Assessing whether ADAM12-L is directly involved in tumor progression or if it serves as a 
marker for cells that have undergone EMT and/or the loss of miR-29 expression is critical to 
determining how to utilize ADAM12 in clinical applications. 
In Chapter 3, I demonstrated the presence of a novel splice variant of ADAM12 in breast 
epithelial and breast cancer cell lines.  The new variant, ADAM12-var1b, is quite similar to the 
canonical long variant, ADAM12-var1a, and these two variants are indistinguishable in most 
common assays and in curated datasets like the Gene Expression Omnibus (GEO) and The 
Cancer Genome Atlas (TCGA).  Many GEO studies were performed using microarrays and they 
recognize only the unique 3’ regions of the ADAM12-L and ADAM12-S transcripts since these 
were the only known variants at the time.  TCGA analyses include both microarray data and 
RNA-Seq data which may show the relative levels of exon 4a and exon 4b inclusion in total 
ADAM12 transcripts.  However, because these RNA-Seq sequence reads are short, usually 50-
100 nt, and the distance between the exon 4 splicing event and the ADAM12-L/ADAM12-S 
splicing events is quite long, ~1700 nt, RNA-Seq will not be able to determine the relative 
abundance of all 4 splice variants.  Yet, detailed analysis of the RNA-Seq raw data could provide 
information about the relative abundance of ADAM12 transcripts that include exon 4a versus 
exon 4b in patient samples.  Unfortunately, the cBioPortal for Cancer Genomics that I used to 
access and the TCGA data only reports gene level expression data, therefore, transcript-specific 
data and and raw sequence data could not be obtained.  In Chapter 2, I analyzed the expression of 
the 2 major ADAM12 variants, ADAM12-L and ADAM12-S in breast cancer cell lines, but 
because the original data were collected using microarray profiling, I could not assess the 
inclusion of exon 4b. 
Interestingly, the inclusion of exon 4b in the ADAM12-L transcript generated a protein 
isoform, ADAM12-Lb, with unique properties.  ADAM12-Lb is retained intracellularly, in the 
endoplasmic reticulum which often implies that a protein is misfolded.  However, ADAM12-Lb 
is heavily glycosylated, does not interact with a number of major chaperone proteins and is not 
rapidly degraded.  Therefore, ADAM12-Lb is most likely not grossly misfolded.  Because it is 
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retained in the endoplasmic reticulum, ADAM12-Lb does not proceed to the Golgi apparatus and 
is not proteolytically processed to remove the pro-domain.  Traditionally, ADAMs are 
considered active only once their pro-domains have been cleaved, however, some non-canonical 
methods of ADAM activation have been described [8–11].  Therefore, it is possible that 
ADAM12-Lb is active inside the lumen of the endoplasmic reticulum.  Activation of ADAM12-
Lb would require displacement of the pro-domain from the active site, presumably via an 
interaction with another endoplasmic reticulum lumenal protein that would pull the pro-domain 
away from the metalloprotease domain.  To test for proteolytic activity, the potential activating 
conditions must be met, in addition to providing a suitable substrate. However, all of the 
currently known ADAM12-L substrates are localized at the cell surface.  Another method of 
testing for proteolytic activity of ADAMs and the related matrix metalloproteases is using in gel 
zymography.  In this technique a native PAGE gel is run with a substrate, such as gelatin, 
embedded in the polyacrylamide gel.  The detergents are removed from the gel by soaking and 
the enzymes are allowed to cleave the gelatin during incubation in an appropriate buffer.  
Staining the gel with Coomassie brilliant blue will show voids where active proteases cleaved the 
gelatin substrate.  Unfortunately, this method is not appropriate for studying ADAM12-Lb since 
the protein most likely requires an interactor to remove the autoinhibitory pro-domain from the 
active site.  At this time, any potential activity of ADAM12-Lb and its role in the biology of 
breast cancer cells are unknown. 
Another important portion of my analyses is the identification of the presence or absence 
of ADAM12-La and ADAM12-Lb in a number of breast cancer cell lines that express high 
levels of ADAM12 mRNA.  The goal of these investigations of the ADAM12-L isoforms in 
breast cancer cell lines was to determine which cell lines are most appropriate for studying the 
role of the different ADAM12-L isoforms.  For example, the MDA-MB-231 cell line expresses 
high levels of the ADAM12-L transcript; however, it is mostly the ADAM12-var1b/ADAM12-Lb 
variant/isoform and should not be used to determine the cell surface roles of ADAM12-L in 
breast cancer.  I determined that other cell lines, especially Hs578T and SUM159PT, express 
very high levels of ADAM12-L and that they almost exclusively express ADAM12-
var1a/ADAM12-La.  Therefore, these cell lines are more appropriate for investigating the cell 
surface role of ADAM12-L in breast cancer.  The special considerations as to which cell line is 
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most appropriate for the investigation of the ADAM12-L physiological roles are critically 
important when performing RNAi/knockdown studies. 
In Chapter 4, I showed the importance of ADAM12-L in TNBC progression.  ADAM12-
L, but not ADAM12-S, has prognostic value in early stage TNBC patients, since patients with 
high ADAM12-L levels are more likely to develop metastases.  Interestingly, ADAM12 is the 
only ADAM for which prognostic value exists in TNBCs.  Since TNBCs rely on EGFR 
signaling, I assessed the relationship between ADAM12-L expression and EGFR activation in 
142 tumor biopsy cores and determined that ADAM12-L expression strongly correlated with 
EGFR activation in patients.  In a mouse xenograft model using cells exogenously expressing 
ADAM12-La or an empty vector, the tumors formed from the ADAM12-La-expressing cells 
also exhibited increased EGFR activation when compared to tumors formed from control cells.  
These data show that ADAM12-L, but not ADAM12-S, is important in TNBC progression and 
that ADAM12-L works to activate EGFR in tumors.  Consequently, ADAM12-L may represent 
a good druggable target for the treatment of TNBC, or may be a good marker for selecting 
tumors that will respond to anti-EGFR therapies that have already made it to clinical trials and 
can be deployed more rapidly [12, 13].  Anti-EGFR therapy alone has failed to offer a clinical 
benefit in TNBC patients [14], and in metastatic TNBC patients who were treated with anti-
EGFR therapy and chemotherapy, only 17% of patients responded well to therapy [12].  In cases 
where anti-EGFR therapy failed, the failure is presumably due to the tumor’s lack of dependence 
on EGFR rather than failure of the drug to inhibit EGFR activity, since efficacy of the EGFR 
inhibition was verified according to study designs.  Therefore, determining molecular markers 
that indicate which tumors rely upon EGFR signaling and, as a result, would benefit from anti-
EGFR therapy, is an important step in generating effective therapies for TNBC tumors.  
ADAM12-L may be a good marker for tumors which are dependent on EGFR signaling and 
more studies should be done to assess this possibility. 
Additionally, ADAM12-L may make a good target for direct therapeutic intervention in 
TNBCs and, potentially, claudin-low tumors.  Both of these tumor subtypes have high rates of 
recurrence and metastasis as well as high expression of ADAM12-L.  The two major options for 
directly targeting ADAM12-L would involve using a small molecule inhibitor (SMI) of the 
metalloprotease domain or using a monoclonal antibody (mAb).  Both SMIs to the tyrosine 
kinase domain and mAbs have been utilized clinically to target HER2 and EGFR and therapies 
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of these types, i.e. trastuzubmab and lapatanib, are currently being used to treat the HER2+ and 
HER2-enriched subtypes of breast cancer.   
An SMI would target ADAM12-L and ADAM12-S equally since the metalloprotease 
domain is identical between these two isoforms.  The major benefit of SMIs over antibody 
therapies is ease of administration.  Many SMIs are specifically designed to be orally dosed, 
which allows patients to self-administer.  The major drawback to developing an SMI for 
ADAM12 is that the drug would most likely be ineffective in preventing the non-catalytic 
functions of the ADAM12 molecule.  For example, stabilization of the TGFβ receptor does not 
require an active metalloprotease and would be uninhibited by this method of treatment [15].   
A number of SMIs for ADAM12 currently exist, however, all of these seem to exhibit 
some non-specific targeting of other ADAM proteins [16].  This highlights one of the major 
problems with utilizing SMIs to target ADAM proteolytic activity, the high level of conservation 
of the ADAM metalloprotease active sites.  Developing a specific inhibitor has proved 
challenging but not impossible, in the case of ADAM17, a number of specific inhibitors have 
been generated as potential drugs [17].  However, due to the high degree of structural and 
sequence similarity between the metalloprotease domains of ADAMs, it may be more promising 
to develop other therapies.   
Using mAbs to target ADAM12 in breast cancer is also a potentially promising treatment 
option.  Since the extracellular region of ADAM12-L and ADAM12-S are so similar in sequence 
and, presumably, structure, any mAb designed to target ADAM12-L will probably also target 
ADAM12-S.  The major benefits to using mAbs to target ADAM12 is that they are quite specific 
and that mAbs are capable of blocking the types of protein-protein interactions that are important 
for non-proteolytic activities.  This blocking may be accomplished directly by covering the 
regions on ADAM12 that interact with other proteins, like the TGFβ receptor, or by inducing 
ADAM12 internalization which diminishes the amount of ADAM12 available on the cell 
surface.  Either way, the mAb is able to prevent more potential activities of ADAM12 in breast 
cancer cells than the SMI. 
Some of the drawbacks to employing anti-ADAM12 mAbs as potential therapies stem 
from difficulties in generating good quality, high specificity antibodies with strong ADAM12 
affinity.  The selection of commercially available antibodies for biochemical analyses is poor and 
our lab generated our own antibody for such purposes.  This poor selection may be due to 
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external factors such as low demand or poor quality control, or it may reflect that ADAM12 is a 
poor epitope or is too similar to other ADAMs to generate a specific antibody.  However, a mAb 
that is suitable for flow cytometric analyses is available commercially.  In our analyses, this 
antibody is specific for ADAM12 but we have only used it on breast cancer cells and not other 
cell types or in in vivo applications.  Additionally, we have not tested if this antibody blocks the 
ADAM12 proteolytic activity or interactions between ADAM12 and other cellular proteins.  Yet, 
this mAb indicates that it is possible to develop the kind of antibody required as a therapeutic, 
high specificity and high affinity to the extracellular portion of ADAM12.  A lesser drawback is 
that mAb therapies need to be administered intravenously and will require visits to medical 
clinics for dosing.  Since ADAM12 therapy is potentially beneficial in only the more aggressive 
subtypes of breast cancer, these patients will probably also be on chemotherapy and will need to 
visit medical clinics regularly for administering both treatments. 
Both methods for targeting ADAM12 in breast cancer assume that ADAM12 plays an 
active role in tumor progression.  In the event that ADAM12 emerges as a marker for BTICs but 
is not required for the survival and proliferation of these cells, it may still be worthy to 
investigate mAb targeting of ADAM12 as a treatment option.  Recently, a new therapy, T-DM1, 
was approved by the FDA for the treatment of HER2+ tumors [18, 19].  This therapy is an 
antibody-drug conjugate (ADC) in which a drug that is too toxic for systemic use is conjugated 
to a mAb, in this case, trastuzumab.  By conjugating the drug to the trastuzumab antibody, the 
drug is targeted only to HER2+ cells where the cytotoxic effects of the drug are concentrated, 
limiting the exposure of healthy cells to the chemotherapy.  Similar to ADCs, 
radioimmunotherapies are being developed where a radionuclide is conjugated to the antibody to 
effectively deliver a continuous source of radiation directly to the targeted cell [20].  Both ADCs 
and radioimmunotherapies may be adapted to targeting ADAM12 in TNBC, claudin-low tumors 
or BTIC populations.  ADC and radioimmunotherapy approaches can be also be used when the 
target molecule is both a marker and active in promoting tumor cell growth and survival.  In the 
case of T-DM1, HER2 is known to be critical to the growth and progression of these tumors but 
is also useful as a targeting molecule and the clinical success of this therapy may result from 
both HER2 inhibition and effects of the cytotoxic drug.  ADAM12 may represent a good 
candidate for this type antibody-conjugate therapy specifically for treating tumor subtypes like 
TNBC and claudin-low tumors that currently have no targeted therapies. 
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Considering all of these data and treatment options, I believe a biologic approach to 
targeting ADAM12 in breast cancer is feasible.  This conclusion is predominantly due to the 
ability of mAbs to target both the proteolytic activity of ADAM12 and any non-catalytic roles 
ADAM12 may play in tumor development.  SMIs may be helpful, but the fact that, even under 
treatment, cells may still have non-proteolytic ADAM12 activity is concerning, especially 
considering that the role of ADAM12 in stabilizing the TGFβ receptor could have negative 
effects on patient prognosis.  Additionally, the possibility for increasing efficacy of anti-
ADAM12 mAbs by conjugating to cytotoxic drugs or radionuclides makes this option more 
versatile and adjustable as additional information about ADAM12 and its role in breast cancers 
emerges. 
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